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SUMMARY
2
Colorectal cancer remains a common public health issue and a leading cause of 
mortality in the industrialised world. Much still needs to be learned about the factors 
regulating the proliferation of colonic epithelial cells but a large body of work suggests 
that the gastric antral hormone gastrin may be a trophic factor for colorectal cancer 
cells. This putative role for gastrin is controversial, however, and several questions 
remain unanswered. The aim of this thesis was to address several of these questions and 
investigate further the possible involvement of gastrin in colorectal neoplasia.
In the first study (Chapter 9), the effects of omeprazole-induced endogenous 
hypergastrinaemia on the subsequent development of azoxymethane-induced colorectal 
neoplasia in rats was examined. Omeprazole was chosen because of the well 
documented elevations in circulating gastrin concentrations seen during therapy with 
this commonly prescribed drug. The azoxymethane model was chosen because of its 
similarities to human carcinogenesis and because it has been well characterised and 
widely used in recent years. Despite having marked hypergastrinaemia throughout the 
study, significantly fewer rats in the omeprazole group developed tumours and had 
fewer tumours per rat. The reasons for this are unclear but omeprazole is a potent 
inducer of the cytochrome P450 enzymes responsible for the metabolism of numerous 
carcinogens. It is possible that omeprazole treatment altered hepatic and/or intestinal 
azoxymethane metabolism, rendering it less effective as a colonic carcinogen. Future 
experiments are merited to investigate further the results of this study and these are 
discussed in Chapter 13.
The second study (Chapter 10) examined the unresolved issue of whether 
plasma gastrin levels are elevated in colorectal tumour patients relative to patients 
without tumours. The study controlled for all known causes of hypergastrinaemia and 
measured both fasting and meal-stimulated plasma gastrin concentrations pre- and 
postoperatively. When studied in this manner, gastrin levels were similar in both tumour 
and control patients. In all but one case very high gastrins occurred in patients with 
positive gastric autoantibodies and were likely to result from undiagnosed atrophic
3gastritis or pernicious anaemia. Furthermore, no fall in gastrin concentrations was seen 
following presumed curative resection. It was notable that five tumour patients with 
perioperative loss of Helicobacter pylori (HP) infection had reductions in postoperative 
plasma gastrin. The results of previous studies should be reconsidered in the light of the 
important effects of HP infection on plasma gastrin. The results of this study have 
shown conclusively that colorectal tumour patients do not have higher circulating 
gastrin concentrations than well-matched controls.
Next (Chapter 11), the content of gastrin and its processing-intermediates in 
samples of colonic carcinomas and disease-free mucosa was determined in a study 
aimed at assessing a possible role for gastrin as an autocrine growth factor in this 
malignancy. The study demonstrated the practical difficulties encountered in accurately 
measuring peptide levels in extracts of heterogeneous tissues. Once early technical 
problems of non-specific interference were resolved, the results showed that significant 
amounts of both bioactive, carboxyamidated gastrin and its processing-intermediates 
were present in both normal and malignant colon. Levels were similar in the two tissues 
although the results of trypsinisation suggest that tumours contain markedly more 
progastrin than corresponding normal mucosa. This is compatible with defective post- 
translational processing of gastrin in tumour cells although the lack of an antibody 
specific for progastrin itself prevents a definitive answer on this point. As peptide 
concentrations were similar in both tissues it is unlikely that synthesis of gastrin 
peptides is a novel feature restricted to neoplastic colorectal epithelium. It does not 
detract, however, from the hypothesis that gastrin produced locally may be a relevant 
trophic factor for tumour cells at this site.
The final study (Chapter 12) explored further the possible presence of 
gastrin/CCK-B receptors in membranes preparations made from human colorectal 
cancers. The well characterised cell line AR42J was used as a 'positive control' to 
establish whether high affinity gastrin/CCK-B receptors could be detected by 
radioligand binding. This proved to be the case and no loss of binding was noted in 
crude membranes prepared from the cells. When a similar assay was applied to 
membranes from normal and malignant human colon, no convincing evidence for high
4affinity receptors was found although small amounts of specific binding of uncertain 
significance were observed. The possible reasons for the negative results are discussed 
as are alternative methods of studying these receptors. This issue is an important one to 
resolve before the increasing number of highly selective and potent gastrin/CCK-B 
receptor antagonists can be considered as possible therapeutic options for patients with 
colorectal cancer.
In conclusion, the studies presented in this thesis have examined the role of 
gastrin in several ways. No convincing evidence supporting a simple trophic role in 
colorectal neoplasia was found. If such a relationship exists it is likely to be more subtle 
and complex than hitherto supposed. Further studies focusing on the 
autocrine/paracrine effects of gastrin peptides (especially progastrin and glycine- 
extended intermediates) are required and advantage needs to be taken of the recent 
cloning and sequencing of the gastrin/CCK-B receptor genes. Together these 
approaches may define more closely what relevance, if any, gastrin has for tumours 
arising from the colon and rectum.
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CHAPTER 1 
INTRODUCTION
22
1.1 C o l o r e c t a l  C a r c in o m a
Colorectal carcinoma continues to be a major health problem in the industrialised world 
and is the second commonest cause of death from malignancy, accounting for fifteen 
percent of all cancers. In 1990, approximately 19,500 people in the United Kingdom 
alone died as a result of large bowel cancer (WHO Statistics Annual 1991). Indeed, 
almost one in twenty of the British population will develop colorectal cancer. Similarly, 
in the United States the most recent figures available (Boring et al 1992) estimate an 
annual incidence of approximately 156,000 new cases with 58,000 deaths annually. The 
incidence rises with age and, considering the proportional increase in the elderly 
population, it is likely that this disease will become even more common in years to 
come.
In the past three decades, overall mortality rates have improved only slightly, if 
at all (Stower and Hardcastle 1985), although the constancy of total deaths is possibly 
due in part to the increased population of elderly people with their higher incidence and 
case-fatality rate. Although advances in surgical management have reduced morbidity, 
the overall 5-year survival rate remains low at 35-40%, reflecting the fact that in the 
majority of cases the disease presents late in its natural history and is often beyond the 
limits of surgical resection at the time of diagnosis. It is therefore surgically incurable, 
the main determinant of prognosis being the extent of disease spread at diagnosis 
(Stower and Hardcastle 1985).
Improving the outlook of this condition is likely to depend on progress in 
several areas. Firstly, impressive recent advances in understanding the molecular genetic 
events underlying colorectal carcinogenesis have highlighted the importance of 
abnormalities in the expression of oncogenes and tumour suppressor genes in the 
carcinogenic process (Scott and Quirke 1993). Future research into these genetic 
changes may hopefully have potential applications in screening, predicting prognosis in 
individual cases and, ultimately, in gene therapy. For the time being, however, while the 
study of molecular genetic alterations in large bowel cancer has provided a wealth of
23
knowledge in our understanding of carcinogenesis in the colon it has not yet had any 
impact on the diagnosis or management of patients with sporadic colorectal neoplasia.
Secondly, because prognosis is related to extent of disease at diagnosis, efforts 
to diagnose large bowel cancer at an earlier stage are being made. Numerous studies 
have stressed the potential benefits of screening programmes for secondary prevention 
(Atkin et al 1993; Selby et al 1992) but screening (for example, by faecal occult blood 
testing and/or colonoscopy) remains a controversial issue and in the United Kingdom 
there is as yet no clear policy on screening for individuals at "average" risk, who 
constitute the vast majority of patients.
Alternatively, outlook could be improved by the development of improved or 
novel methods of treatment, especially therapies effective against locally advanced or 
systemic disease which cannot be cured by current surgical techniques or radiotherapy. 
The need for such treatment modalities has been emphasised by August et al (1984) 
who estimated that over fifty percent of deaths are due to disease which is beyond cure 
by primary surgery; the remaining deaths are due to recurrence of disease which was 
initially thought curable by surgery, but which is now beyond the limits of local therapy. 
While trials of adjuvant chemotherapy have demonstrated improvements in recurrence- 
free survival in patients with Dukes' C tumours (Saltz 1991), the benefits have been 
modest and at present chemotherapy seems likely to be restricted to this subgroup of 
patients. Furthermore, other systemic treatments such as biological response modifiers 
and immunotherapy have not fulfilled early promise and are not likely to be of practical 
value in the foreseeable future.
Given the limitations of current treatments for colorectal cancer and the lack of 
a safe, effective and widely applicable systemic therapy, an increasing volume of 
research in the last fifteen years has focused on the possible role of endocrine therapy 
for patients with large bowel and other gastrointestinal cancers. The concept that 
endocrine manipulation may be of therapeutic value in the treatment of a variety of 
malignancies is not new. Following the pioneering work of Beatson last century 
(Beatson 1896), who demonstrated the value of oophorectomy in inoperable breast 
cancer, the role of oestrogens in breast cancer has become established, as has the place
24
of the anti-oestrogen tamoxifen. Similarly prostatic carcinoma patients often benefit 
from treatment with anti-androgens as originally shown by Huggins et al (1941).
An appreciation of the endocrine significance of the gastrointestinal tract only 
developed with the isolation and purification of gastrin, cholecystokinin and secretin in 
the 1960's. Subsequently, a large and increasing number of peptides have been localised 
to cells of the digestive tract and shown to play regulatory roles in gastrointestinal 
function. The significance of many of these recently identified peptides has become 
clearer as a result of greater understanding of paracrine, neurocrine and autocrine 
modes of cell signalling in addition to the traditional endocrine concept of hormone 
action.
A number of gastrointestinal peptides, growth factors and non-gastrointestinal 
hormones are capable of affecting the proliferation and differentiation of epithelial cells 
in various parts of the digestive tract (Johnson 1987; Lemoine et al 1992). Many can 
also modify the growth of colorectal cancer cells, either in vitro or in vivo (Tahara 
1990; Townsend et al 1987), raising the possibility of endocrine manipulation as a novel 
adjuvant treatment in colorectal carcinoma.
The antral hormone gastrin was the first for which trophic properties in the 
gastrointestinal tract were described. Subsequently, the majority of research into 
unravelling the role of hormones in the control of colonic epithelial proliferation, and 
the potential for endocrine manipulation of tumours arising from the colon (and other 
parts of the digestive tract), has concerned gastrin.
The remainder of this introduction will describe firstly the evidence for gastrin 
being an important physiological regulator of growth in the colon. Secondly, studies 
concerning the mitogenic effects of gastrin on colorectal cancer cell growth will be 
presented, along with discussion of the mechanisms of such effects. Thirdly, the state of 
our current knowledge regarding putative gastrin receptors will be reviewed along with 
the effects of newly developed specific gastrin receptor antagonists on the growth of 
colorectal cancer cells in vitro and in vivo. Studies of gastrin in human colorectal 
neoplasia will be described and then the aims of the current thesis presented.
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CHAPTER 2 
THE TROPHIC PROPERTIES OF GASTRIN
26
2.1 In tr o d u c t io n
Before considering the effects of gastrin itself, several general points regarding the 
regulation of gastrointestinal growth deserve mention. Firstly, the epithelium of the 
digestive tract is complex in that it is continuously and rapidly renewing itself. It exists 
in a delicate steady state where cell division is carefully balanced by exfoliation of cells 
into the lumen of the gastrointestinal tract as cells migrate and differentiate along the 
crypt.
Furthermore, division of cells in the gastrointestinal mucosa is restricted to 
distinct and definable regions of the epithelium, namely the crypt base in the colon. 
Division of undifferentiated crypt stem cells (the "vacuolated crypt base stem cell" in 
the colon) is followed by migration and differentiation of non-dividing cells as they pass 
up the length of the crypt, a process thought to take three to four days in the colon 
(Lipkin 1987). The rapid turnover of the epithelium, along with the distinct areas of 
mitosis make the digestive tract mucosa a useful experimental model for the study of 
epithelial growth control in general.
The control of growth in the gastrointestinal tract is, however, multifactorial 
and more complex than that in many other tissues. As well as being regulated by 
gastrointestinal peptides, the epithelium is also influenced by non-gastrointestinal 
hormones such as thyroxine, growth hormone and insulin (Johnson 1987). The mucosa 
is also constantly being exposed to ingested food, with its numerous effects. In addition 
to stimulating the release of various regulatory hormones and peptides, the very 
presence of food in the lumen of the gastrointestinal tract may have a trophic effect 
related to non-absorbed nutrients (luminal nutrition) and/or intestinal workload. A third 
mechanism postulated to play a role in the process is a local negative feedback loop 
from the crypt surface to the crypt base, of which little is known. Finally, neural control 
of colonic proliferation has been suggested (Tutton and Barkla 1982), but although this 
aspect of growth control has been studied in other tissues, relatively little research has 
been conducted in the gastrointestinal tract. Thus, a variety of diverse and interacting 
mechanisms are likely to operate in the normal regulation of colonic epithelial
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proliferation and this has to be borne in mind when studying the influence of one 
particular aspect of the process in isolation. The results of such studies require careful 
interpretation before concluding that a given stimulus is directly responsible for a given 
effect because several other mechanisms may also be operative.
It is also important to consider the wide range of methods used to study 
growth in the digestive tract and the end-points and parameters used to define growth. 
The methods used vary greatly and include crude and insensitive measures such as 
estimates of tissue weight or volume, villous height and crypt depth, to simple and 
potentially inaccurate counts of mitotic figures. Many early studies of the trophic effects 
of gastrin used these methods. Later studies in the 1970's and 1980's utilised total DNA, 
RNA and protein contents to indicate a trophic response and many also measured 
tritiated thymidine uptake by tissues as a marker of DNA synthesis. This latter 
approach, although extensively adopted and still frequently used, has numerous pitfalls 
and may not accurately reflect DNA synthesis (reviewed in Maurer 1981). Studies 
based on this technique therefore have to be interpreted with caution. Furthermore, 
measuring total DNA or RNA content in vivo, or content of any particular substance 
for that matter, usually necessitates whole tissue measurements or, at best, analysis of 
mucosal homogenates. Even the gastrointestinal mucosa has a heterogeneous cell 
composition including significant numbers of non-epithelial cells and this may lead to 
erroneous results if measurements based on tissue homogenates are used. More 
accurate and sensitive methods of analysing cell proliferation in the gastrointestinal tract 
have been developed (Quinn and Wright 1990) and include bromodeoxyuridine 
labelling, immunocytochemical analysis of Ki67 antigen expression, quantification of 
crypt cell production rates in dissected but intact crypts and flow cytometric analysis of 
cell-cycle distributions.
Biochemical and molecular events associated with cell proliferation are 
increasingly being used as end-points in the study of trophic stimuli, for example 
ornithine decarboxylase activity and polyamine synthesis, membrane inositol 
phospholipid turnover and intracellular calcium measurements. All of these techniques 
have advantages and disadvantages in the study of cell turnover and the use of these
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diverse methods of quantifying proliferation makes comparison of results from different 
studies difficult. The wide range of parameters for quantifying growth used by different 
research groups is probably responsible in large part for the failure to date to answer 
conclusively the question of whether gastrin is a trophic factor of physiological 
relevance to the colon.
Diverse experimental approaches and models have been employed in the study 
of gastrin's trophic role and this also compounds the problem of comparing the results 
of different investigators and drawing general conclusions about the hormone's 
importance. Most in vivo studies have been carried out in rats although mice (Balas et 
al 1985), guinea pigs (Hakanson et al 1986, 1988), hamsters (Chu et al 1992) and dogs 
(Willems et al 1972) have also been used. Even within the same species there is 
evidence that gastrointestinal tissues of young and adult rats behave differently in their 
response to gastrin (Poston et al 1991) and thus, the age and maturity of animals under 
study has to be considered when analysing experimental results.
Much experimental work in endocrinology has traditionally involved studying 
the effects of acutely or chronically elevating or lowering the level of the regulatory 
hormone of interest and observing the subsequent effects on tissue structure and 
function. Early studies of gastrin involved exogenous administration of gastrin or its 
synthetic analogue, pentagastrin, by injection (Johnson and Guthrie 1976; Johnson 
1977; Mak and Chang 1976), or by continuous infusion using osmotic minipumps 
(Johnson et al 1975a; Ryberg, 1990). It has been argued that it is necessary to show 
that the endogenous hormone under study can produce the same effects in order to be 
of physiological relevance. Thus, a widely used alternative approach in endocrine 
research has been to remove surgically the source of a hormone, observe the subsequent 
effects and then try to reverse these effects by re-supplying the hormone exogenously. 
While many gastrointestinal peptides are expressed widely throughout the digestive 
tract the vast majority of circulating gastrin emanates from the gastric antrum, an 
anatomically well-defined area in rodents. As a result, many authors have used 
antrectomy to produce chronically low gastrin levels (Oscarson et al 1979; Dembinski 
and Johnson 1979; Chu et al 1992;). In contrast, a range of surgical procedures have
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been successfully utilised to produce variable hypergastrinaemia in experimental 
animals. These include: vagotomy (Oscarson et al, 1979), fundectomy i.e. removal of 
the acid-secreting oxyntic mucosa (Chu et al 1992; Deveney et al 1983; Oscarson et al 
1982) and antral exclusion (Oscarson et al 1979; McGregor et al 1983; Karlin et al 
1985). Although trophic changes observed after such surgical manoeuvres have often 
correlated with parallel changes in gastrin levels, this does not prove a causal 
relationship and major surgical operations such as those mentioned invariably affect 
many aspects of gastrointestinal function, including subsequent food intake and weight 
gain, release of other regulatory peptides, acid-secretory capacity and the composition 
of intestinal flora. All of these factors may influence cell proliferation in the colon, either 
independently or in combination. Interpretation of such studies is therefore not always 
straightforward.
Non-surgical methods have been used to produce both elevated and lowered 
gastrin concentrations. Keeping rats fasted, but maintaining calorie intake and nitrogen 
balance with parenteral nutrition, results in significantly reduced gastrin (Johnson et al 
1975b; Ryan et al 1979) and this model has proved useful for studying the effects of 
hormones without the presence of food in the gastrointestinal lumen. Alternatively, 
pharmacological blockade of the effects of gastrin on target tissues using specific 
gastrin receptor antagonists provides a convenient, non-surgical means of lowering 
'effective' gastrin concentrations. In recent years an increasing number of specific and 
potent gastrin/CCK receptor antagonists have been developed and found applications in 
studying the trophic properties of gastrin on the mucosa of the gastrointestinal tract 
(Johnson and Guthrie 1984; Presti and Gardner 1993; Watson et al 1992).
Marked hypergastrinaemia can also be produced by dosing animals with acid- 
suppressing drugs, such as histamine-receptor antagonists or omeprazole. The powerful 
acid suppression so produced results in considerable and often chronic elevations in 
circulating gastrin (Hakanson et al 1986; Jansen et al 1990).
In summary, a large number of factors contribute to the lack of definitive 
conclusions about the role of gastrin as a physiologically important trophic hormone for 
the colon and other parts of the gastrointestinal tract. The complex control of
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gastrointestinal epithelial proliferation and interspecies variation, along with differences 
in both study design and the choice of endpoints used to define and quantify growth 
have to be borne in mind when interpreting the data available to date.
2.2 E v id e n c e  f o r  t h e  T r o p h ic  P r o p e r t ie s  o f  G a s t r in
2.2.1 Synthesis and Processing of Gastrin
Gastrin, the first gastrointestinal hormone to be discovered, was originally described by 
Edkins (1905) as a gastric acid-stimulating factor present in extracts of antral mucosa. 
It was nearly sixty years, however, before gastrin was purified as a hepadecapeptide by 
Gregory and Tracy (Gregory and Tracy 1964). Although it is now known that small 
amounts of gastrin may be synthesised by a wide variety of cells in diverse tissues 
(discussed more fully in Chapter 7), the vast majority of circulating gastrin originates 
from specialised G cells in the mucosa of the antrum and proximal duodenum. In recent 
years the complex biosynthetic pathway of gastrin has become well documented 
(Rehfeld and Hilsted 1992).
Gastrin is initially synthesised as preprogastrin, 101 amino acids in length. 
From this the signal peptide is enzymatically cleaved to yield progastrin which is then 
subjected to an orderly sequence of proteolytic cleavages (see Figure 2.1). The resulting 
caboxyl-terminal glycine-extended intermediate is then carboxyamidated to give the 
biologically active hormone (reviewed in Rehfeld and Hilsted 1992; Walsh 1993). 
Antral G cells thus release a number of different gastrins, although ninety percent is 
gastrin-17, five percent is gastrin-34 and smaller fragments of uncertain biological 
significance constitute the remainder. The crucial step for biological activity is alpha- 
amidation and the common C-terminal tetrapeptide amide (-Trp-Met-Asp-Phe-NH2) 
has traditionally been regarded as responsible for all of the biological effects of gastrin. 
In 1994, however, several groups presented preliminary evidence that progastrin- 
derived glycine-extended intermediates may possess both trophic (Seva et al 1994a; 
Negre et al 1994) and acid regulatory properties (Kaise et al 1994). This new discovery
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Schematic representation of gastrin processing. Arrows indicate 
binding sites of antigastrin antisera (R98, GP168) used in this study 
(see chapter 11).
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is clearly going to develop further in the near future and is discussed later (Chapter 11). 
While this tetrapeptide sequence is also present in other members of the gastrin peptide 
family (most notably cholecystokinin), gastrin specificity is conferred by a tyrosine 
residue at position six.
2.2.2 Regulation of Gastrin Release
Just as complex as the synthesis of gastrin is the regulation of its release, with 
contributions from luminal, humoral and neural factors (Walsh 1994; Schubert 1993). 
Ingestion of a meal, especially one containing beef protein, is the most important 
stimulant of gastrin release. Peptone and amino acids derived from partial digestion of 
protein are particularly potent (McArthur et al 1988) whereas fat and carbohydrates are 
ineffective. Similarly, gastrin is released when intragastric pH rises above three and 
conversely antral acidification after a meal potently inhibits gastrin release. Vagal 
innervation stimulates gastrin release probably via release of gastrin-releasing peptide 
(GRP) from enteric nerve endings. Vagal reflexes can also inhibit gastrin release, 
although the mechanism of this is unclear. A number of gastrointestinal peptides also 
inhibit gastrin release, by far the most important of which is somatostatin, derived from 
antral D cells and which acts in a paracrine manner on adjacent G cells (Chiba and 
Kinoshita 1993). Although secretin, glucagon, vasoactive intestinal polypeptide and 
cholecystokinin can also inhibit gastrin release, their effects may be indirect via 
stimulation of somatostatin release and their physiological importance is uncertain.
2.2.3 Trophic Effects of Gastrin on the Stomach
(i) Historical
While the central importance of gastrin in gastric acid stimulation has long been 
acknowledged its putative role as a physiological trophic hormone for parts of the 
gastrointestinal tract mucosa has only become appreciated in the last twenty years or so. 
Initial clues to the mitogenic properties of gastrin came from clinical observations of the 
gastric mucosa in disease states which alter endogenous gastrin levels. Patients with
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Zollinger-Ellison syndrome resulting from a gastrin-secreting endocrine tumour of the 
digestive tract have long been known to have thickened gastric rugae, gastric mucosal 
hyperplasia and an increased parietal cell mass (Ellison and Wilson 1967). Conversely, 
gastric biopsies in patients with a previous antrectomy show mucosal atrophy (Lees and 
Grandjean 1968) and these findings stimulated laboratory research into the growth 
properties of gastrin.
(ii) Experimental evidence
The first experimental work supporting the above findings came simultaneously from 
Crean et al in Edinburgh and Johnson et al in Texas in 1969. While studying the effects 
of pentagastrin injections on the gastric mucosa of rats Crean et al (1969) observed 
increased oxyntic mucosal height, weight and volume along with an increased parietal 
cell mass following treatment with the hormone. At the same time exogenous doses of 
pentagastrin which were submaximal for acid secretion were found to stimulate gastric 
mucosal protein synthesis as measured by [14C]leucine incorporation into protein 
(Johnson et al 1969). Furthermore, this was independent of acid secretion as histamine 
was without effect and was also tissue-specific as no effect on either liver or skeletal 
muscle was observed.
Since these initial studies evidence for a physiologically important trophic role 
for gastrin in the stomach has steadily accumulated. Using in vitro tritiated thymidine 
uptake, pentagastrin was shown to stimulate DNA synthesis in the rat stomach by 275% 
(Johnson and Guthrie 1974), with significant uptake occurring after eight hours and 
reaching a maximum at sixteen hours. Because pentagastrin is a synthetic gastrin 
analogue which may also interact with cholecystokinin receptors, the same authors 
repeated their studies, showing that both G-17 and G-34 were of similar efficacy as 
pentagastrin. Both peptides doubled oxyntic mucosal DNA synthesis and were 
considerably more potent than pentagastrin on a molar basis. The presence or absence 
of sulphation appeared to make no difference to the effect (Johnson and Guthrie 1976; 
Johnson 1977). To counter criticisms that the doses of pentagastrin used were 
pharmacological (i.e. supranormal), they showed that doses less than half-maximal
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(D5q) for gastric acid secretion were also trophic (Johnson et al 1975). Rats deprived of 
any oral dietary intake, but parenterally fed to maintain positive nitrogen balance, 
growth and weight gain, develop reduced mucosal weight and height in the oxyntic area 
of the stomach and elsewhere in the gastrointestinal tract (Johnson et al 1975). Such 
atrophy occurs in association with greatly reduced serum gastrin and antral gastrin 
content, the latter being thirty-fold lower compared to control animals (Johnson et al
1975). Of more relevance, coadministration of pentagastrin prevented these structural 
changes providing further evidence for a physiological trophic role for gastrin. From 
these experiments it seems that the presence of food in the gut lumen is necessary for 
the maintenance of both mucosal structure and antral gastrin stores. Similar effects of 
fasting on oxyntic gland weight, protein and DNA content and in vivo [3H]thymidine 
incorporation, in association with a 90% decrease in serum gastrin, have been shown 
(Solomon, 1986). Again even the lowest dose of pentagastrin studied (which stimulated 
peak gastric acid output) was able to reverse some of these changes.
In other studies the physiological relevance of gastrin for the oxyntic mucosa 
has been examined by observing the effects of antrectomy on the trophic state of the 
mucosa. In the study of Dembinski and Johnson (1979), antrectomy lowered serum 
gastrin concentrations to around one third of control values. Similarly oxyntic gland 
DNA and RNA contents were reduced by 45% and 35%, respectively. Pentagastrin, at 
a dose of 250pg.kg'1 four times daily, completely prevented such changes. Others have 
also found antrectomy to result in reduced gastric mucosal weight and height (Oscarson 
et al 1979) and content of nucleic acids (Dembinski et al 1987). As measured by in vivo 
[3H]thymidine uptake, the labelling index in mice was increased after twelve days of G- 
17 injections (300pg.kg_1), as were the number and diameter of parietal cells (Balas et 
al 1985). Interestingly cholecystokinin had no such effects but, in contrast to gastrin, it 
increased both the number of gastric chief cells and their total pepsin content. The 
effects of gastrin on the oxyntic mucosa occur not only in response to short-term 
studies involving intermittent injections of the hormone but are also seen following 
continuous infusions (Lehy et al 1979; Ryberg et al 1990). In the study of Ryberg et al, 
female Sprague-Dawley rats received a subcutaneous infusion of human G-17
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continuously for twenty-eight days. Circulating gastrin levels were raised by a mean of 
130% (range 50-285%), resulting in a 25% increase in oxyntic mucosal height relative 
to control animals.
(iii) Kinetics of the trophic response to gastrin
The time course of these trophic effects of gastrin has also been examined. Following a 
single intraperitoneal injection of pentagastrin (250pg.kg_1), significant increases in rat 
oxyntic mucosal messenger RNA content were seen within one to two hours and 
remained elevated for up to twelve hours. Protein synthesis, as detected by 
[14C]labelled amino acid uptake began within four hours, became significant by six 
hours (> 300% of control) and remained elevated for twelve to eighteen hours (Enochs 
and Johnson 1977). The same authors had previously shown maximal DNA synthesis to 
occur around sixteen hours after injection of pentagastrin (Johnson and Guthrie 1974). 
Others observed increases in mouse gastric labelling index at four hours and small 
intestinal increases at eight hours after gastrin treatment (Balas et al 1985).
(iv) Gastrin and enterochromaffinlike (ECL) cells
Gastrin exerts trophic effects not only on parietal cells but also has important effects on 
enterochromaffinlike (ECL) cells, the predominant endocrine cell in the oxyntic mucosa. 
These cells produce and store histamine along with other as yet unidentified peptides. 
Sustained hypergastrinaemia induced either by continuous infusions of gastrin (Ryberg 
et al 1990) or by chronic treatment with inhibitors of acid secretion such as ranitidine 
(Havu et al 1990) or omeprazole (Havu 1986; Ekman et al 1985), results in ECL cell 
hyperplasia with continued treatment. ECL carcinoid tumours develop in the stomachs 
of treated animals, although these changes can be prevented by prior antrectomy 
(Larsson et al, 1988). ECL cell hyperplasia and carcinoid tumour formation are also 
seen in patients with chronic hypergastrinaemia secondary to atrophic gastritis and/or 
pernicious anaemia (reviewed in Freston 1992). The role of gastrin in stimulating 
proliferation of ECL cells has been reviewed recently (Hakanson and Sundler 1991; 
Berlin 1991).
35
The notable effects of gastrin on ECL cells came to light during the 
development and testing of potent antisecretagogues such as ranitidine and omeprazole, 
widely prescribed drugs used in the management of peptic ulcer disease and other acid- 
related disorders. The endogenous hypergastrinaemia consequent upon administration 
of these drugs to experimental animals not only stimulates ECL cell proliferation but is 
also trophic to the oxyntic mucosa in general. Chronic omeprazole treatment has been 
shown to increase the numbers of parietal, chief and mucous cells in rat gastric glands 
by 25-30% (Hakanson et al 1986) while increases in oxyntic mucosal height and 
thickness are seen to occur in rats (Sundler et al 1986) and other species including 
chickens, hamsters and guinea-pigs (Hakanson et al 1988).There have, however, been 
fewer studies in humans with acid-suppressing drugs.
Changes in ECL cells after omeprazole therapy have been reviewed recently 
(Freston 1992) and no consistent pattern has been observed. There appears to be 
marked inter-individual variation in the ECL cell response to these drugs with no 
significant increase in the majority of patients. Little if anything is known about the 
trophic effects of acid-suppressing agents on the remainder of the oxyntic mucosa. The 
widespread use of these drugs, with around 1.7 million prescriptions per year in 
Scotland alone (Dr. P. Rutledge, Medical Prescribing Adviser, Lothian Health Board - 
personal communication) and the documented experimental effects of gastrin on gastric 
mucosal growth, gives study of the trophic effects of gastrin direct clinical relevance.
(V) Effects on gastric antrum
While the vast majority of experimental studies support a physiologically important 
trophic effect of gastrin on the mucosa of the oxyntic area of the stomach, they also 
demonstrate a complete lack of effect on the antral mucosa. Johnson (1977) found that 
intraperitoneal injections of pentagastrin (250pg.kg_1) had no effect on antral mucosal 
[3H]thymidine incorporation, while at the same time stimulating oxyntic mucosal uptake 
by 150% compared to control rats. Others have corroborated these findings (Balas et al
1985) and in the study of Casteleyn et al, gastrin actually reduced the labelling index in 
rat antrum despite being stimulatory to the oxyntic mucosa (Casteleyn et al 1977).
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Although Lehy et al (1979) found gastrin to be equally effective at stimulating [3H] 
thymidine uptake in both glandular and antral portions of the rat stomach, the weight of 
evidence would suggest that the antrum is not regulated trophically by gastrin. As 
Johnson has pointed out (Johnson 1987), this is perhaps not surprising given the 
neuroendocrine function of the antrum. As a rule endocrine organs such as thyroid, 
adrenals and gonads, do not respond trophically to the hormones that they themselves 
produce but are under the control of hormones originating elsewhere.
(vi) Studies using gastrin/CCK-B receptor antagonists
In recent years an increasing number of receptor antagonists for gastrointestinal 
peptides have become available as powerful tools with which to study many aspects of 
gastrointestinal function. At least eight classes of antagonists for the gastrin/CCK-B 
receptor have been described (Presti and Gardner 1993) and have been used mainly to 
classify receptor subtypes and study second messenger systems. To date their use in 
studies of gastrointestinal growth has concentrated mostly on their effects on the 
growth of malignant cells and not on normal epithelium (Watson et al 1991a; 1992). 
One of the first of these antagonists to be described was proglumide ((±)-4- 
(benzoylamino)-5-(dipropylamino)-5-oxopentanoic acid), a derivative of glutaramic 
acid. Although it has a relatively low affinity for the gastrin/CCK-B receptor it has been 
shown to inhibit pentagastrin-stimulated increases in DNA, RNA and protein content in 
rat oxyntic mucosa as well as the rate of DNA synthesis (Johnson and Guthrie 1984). It 
is notable that proglumide on its own had no effects on these parameters. The results of 
similar studies using newer and more powerful antagonists are still awaited. The effects 
of gastrin/CCK-B receptor antagonists on the growth of gastrointestinal tumour cells 
are discussed more fully later (Chapter 5).
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2.2.4 Trophic Effects of Gastrin on Small Intestine
Whether gastrin is a physiologically relevant trophic hormone for parts of the 
gastrointestinal tract outwith the stomach is unclear, although many studies have 
addressed this issue and much has been published, virtually all of it using rodents as 
experimental models.
In addition to its lack of trophic effects on antral mucosa, the hormone does 
not appear to influence the growth of oesophageal epithelium (Mak and Chang 1976; 
Johnson 1977). Opinion is divided about possible growth-stimulatory effects in the 
small intestine and much of the conflicting data results from the widely differing 
methodologies used by different groups.
Some have used pooled mucosal samples from the entire length of the small 
intestine (Johnson et al 1975; Solomon 1986), while others have looked separately at 
duodenum, jejunum and ileum (Fatemi et al 1984; Balas et al 1985; Hakanson et al
1986). As discussed above, a variety of morphological, biochemical and kinetic 
techniques have been used to quantify trophic responses and this is likely to contribute 
to the uncertainty. In many studies the epithelium of the proximal duodenum has 
responded to gastrin in a manner similar to the oxyntic mucosa (Lehy et al 1979; Balas 
et al 1985; Johnson and Guthrie 1976; Johnson 1977) although these findings have not 
been unanimous (Fatemi et al 1984; Hakanson et al 1986; Ryberg et al 1990). 
Similarly, observed effects of gastrin on jejunal and ileal mucosae have been variable. 
Early studies by Johnson and co-workers (Johnson and Guthrie 1974; Johnson et al 
1981) and others (Lehy et al 1979; Balas et al 1985) demonstrated trophism in jejunum 
and ileum but others have been unable to substantiate such findings (Oscarson et al 
1977; Hakanson et al 1986; Ryberg et al 1990). Again choice of animal models and 
methods of quantifying growth are likely to have contributed to the disparity. The 
regulation of small bowel growth has been reviewed elsewhere (Johnson 1987; 
Vanderhoof 1993) and it is evident that, while gastrin is likely to be the major peptide 
regulating gastric mucosal growth, it is only one of a number of peptides capable of
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stimulating cell renewal in the small bowel. Indeed it may well be of only secondary 
importance at this site.
2.2.5 Effects on the Exocrine Pancreas
Exogenous gastrin-17 or pentagastrin, as well as endogenous hypergastrinaemia 
induced by surgical procedures, have been shown to be trophic to the exocrine pancreas 
in animal models of pancreatic growth. Antrectomy resulted in reduced pancreatic 
weight, DNA synthesis and contents of DNA and RNA in rats and these changes were 
completely prevented by concomitant injections of pentagastrin (Dembinski and 
Johnson 1979). In contrast resection of the acid-secreting oxyntic mucosa (fimdectomy) 
with consequent hypergastrinaemia significantly increases pancreatic weight and DNA 
content, as well as the proportion of cells in the DNA synthetic phase (S-phase) of the 
cell cycle (Chu et al 1993). Others have observed increases in exocrine pancreatic 
labelling index (Balas et al 1985) and DNA content (Poston et al 1991) after injections 
of exogenous gastrin-17 or pentagastrin.
A number of other peptides, most notably cholecystokinin, are also trophic to 
the exocrine pancreas (Solomon 1990; Mangino et al, 1992). Current evidence suggests 
that the stimulatory effects of gastrin on pancreatic growth are probably minor and of 
secondary importance in comparison to those of cholecystokinin. Experimental models 
of pancreatic growth and neoplasia and the contributions played by gastrin and 
cholecystokinin have recently been reviewed (Watanapa and Williamson 1993).
2.2.6. Trophic Effects of Gastrin on the Colon
(i) Effects of fasting and re-feeding
Once trophic properties of gastrin on the gastric mucosa of animals had been described, 
investigators began to examine the remainder of the gastrointestinal epithelium for 
evidence of gastrin-responsiveness and it was not long before effects on the colon were 
observed. In 1976 Mak and Chang found that a single injection of pentagastrin 
(250pg.kg_1) in rats led to a five-fold increase in the labelling index of colonic crypts as
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measured by autoradiography after in vivo [3H]thymidine-labelling (Mak and Chang
1976). The labelling index was increased at all levels in the lower two-thirds of the 
crypts, the authors concluding that the hormone affected mainly the zone of 
proliferation-differentiation in the mid-crypt but not the fully differentiated cells at the 
top of the crypt. Interestingly, the stimulatory effects of pentagastrin were seen in fasted 
rats but not in their freely-fed counterparts. Fasting reduced the labelling index greatly 
and pentagastrin returned it to levels seen in freely-fed rats, the authors suggesting that 
in freely-fed rats circulating gastrin levels were sufficient for the maintenance of cell 
renewal with no further responsiveness to exogenous pentagastrin.
As noted above, fasting results in reduced cell proliferation and mucosal 
atrophy in the stomach and elsewhere in the gastrointestinal tract, even if adequate 
parenteral nutrition is given (Johnson et al 1975; Morin et al 1980). Refeeding results in 
a return of the proliferative parameters to their original level and while the local effects 
of food entering the colon may play a part ("luminal nutrition"), Delvaux et al showed 
that the response is seen in segments of colon defunctioned by a diverting colostomy 
(Delvaux et al 1984). Thus, an important humoral component is probable and gastrin 
has been suggested as a likely candidate as antral and serum gastrin are dramatically 
reduced by fasting, the effects of which can be reversed by exogenously supplying the 
hormone (Mak and Chang 1976; Majumdar 1984). To test this the same group 
examined the effects of fasting and re-feeding on [3H]thymidine uptake in the 
defunctioned colon of rats with or without prior antrectomy (Haentjens et al 1986). 
Antrectomy abolished the post-prandial rise in serum gastrin and yet re-feeding still 
resulted in increased DNA synthesis in the defunctioned colon, suggesting that gastrin is 
either not the humoral mediator or only one of several released postprandially and 
capable of stimulating colonic mucosal proliferation. In support of this, Goodlad et al 
found no significant correlation between plasma gastrin levels after re-feeding and crypt 
cell production rate in the colon (Goodlad et al 1983).
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(ii) Effects of antrectomy
A number of studies have examined the effect of removing the endogenous source of 
gastrin by antrectomy. Dembinski et al subjected rats to either antrectomy or sham 
operation and treated half the antrectomised animals with pentagastrin (250pg.kg_1 
eight hourly) for one week after recovery from surgery (Dembinski and Johnson 1979). 
Compared to sham-operated controls antrectomy reduced serum gastrin by 62% and 
colonic weights in these animals were also approximately 15% lower. DNA synthesis 
(in vitro [3H]thymidine uptake) in colonic mucosal scrapings was only 59% of that in 
controls and similar reductions in total RNA and DNA contents were also observed. In 
addition, the changes in all these parameters were completely prevented by pentagastrin 
treatment.
In a study using small numbers of hamsters (n=8 per group), Chu et al found 
that antrectomy lowered fasting plasma gastrin by 50% both five and twenty-five days 
after the procedure (Chu et al 1992). Using autoradiography and quantitative 
histological analysis of the colonic mucosa, colonic mucosal [3H]thymidine uptake was 
significantly reduced at day five compared to sham-operated control animals, and the 
number and percentage of goblet cells per crypt were lower by day twenty-five.
Other authors have been unable to confirm these findings. In one study 
antrectomy (with proximal duodenectomy) did not result in a fall in colonic weight, 
DNA synthesis or content of nucleic acids (McGregor et al 1983). In this study, 
however, serum gastrin did not fall after antrectomy for reasons which the authors 
could not explain. It is impossible to negate a role for gastrin from these results. 
Likewise, Deveney et al (1983) found that antrectomy lowered post-prandial gastrin 
levels but had no effect on fasting gastrin. Again antrectomy affected neither colonic 
weight nor mucosal thickness at three months postoperatively, although the parameters 
measured are relatively crude and insensitive markers of proliferative status. Thus, 
definite conclusions about the effect of removing endogenous gastrin on the trophic 
state of the colon are difficult to draw because of methodological differences in these 
studies.
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(iii) Effects of surgically-induced endogenous hypergastrinaemia 
The effects of surgically-produced chronic endogenous hypergastrinaemia on the colon 
have also been assessed. A variety of surgical procedures have been used to induce 
hypergastrinaemia, all of them by interfering with acid-mediated inhibition of antral 
gastrin release.
In 1976 MacGregor and Way reported that antral implantation into the colon, 
which raised fasting gastrin five-fold and postprandial levels three-fold, resulted in a 
small but significant increase in colonic weight (McGregor and Way 1976). 
Furthermore, antral implantation with similar elevations of gastrin concentrations, 
increased transverse colonic weight by 27% and mucosal thickness after twelve weeks 
(Deveney et al 1983). These changes also occurred in rats with both antral implantation 
and total gastrectomy and were therefore independent of the presence of acid.
Antral exclusion, consisting of gastric partition across the antrum and 
gastrojejunostomy, diverts the gastric contents past the antrum and also causes chronic 
hypergastrinaemia. In this way serum gastrin was elevated four-fold compared to sham- 
operated control rats, in association with a two-fold increase in DNA and RNA content 
of colonic mucosa (McGregor et al 1983). Rates of synthesis of DNA (in vivo 
[3H]thymidine uptake) and RNA (in vivo [14C] uptake) were increased two and-a-half 
and four-fold, respectively).
Other authors have produced endogenous hypergastrinaemia by fiindectomy 
with removal of the entire oxyntic gland area of the stomach. In an early study Oscarson 
et al (1979) used various surgical procedures, including fiindectomy, to elevate 
endogenous gastrin levels. Despite mean gastrin levels being three and-a-half times 
those in unoperated controls, only minor non-significant increases in large bowel 
mucosal weight, DNA and RNA content were seen. Beauchamp et al reported in an 
abstract that fiindectomy resulted in a 21% increase in total colonic weight after two to 
six weeks (Beauchamp et al 1985a). This effect was no longer apparent in rats followed 
for five to seven months and no significant increase in colonic DNA, RNA or protein 
content was observed at either time point. Unfortunately the whole colon was used for
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analysis, including submucosa and muscle layers, so significant effects on the epithelium 
alone could have been missed for technical reasons. More recently Chu et al subjected 
hamsters to either antrectomy, fiindectomy or sham operation. In addition to the effects 
of antrectomy discussed above (Chu et al 1992), fiindectomy raised basal plasma 
gastrin four-fold compared to controls and doubled DNA synthesis by day five. By day 
twenty-five, rates of DNA synthesis were similar to control animals but there were 
significant increases in crypt size (30%), number of goblet cells per crypt (46%) and the 
percentage of goblet cells per crypt (13%). Although surgical manipulations such as 
those described above are likely to have a variety of effects and alter levels of other 
hormones and growth factors, it is likely that chronic endogenous hypergastrinaemia 
does indeed stimulate colonic hyperplasia in animals. Furthermore, the fact that these 
changes occur at gastrin levels similar to those seen postprandially argues in favour of 
the trophic response being physiological rather than a pharmacological phenomenon.
(iv) Effects of exogenous gastrin
Shortly after Mak and Chang reported the trophic effect of pentagastrin on the colon 
(Mak and Chang 1976), Johnson compared different doses of pentagastrin and found 
that DNA synthesis (in vitro [3H]thymidine uptake) in colonic mucosal scrapings was 
significantly stimulated even at the lowest dose tested (62.5pg.kg-1), a dose which is 
submaximal for gastric acid secretion (Johnson 1977). Maximum label incorporation 
(150% compared to control) occurred at 250pg.kg-1 and increasing the dose further 
was significantly less effective. The author also noted that for each dose greater 
stimulation occurred in the colon than in the duodenum. Intriguingly, the same group 
have also shown that a continuous infusion of gastrin-17 into the ileal lumen resulted in 
a doubling of colonic DNA synthetic rate even though no rise in circulating gastrin was 
seen (Johnson et al 1981).
Fatemi et al (1984) compared the effects of intermittent injections of either 
pentagastrin or a single injection of porcine gastrin on colonic mucosal proliferation. In 
this detailed study two different strains of rats (Lewis and Wistar) were compared, a 
range of different doses were used and triplicate samples of fifty individually dissected
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crypts were analysed for DNA synthesis ([3H]thymidine uptake in vivo) and protein 
synthesis ([14C]leucine incorporation in vivo). While pentagastrin at supraphysiological 
doses (lOOOpg.kg-1) was trophic, gastrin was trophic at all doses (KMOpg.kg-1) tested. 
Regression analysis suggested a significant quadrantic relationship between gastrin dose 
and the number of crypts per colon.
These growth-stimulating effects of gastrin on the colon have, in one study, 
been prevented by the relatively weak gastrin/CCK-B receptor antagonist proglumide 
(Johnson and Guthrie 1984). While pentagastrin injections doubled the rate of mucosal 
DNA synthesis, proglumide completely abolished this response in the same dose range 
as that required to inhibit the binding of gastrin to its receptor. Similar studies using 
newer antagonists with greater specificity and higher affinity for the gastrin/CCK-B 
receptor are awaited and will hopefully shed further light on the trophic role of gastrin 
on the colon.
Like the studies described above using surgical models of altered gastrin levels, 
experimental work using exogenous gastrin have not produced unanimous results. 
Solomon (1986) injected rats with a range of doses of pentagastrin and measured 
gastric acid output to establish the doses which stimulated maximal acid output. Using 
doses maximal and supramaximal for acid secretion, no effect on colonic weight, 
content of protein or DNA, nor [3H]thymidine uptake was seen. More recently Ryberg 
et al studied the trophic effects of continuous intravenous gastrin infusions for twenty- 
eight days on proliferation on all parts of the digestive mucosa (Ryberg et al 1990). 
While two to four-fold mean rises in circulating gastrin levels were achieved, no 
increases in either colonic mucosal wet weight or thickness were observed. 
Unfortunately, more sensitive and subtle indices of trophism, such as DNA synthesis, 
labelling index or crypt cell production rate, were not studied. In a recent abstract with 
few details, neither gastrin nor pentagastrin by continuous infusion for one week was 
found to be trophic to rat colon even though effects on gastric fundus were observed 
(Ekundayo et al 1993).
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(v) Effects of drug-induced endogenous hypergastrinaemia
The effects of omeprazole-induced hypergastrinaemia on colonic mucosal growth have 
also been examined. In 1991 Pawlikowski et al (1991) treated rats with omeprazole 
with an approximate two-fold rise in gastrin levels. Compared to control rats the 
colonic mitotic index (vincristine-arrested metaphases) in omeprazole-treated rats was 
doubled. Also, the weak gastrin receptor antagonist proglumide prevented the effects of 
omeprazole. It should be noted that proglumide on its own seemed to stimulate mitotic 
activity, possibly because it possesses weak intrinsic agonist activity in addition to its 
antagonist properties. In another study, thirty days of omeprazole treatment elevated 
gastrin levels twelve-fold, with an associated increase in colonic polyamine content 
(74%) and a small but statistically significant increase (7%) in crypt cell production rate 
(Gray et al 1993). In contrast, Hakanson et al were unable to demonstrate any effect of 
omeprazole-induced hypergastrinaemia on colonic wet weight or mucosal thickness in 
either rats (Hakanson et al 1986), hamsters or chickens (Hakanson et al 1988).
Very recently, the effects of this widely used drug on human colonic 
proliferation have been examined. In a small study of eight patients taking omeprazole 
for treatment of Barrett's oesophagus, omeprazole increased both in vitro 
[3H]thymidine uptake in colonic biopsies and ornithine decarboxylase activity, although 
the increases did not reach statistical significance (Murphy et al 1993). The authors 
concluded that omeprazole-induced hypergastrinaemia did not increase colonic mucosal 
proliferation, although there was considerable inter-individual variation in the rise in 
gastrin resulting from treatment. Patient numbers were also very small (thus, a type 2 
error cannot be excluded) and the methodology used can be prone to inaccuracies.
Despite the considerable volume of reported work, no clear consensus 
regarding a physiological role for the hormone in the colon has been reached. 
Nevertheless, many investigators have examined the effects of gastrin on colorectal 
cancer cells. The following chapters review this work, both animal studies and in vitro 
cell culture studies.
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CHAPTER 3
TROPHIC EFFECTS OF GASTRIN ON COLORECTAL 
CANCER CELLS IN  VITRO
3.1 G a s t r i n  a n d  C o l o r e c t a l  C a n c e r  C e l l s  In  Vit r o
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The use of in vitro cell culture systems provides a powerful method for studying in a 
carefully controlled environment the cellular, biochemical and genetic mechanisms 
involved in regulating cell growth. It is only relatively recently that techniques became 
available to grow normal gastrointestinal epithelial cells in pure populations without the 
problems of fibroblastic overgrowth and short survival of the cultured cells (Moyer 
1983; Moyer etal 1990).
The earliest report was that of Aspegren et al in 1977 who studied in vitro 
[3H]thymidine uptake into freshly disaggregated gastric carcinomas in response to 
pentagastrin. In this study (Aspegren et al 1977) they also examined two fresh human 
colonic carcinomas although few details are given regarding the tumour characteristics, 
assay methodology or whether the cells were passaged or not prior to use. While 
gastrin stimulated [3H]thymidine uptake in three of five gastric cancers, no effect on the 
two colonic cancers was observed. A few years later Murakami and Masui (1980) 
managed to establish the growth of a human colon cancer (HC84S), normally 
transplanted serially in nude mice, in cell culture using a hormone-supplemented, serum- 
free medium. They then studied the trophic effects of a large number of diverse 
hormones and noted that gastrin at a concentration of 50pM stimulated growth of the 
cells compared to control cells. The response to gastrin (14% increase) was small 
relative to the effects of insulin (134%) and glucagon (57%) but nevertheless the 
hormone dependence of colonic cancer cells in vitro had been demonstrated. The first 
major study of the effects of gastrin on human colonic cancer cells in vitro was that of 
Sirinek et al (1985) who found that pentagastrin at a dose of 5pg.ml_1 stimulated a 29% 
increase in cell numbers compared to control cells using the established human colonic 
carcinoma cell line HT-29. This increase above and beyond that seen in untreated 
control cells over the same period (310%) was small, however, and did not reach 
statistical significance. In the same study they also looked at four newly established 
cultures from human colonic carcinomas along with five normal human colonic 
epithelial cell cultures. In contrast to the HT-29 cells these cultures were "early
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passage" and pentagastrin (5pg.ini'1) increased both normal and malignant cell numbers 
compared to controls by means of 65% and 59%, respectively. In support of this 
Watson et al (1989a) found that two freshly established human colorectal cancers 
responded trophically to 250pg.L_1 pentagastrin at passage two (with a two-fold 
increase in [75Se]selenomethionine uptake). In contrast, none of seven established 
colorectal cell lines, including HT-29, exhibited a trophic response to pentagastrin in 
doses ranging from 1.5-1500pg.L_1. Suspension cultures of clumps of three freshly 
disaggregated human colonic carcinomas also showed a significant trophic response to 
pentagastrin compared to control cultures. The authors concluded that trophic 
responses to gastrin are lost during in vitro culture and that gastrin responsiveness may 
not be seen if only long-established cell lines are studied.
In the last ten to fifteen years a considerable number of studies have examined 
the trophic effects of gastrin on colorectal cancer cells in vitro with conflicting results 
and these are summarised at the end of this chapter in Table 3.1. Some authors have 
found gastrin responsiveness in some cell lines but not others while a given cell line has 
responded differently to gastrin in different studies. Many factors, including the duration 
of culture and number of passages of a given cell line, are likely to contribute to these 
conflicting results. In addition to methodological differences such as choice of culture 
media, incubation conditions, addition of varying supplements to media and parameters 
used to measure proliferation, several other important observations are worth 
highlighting. Firstly, several authors have demonstrated the importance of 
"synchronising" cells in culture prior to studying the trophic effects of gastrin and other 
exogenous factors (Kusyk et al 1986; Watson et al 1988, 1989a; Guo et al 1990). 
Synchronisation refers to the exposure of cells to excess thymidine prior to study, with 
the result that all cells are held at the Gj phase of the cell cycle. Removal of the 
thymidine prior to addition of the trophic factor(s) under investigation releases the cells 
from growth-arrest. In one study asynchronous LoVo cells showed an inconsistent 
response to gastrin which varied from stimulation to actual inhibition of growth in 
different experiments (Kusyk et al 1986). When the cells were synchronised, however, 
reproducible and pronounced trophic effects were observed as measured by both
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[3H]thymidine uptake and counts of cell numbers. Furthermore, gastrin was effective 
even at a concentration as low as 1.8 x 10"10M, similar to the upper level seen 
postprandially in humans and this dose increased cell numbers by 44% at forty-eight 
hours relative to control cells. Similarly Guo et al (1990) found that gastrin had no 
effect on either total cell number or [3H]thymidine uptake by mouse colon cancer (MC- 
26) cells but was significantly trophic in doses ranging from 1-25 x 10'9M when the 
cultures were synchronised. In contrast Watson et al (1988) found that neither LoVo 
nor ST 16 cells responded to gastrin irrespective of whether they were synchronised or 
not. These were long-established cell lines and as the authors pointed out, gastrin 
responsiveness may have been lost for this reason. Thus, several studies have 
highlighted the importance of cell synchronisation in allowing the trophic effects of 
exogenous compounds such as gastrin to be revealed when they would otherwise not 
have been seen. Results of studies using asynchronous cells therefore have to be 
interpreted in this light.
A second important point is the effect of serum supplementation on the 
growth-stimulating properties of gastrin. In addition to highlighting the importance of 
synchronisation, Kusyk etal (1986) observed that cells were more responsive to gastrin 
in the presence of 10% foetal bovine serum (FBS), with maximal [3H]thymidine uptake 
(220%) occurring at a dose of 7.2 x 10"10 M. While cells grown in the absence of serum 
had a similar maximal [3H]thymidine uptake (200%), this required a gastrin dose of 3.6 
x 10"9 M i.e. five-fold higher, leading the authors to suggest that serum either contained 
a factor which enhanced the action of gastrin or upregulated the gastrin receptors 
present on the cells. In another study neither gastrin nor 17P-oestradiol stimulated the 
growth of LoVo or HCT-15 human colorectal cancer cells initially when grown in 
ordinary 10% serum-supplemented medium (Kiss et al 1991). When these "hormone- 
insensitive" cells were repeatedly passaged in medium containing only 1% serum but 
also containing gastrin, responsiveness to further added exogenous gastrin was 
restored. In stark contrast to the findings of Kusyk et al noted above, Guo et al (1990) 
observed that synchronised mouse colon cancer (MC-26) cells showed a trophic 
response to gastrin only in the complete absence of foetal bovine serum. Thus, the
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effects of serum on cellular responses to gastrin appear to be complex, possibly partly 
due to the complex composition of serum itself, the different animal sources used in its 
manufacture and the well-recognised variations noted in different batches of serum from 
the same source. That serum should modulate the effects of gastrin is not surprising 
given the possible requirements of hormones for receptor-binding and stimulation and 
the vast number of other hormones, peptides and co-factors present in serum. 
Colorectal cancer cells contain a diverse array of peptide and steroid hormone receptors 
(Frucht et al 1992; Alford et al 1979; Singh et al 1993b). Few studies have specifically 
addressed the possible synergistic or co-operative actions of other hormones on the 
trophic effects of gastrin but in one study gastrin and transforming growth factor-alpha 
(TGF-a) had additive growth stimulatory effects on one of three human colorectal 
carcinoma cell lines (Durrant et al 1991). Synergistic effects were also observed on a 
human gastric carcinoma cell line (MKN45) in the same study.
Finally it should be noted that, while many studies used synthetic human G-17 
to stimulate growth of cells, a considerable number actually used pentagastrin 
(Aspegren et al 1977; Sirinek et al 1985; Tanaka et al 1986; Eggstein et al 1991). 
While the biological activity of gastrin is thought to reside in the C-terminal 
tetrapeptide, receptor affinity is influenced by the tertiary structure of the whole 
molecule. Indeed pentagastrin has a lower binding-affinity than G-17 for gastrin 
receptors (Takeuchi et al 1979) and is far less potent at stimulating DNA synthesis, at 
least in rat gastric mucosa (Takeuchi et al 1980). Also, Mauss et al (1994) found that 
G-17 at concentrations of 10'9-10'12M significantly increased HT-29 cell numbers 
whereas pentagastrin at concentrations ranging from 5 x 10'16 - 5 x 10"5M had no 
effect. Thus, the results of some studies using pentagastrin alone could conceivably 
have been different if G-17 had been used. Gastrin has also been extensively studied in 
vitro as a potential proliferative hormone for gastric and pancreatic carcinomas 
(reviewed in Tahara 1990; Townsend Jr et al 1988; Morris et al 1989). It may also be a 
growth factor for small cell lung cancer cells (Sethi and Rozengurt 1992; Yoder and 
Moody et al 1987). Further discussion of the growth-stimulating effects of gastrin in 
these cancers is beyond the scope of this thesis.
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In summary, a wealth of data dealing with the growth-stimulating effects of 
gastrin on colorectal cancer cells in vitro has accumulated in recent years. While overall 
the results of such studies suggest that gastrin is capable of acting as a trophic factor for 
some colorectal tumours under certain conditions, this is not universally the case. Also, 
the physiological relevance of these findings has not been convincingly demonstrated 
and at present it cannot be concluded from in vitro studies that gastrin is an important 
trophic factor of clinical relevance in colorectal cancer. The next chapter reviews 
evidence regarding the trophic effects of gastrin on colorectal tumours in vivo using 
animal models.
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CHAPTER 4
TROPHIC EFFECTS OF GASTRIN IN ANIMAL MODELS 
OF COLORECTAL NEOPLASIA
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4.1 In t r o d u c t io n
The use of in vitro culture methods allows us to study pure populations of cancer cells 
in isolation and under rigidly controlled conditions. Such techniques inevitably have 
drawbacks and inherent limitations, being especially open to the criticism that cancer 
cells in vitro may be unrepresentative of their counterparts in vivo and may behave 
differently in vitro. Tumours in vivo also have heterogeneous cell compositions and 
interact with their host in many complex ways which cannot be studied (or controlled 
for) in vitro. These drawbacks of cell culture methods along with the practical problems 
and ethical constraints of human studies have resulted in much effort being expended in 
recent years into developing suitable animal models of colorectal cancer. Although 
hampered by the rarity of spontaneously occurring adenocarcinoma of the colon in 
animals several different experimental models of colorectal cancer now exist, each with 
its own strengths and weaknesses.
These models not only allow study of the numerous steps in the carcinogenic 
process, identification of novel tumour markers and understanding of the role of the 
immune system in tumourigenesis, but also allow investigators to manipulate factors 
such as diet and intestinal bacteria. The effects of novel therapies on tumour growth and 
survival can be assessed and, in this context, the use of gastrin-receptor antagonists will 
be discussed later (Chapter 6). Similar to in vitro methods, experimental conditions in 
animal models can be strictly controlled.
4.2 A n im a l  M o d e ls  o f  C o l o r e c t a l  N e o pl a sia
Virtually all experimental studies have used rodents and, unless otherwise stated, what 
follows refers to rodents. Traditionally the two main animal models employed have been 
chemical carcinogen-based systems and transplantable "xenograft" systems involving 
nude mice (Lamont and O'Gorman 1978; Galloway 1989; Pories et al 1993). Very 
recently investigators have begun to take advantage of advances in molecular biology to 
study genetic factors in colonic carcinogenesis, using chimeric animals, transgenic mice
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and "reconstruction" models (Pories et al 1993). These latter models will not be 
discussed further.
4.2.1 Chemical Colorectal Carcinogenesis
At least five structurally different classes of compound can induce cancer in the large 
intestine and these have been reviewed elsewhere (Lamont and O'Gorman 1978; 
Weisburger and Fiala 1983; Rogers and Nauss 1985). N-methyl-N1 -nitro-N- 
nitrosoguanidine (MNNG) differs from the other carcinogens in that it acts directly on 
the colonic mucosa following intrarectal instillation and produces cancers without prior 
metabolic activation by the host animal. In spite of this, hydrazine derivatives such as 
1,2-dimethylhydrazine (DMH) and azoxymethane (AOM) have been shown to be the 
most potent inducers of colonic tumours (which are also transplantable) and have 
become the most widely used for studies of chemical colorectal carcinogenesis. As this 
model has been used in the present thesis, it will be described further before the results 
of studies involving gastrin in experimental colorectal cancer are discussed.
(i) Hydrazine carcinogenesis
The story of the discovery of hydrazines as potent colonic carcinogens has been 
recounted in detail elsewhere (Lamont and O'Gorman 1978; Galloway 1989). Briefly, 
while investigating the unusually high incidence of amyotrophic lateral sclerosis on the 
island of Guam, Lacquer et al (1963) noted that cycad flour, from the nut of the plant 
Cycas circinalis, formed a major component of the local diet. When fed to rats, 
however, no neurological lesions were produced but a small number of animals 
developed colonic adenocarcinomas. Cycasin was shown to be the P-glucoside of the 
chemically unstable compound methylazoxymethanol. Separately, Druckrey had 
discovered that 1,2-dimethylhydrazine also produced a similar pattern of intestinal 
tumours and was structurally similar to cycasin (Druckrey 1970). Further work 
(reviewed in Lamont and O'Gorman 1970; Rogers and Nauss 1985) demonstrated the 
carcinogenicity of azoxymethane and the likely metabolic pathway from
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dimethylhydrazine to the highly unstable methyl carbonium ion, which alkylates cellular 
macromolecules including DNA. The metabolic pathway of hydrazine carcinogens is 
illustrated in Figure 4.1. The potency, relative ease of synthesis and chemical stability of 
azoxymethane (AOM) has made it the most widely used of this group of carcinogens.
Exactly why 1,2-dimethylhydrazine and azoxymethane should exhibit their 
characteristic organotropism following parenteral administration remains to be fully 
explained. Initial suggestions that the carcinogen underwent biliary excretion as a 
glucuronide conjugate, to be split by intestinal bacteria with carcinogen release in the 
colonic lumen, have not been substantiated. Segments of colon from which the faecal 
stream has been surgically diverted still develop tumours in response to hydrazine 
carcinogens (Campbell et al 1975). Thus important factors may be either the vascular 
delivery of carcinogen to the colon or properties inherent in colonic epithelial cells such 
as cell-cycle kinetics or expression of particular xenobiotic metabolising enzymes.
In rats and mice both DMH and AOM are highly effective as colonic 
carcinogens and even a single dose is sufficient for tumour induction after a prolonged 
latent period. Tumourigenesis is dose-related in terms of both the number of tumours 
formed and their rapidity of onset. In most studies doses of 10-20mg.kg_1 body weight 
are given by weekly subcutaneous injection for approximately twelve weeks 
(Shamsuddin 1983). Doses in this range preferentially induce colonic lesions while 
higher doses result in a higher yield of extracolonic abnormalities including benign renal 
cysts, hepatic haemangioendotheliomas, adenocarcinomas of the duodenum and 
squamous carcinomas of the external ear.
Hydrazine derivatives have recently been shown to induce colon cancers in 
monkeys as well as rodents (Beniashvili et al 1992) but are not known to be relevant 
carcinogens for human colorectal cancer. Substituted hydrazines are used as 
components of rocket fuel, as a ripener for pineapples and are found in some edible 
mushrooms (Lamont and O'Gorman 1978). Although evidence for a role in human 
disease is lacking, there are important similarities between the colonic tumours induced 
by hydrazines and their human counterparts, both in morphology and in their propensity 
to develop in the distal colon. The majority of lesions are adenomas and non-mucinous
CH3 - NH - NH - CH3 1,2 dimethylhydrazine
*
CH3 - N = N - CH3 azomethane
*
CH3 - N = N - CH3 azoxymethane
I
O
CH3 - N = N -CH2OH methylazoxymethanol
I
O
CH3 - N = N • carbonium ion
Figure 4.1. Metabolic pathway of hydrazine carcinogens.
55
adenocarcinomas, the latter being locally invasive. Less often aggressive mucinous 
carcinomas are also found (Shamsuddin 1983). While there are marked histological and 
ultrastructural similarities with human colonic adenocarcinomas there are also 
differences. The well-documented "adenoma-carcinoma" sequence in human disease is 
less clearly established, although evidence in favour of it occurring in this experimental 
model has been presented (Sunter et al 1978). More often carcinomas arise de novo in 
macroscopically flat mucosa (Shamsuddin 1983; Pozharisski 1975). The most 
significant deviation, however, from the human situation is the rarity of hepatic 
metastasis, a factor which does detract from this otherwise highly valuable model of 
colorectal cancer.
The hydrazine carcinogen model has been used as a standard means of 
inducing colorectal cancer in animals, allowing the influence of putative promoting 
factors, inhibitors and novel therapeutic strategies to be studied. Several groups have 
utilised this model to examine the influence of gastrin and their work is described next.
(ii) Studies of gastrin in hydrazine carcinogenesis
There have been relatively few studies involving gastrin and hydrazine-induced 
colorectal tumours in rodents. Although detailed and labour-intensive, such studies 
involve small numbers of animals in each treatment group and, as a result, 
demonstrating a statistically significant difference in tumour incidence, propensity for 
metastasis or survival has been difficult. Also, studies are difficult to compare because 
of differences in experimental design, species, strain, age and sex of animals used, 
methods employed to induce hypergastrinaemia and means of assessing tumour 
proliferation and growth.
Two other problems pertinent to studies of gastrin in experimental colorectal 
carcinogenesis deserve mention. Firstly, surgical methods of inducing 
hypergastrinaemia, for example by fimdectomy or antral exclusion, may lead to a 
reduced gastric capacity with subsequent lower food and caloric intake, resulting in 
diminished weight gain compared to control animals. Calorie restriction with impaired 
weight gain has been shown to inhibit carcinogenesis in many different animal models
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(Albanes 1987; Birt et al 1992) and this is discussed in more detail later (Chapter 9). 
Secondly, intestinal surgery produces non-specific tissue injury and enhancement of 
hydrazine-induced tumour formation at sites of surgical anastomoses and suture lines 
has also been documented (McGregor 1988). These potential confounding factors must 
be borne in mind when interpreting the results of animal carcinogenesis studies.
In an initial report, McGregor et al (1982) injected male Sprague-Dawley rats 
weekly with methylazoxymethanol for six weeks and then randomised them to undergo 
either antral exclusion (hypergastrinaemia), antrectomy (hypogastrinaemia), sham 
operation or sham plus pentagastrin injections (for forty-eight hours prior to death). 
When the animals were killed ten weeks later no difference in the number of tumours 
nor their distribution was observed among the groups. Mean tumour volume and total 
tumour "burden" were two-fold greater in hypergastrinaemic rats compared to 
normogastrinaemic animals although this was not statistically significant because of the 
wide range of individual values. Tumour contents of DNA, RNA and protein (measured 
by [3H]thymidine, [14C]orotic acid and [14C]leucine uptake, respectively) were 
markedly higher in rats from the antral exclusion group as were calculated rates of 
DNA, RNA and protein synthesis. Similar results were observed in sham-operated rats 
which had received pentagastrin (2mg.kg-1) for forty-eight hours prior to death, when 
compared to sham-only animals. In contrast antrectomy failed to produce a sustained 
fall in gastrin levels and results in this group did not differ from control animals.
As this study examined the effects of gastrin after tumour initiation had already 
occurred, the authors repeated the study except that rats underwent either antral 
exclusion or sham operation two weeks before carcinogen (1,2-dimethylhydrazine) was 
given (Karlin et al 1985). Antral exclusion elevated mean fasting gastrin concentrations 
by almost three-fold relative to sham controls and all 100% (n = 23) of this group 
developed colorectal tumours as opposed to 72.7% of the normogastrinaemic control 
animals (n = 22). Rats in the antral exclusion group had on average more tumours per 
rat (4.2 versus 1.8) and two-fold greater mean tumour weight and volume. From these 
two studies the authors suggested that gastrin may not only promote the growth of
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established colorectal tumours but that hypergastrinaemia itself may predispose to 
tumour development.
At around the same time Oscarson et al tested the same hypothesis by 
performing either antrectomy or fundectomy on male rats, immediately after which a 
course of DMH injections was begun (Oscarson et al 1982). Although gastrins were 
only measured in three animals per group, antrectomy modestly reduced hormone levels 
while fundectomy raised them up to five-fold compared to "control" animals (which had 
not undergone any sham procedure). No difference in tumour incidence or mucosal 
content of DNA or RNA was seen and colonic villous weight and crypt depth were also 
similar in the two groups. These histological parameters are crude ways of assessing 
trophic effects and there were also considerable weight differences among the groups 
with fimdectomised rats weighing on average one hundred grams less than control 
animals. This represented a weight difference of approximately 40% and may well have 
influenced the carcinogenic process. In another study antral exclusion raised fasting 
gastrin levels four-fold and significantly stimulated DNA content and the rate of DNA 
synthesis ([3H]thymidine uptake) in both DMH-induced tumours and "normal" colonic 
mucosa, compared to sham-operated animals (Elwyn et al 1985). No difference in 
tumour number, size, weight or position was observed although each treatment group 
consisted of less than ten rats.
In an autoradiographic study two injections of pentagastrin (120pg.kg_1) given 
to rats with DMH-induced colorectal tumours led to a 45% increase in the labelling 
index of cancer cells relative to control animals (Lamote and Willems 1988). The 
authors repeated the study and assessed tumour proliferation by a stathmokinetic 
technique and again pentagastrin was trophic to the cancer cells, increasing the number 
of vincristine-arrested metaphases (the metaphase index) by 108% compared to 
controls. From these results the authors concluded that pentagastrin increased both the 
proportion of cells in the DNA-synthesis phase (S-phase) of the cell-cycle and the 
number of these progressing to the mitotic phase (M-phase).
Given the recent controversial evidence that surgery for peptic ulcer may 
predispose to the late development of colorectal cancer (Bundred et al 1985), several
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investigators have examined the effect of such surgery on chemical carcinogenesis in 
rats, with conflicting results (Houghton etal 1990; Oscarson etal 1982). While surgical 
procedures such as vagotomy and Billroth I partial gastrectomy induce endogenous 
hypergastrinaemia, several other important variables are also altered, for example acid 
secretion and bile acid metabolism. When the possible effects of altered calorie intake 
and weight gain are also considered it is difficult to draw clear conclusions about the 
relevance of gastrin to any observed changes in colonic cancer development in such 
studies. Similarly, while proximal small bowel resection in animals causes 
hypergastrinaemia, it has several other effects which could equally explain the 
enhancement of hydrazine-induced colorectal carcinogenesis produced by the operation 
(Williamson etal 1978; Tilson 1980).
(iii) Studies of gastrin in other models of chemical carcinogenesis 
Apart from hydrazines, of the other colonic carcinogens described above, only N- 
methyl-N1 -nitro-N-nitrosoguanidine (MNNG) has been used in studies of the effects of 
gastrin on tumourigenesis. In one study depot injections of tetragastrin given during and 
after intrarectal MNNG treatment significantly reduced the development of colorectal 
tumours in rats (Tatsuta et al 1983). The authors confirmed these results in a further 
small study, showing that tetragastrin reduced tumour incidence and size when given 
from the start of MNNG treatment but had no effect if delayed until after MNNG 
dosing was complete (Tatsuta et al 1985). While some studies of gastrin and colorectal 
cancer have failed to demonstrate a stimulatory effect, these two papers are the only 
ones to record inhibitory effects of the hormone on tumourigenesis and the results have 
not been corroborated by other groups.
59
4.2.2. Xenograft Models of Colorectal Cancer
(i) Introduction
The availability of strains of genetically athymic 'nude' mice allows us to grow a wide 
range of tumours as subcutaneous xenografts in such animals without the problems of 
immune rejection. Notably, human tumours can be grown in nude mice, their growth 
can be closely followed and the effects of experimental interventions on tumour growth 
and animal survival can be quantitated. As such, this model has been extensively used to 
study the effects of gastrin on the growth of colorectal cancer cells.
(ii) Effects of gastrin on colorectal cancer xenografts
A trophic effect of gastrin on colorectal cancer in vivo was first noted by Svet- 
Moldavsky (1980). In a short report, repeated injections of pentagastrin (250pg.kg_1) 
increased the weight of a mouse adenocarcinoma (AKATOL-1-71) twenty-fold 
compared to saline-treated control animals. Interestingly, a higher dose of pentagastrin 
(600pg.kg_1) had a less pronounced effect on tumour growth. No effect was noted on 
other tumours, including a hepatoma and a small bowel adenocarcinoma. Two 
subsequent reports followed, the first finding no effect of pentagastrin on the growth or 
labelling index of a transplantable human colorectal cancer (Sumiyoshi et al 1984). In 
the second, one of three human colonic tumour xenografts did respond to pentagastrin 
with an increase in weight and a decrease in tumour doubling time (Tanaka et al 1986).
Around the same time investigators in Texas were studying a carcinogen- 
induced murine colorectal cancer (CT-26) and established it as a transplantable tumour 
in nude mice, since when it has been extensively characterised and shown to be gastrin- 
receptor positive and gastrin-responsive (Townsend et al 1990). Winsett et al (1985) 
found varying doses of pentagastrin stimulated growth and significantly increased DNA 
content in this tumour, with the maximal response to pentagastrin occurring at a lower 
dose in the tumours than in normal gastric fundic mucosa. In addition, pentagastrin- 
treated animals had significantly reduced survival at thirty-five days (55%) compared to 
saline-treated controls (90%). By day fifty-five all pentagastrin-treated animals were
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dead whereas 80% of control mice were still alive. In a subsequent study the same 
group were able to prevent these effects of pentagastrin with the gastrin-receptor 
antagonist proglumide (Beauchamp et al 1985b) and this is discussed more fully later.
The trophic effects of pentagastrin on MC-26 tumours have been confirmed in 
a number of different studies (Singh et al 1986b, 1987, 1993b). Recently others 
repeated the study of the Texas group (Alonso et al 1992) and confirmed the growth- 
stimulatory effects of gastrin, with significant increases in mean tumour weight (40%), 
volume (55%) and DNA content (30%). Mean survival in pentagastrin-treated mice 
was also significantly shortened (29.6 days) relative to control animals (42.5 days).
Initial investigations by Watson et al found that while gastrin stimulated 
growth of a human gastric cancer xenograft (MKN45), repeated injections of gastrin 
had no effect on HT29 colorectal cancer cells (Watson et al 1988). When gastrin was 
administered as a continuous infusion by osmotic minipump, however, a trend towards 
increased growth of HT29 cells was observed although statistical significance was not 
reached. Using the same technique in a later study, the authors reported significant 
growth stimulation of another human colonic cancer cell line (C523) grown as 
xenografts (Watson et al 1992). It may, therefore be that continuous exposure of 
tumour cells to relatively constant low concentrations of gastrin may be more relevant 
than repeated bolus injections at high doses and at relatively long dosage intervals.
Several other authors have reported on the effects of gastrin on a variety of 
different human colorectal cancer cells grown as xenografts in nude mice with variable 
and sometimes conflicting results (Smith et al 1988, 1993; McGregor et al 1989; 
Eggstein et al 1992). As discussed in previous sections methodological differences are 
likely to account for much of this. The results of all of these, along with other published 
experimental studies, are summarised in Table 4.1. It should be noted that a number of 
other 'negative' studies which have not been published are likely to exist.
Of all the studies on gastrin and colorectal cancer growth in animals, only one 
has used pharmacologically-induced endogenous hypergastrinaemia as opposed to 
surgical methods or exogenous gastrin. In this paper mice were inoculated with MC-26 
cells and were dosed with omeprazole or buffer by oral gavage for nineteen days
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(Grafifner et al 1992). Although omeprazole-treated animals had five-fold elevated 
median serum gastrin levels compared to controls, no effect on tumour size nor animal 
survival was noted. The mice were inoculated with large numbers of cancer cells, 
however, resulting in rapidly growing tumours and death occurred very quickly in both 
groups. It is possible, therefore, that this made differences in tumour growth and 
survival difficult to detect.
The xenograft model has provided much useful information to compliment that 
derived from other animal studies and in vitro systems. While methodological 
differences have to be borne in mind, such experiments have shown that large doses of 
gastrin are capable of stimulating the growth of colorectal cancer in vivo and may also 
affect animal survival.
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CHAPTER 5
GASTRIN/CCK-B RECEPTORS IN 
COLORECTAL NEOPLASIA
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5.1 In t r o d u c t io n
Like other gastrointestinal peptides, gastrin exerts its biological actions by interacting 
with specific cell surface receptors. If gastrin is of relevance to human colorectal 
cancer, then identifying and characterising gastrin receptors on tumour cells is of crucial 
importance before gastrin receptor antagonists are to be considered as therapeutic 
options in this disease.
For nearly twenty years the binding of radiolabelled biologically active gastrin 
(or agonists of gastrin) to tissues of interest has been used to identify and characterise 
gastrin receptors. Analysis of binding data enables the number of binding sites and 
dissociation constant (Kd) to be calculated (Kleveland and Waldum 1991; Bylund and 
Yamamura 1990). Using this method specific receptors are generally considered to be 
present if binding is specific, saturable and restricted to tissues known to be biologically 
regulated by the hormone of interest. Furthermore, the Kd should be similar to the 
plasma concentrations of peptide seen physiologically and certain other kinetic criteria 
should also be fulfilled. Lastly, and perhaps most importantly, the observed binding 
should result in a biological response although this has often been difficult to 
demonstrate, especially with respect to gastrin's trophic effects on neoplastic cells.
A great deal has been published on gastrin receptors in the gastric mucosa and 
their role in the control of acid secretion and this is reviewed elsewhere (Chaung et al 
1993). Before discussing evidence pertaining to gastrin receptors in colorectal cancer, 
several points deserve emphasis. Firstly, the radioligand binding assay itself is not 
without problems, depending on the presence of a stable gastrin tracer which retains 
biological activity, a suitable in vitro tissue preparation and suitable incubation 
conditions. Early methods of iodinating gastrin resulted in loss of biological activity 
although this has been overcome in recent years. The procedure depends on tissue 
homogenisation, thus making cellular localisation of receptor-binding impossible in 
tissues composed of heterogeneous cell types. Homogenisation itself may result in loss 
of receptors especially through release of proteolytic enzymes and, depending on the
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exact incubation conditions, incubation damage can occur during the binding assay itself 
with loss of label and/or receptors.
The second point concerns the identification, characterisation and classification 
of "gastrin receptors". Gastrin and cholecystokinin (CCK) are the key members of a 
peptide family which share the common carboxyl terminal sequence (-Gly-Trp-Met- 
Asp-Phe.NH2). The receptors which bind gastrin and CCK have traditionally been 
classified according to their relative affinities for different agonists (Presti and Gardner 
1993; Hughes et al 1993). CCK-A ("alimentary") receptors have much higher affinity 
for CCK than gastrin whereas CCK-B ("brain") receptors bind CCK with only slightly 
greater affinity than gastrin. Sulphated CCK has much greater affinity for receptors than 
non-sulphated hormone whereas sulphation appears to make little difference to the 
binding of gastrin (Huang et al 1989). The existence of a third class of distinct gastrin 
receptors (CCK-C or CCK-G), which bind CCK and gastrin with equal affinity is 
debated (Bold et al 1994). Overall considerable interspecies variation (and even tissue 
variation with a given species) seems to exist and current evidence suggests that CCK- 
B and gastrin receptors are pharmacologically identical within a species, although they 
may be linked to different G-proteins (Hughes et al 1993). It is likely that a conclusive 
answer to this question will depend on further analyses at the molecular level (discussed 
later) but from this point on the terms "gastrin receptor" and "CCK-B receptor" are 
considered to represent the same receptor and referred to as the "gastrin/CCK-B" 
receptor. The possibility that different affinity states for the same receptor (high and 
low) may co-exist in the same tissue should be borne in mind, as should the possibility 
that malignant tumours may express different or abnormal receptors compared to their 
normal tissue of origin.
5.2 Ga st r in /C C K -B  Re c e p t o r s  a n d  Ca n c e r
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5.2.1 Colorectal Cancer
Although specific binding of gastrin to receptors in rat gastric mucosa had been 
demonstrated as early as 1976 (Lewin et al 1976) and the receptor assay methodology 
described in 1979 (Takeuchi et al 1979), the first major demonstration of gastrin 
receptors on colonic epithelial cells was not published until 1985 (Singh et al 1985). 
This group, from Galveston in Texas, has subsequently produced many studies on the 
role of gastrin receptors in colon cancer. In their initial detailed study, high-affinity 
gastrin receptors (K^ 0.4-0.55nM) were found on crude membrane fractions from 
normal rat colonic mucosa. High-affinity (K^ = 0.25-0.6nM) sites were also identified 
on membranes from one human (LoVo) and one murine (MC-26) colon cancer cell line 
whereas two other human cell lines (HT29 and HC845) showed little or no binding 
(Singh et al 1985). Furthermore the binding affinities for the colon cancer cell lines and 
normal rat gastric mucosa were similar. Subsequent studies using the MC-26 model 
confirmed the presence of gastrin receptors in this tumour (Singh et al 1986b, 1987, 
1993; Chicone et al 1989; Guo et al 1990). These reports demonstrated not only that 
the trophic effects of gastrin were mediated via gastrin receptors, but also suggested 
that gastrin was necessary to maintain both receptor numbers and their binding affinity 
as the tumours grew. Thus, tumours in rats which were not pentagastrin-treated lost 
their high-affinity gastrin receptors as they progressed (Singh et al 1987). This supports 
the earlier work of Takeuchi et al (1980) suggesting that gastrin "upregulates" its own 
receptor possibly by stimulating production of the receptor.
A number of other authors have also examined the presence of gastrin 
receptors in colorectal cancer cells with variable results. Once again differences in assay 
methodology, use of long-established cell lines and species differences etc., which have 
been highlighted in preceding sections, probably apply to studies of gastrin receptors 
and these points need to be borne in mind when interpreting the results of these papers. 
For example, the effects of cell "synchronisation" on the trophic effects of gastrin in 
vitro (discussed in Chapter 3) could be explained by changes in gastrin receptor
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numbers. Guo et al found that gastrin receptor content in synchronised MC-26 cells 
was three-fold greater than in asynchronous cells (Guo et al 1990). It should also be 
noted that some workers have only identified gastrin binding of low-affinity, with Kd's 
in the micromolar or millimolar range and the significance of such receptors is as yet 
unclear (Weinstock and Baldwin 1988).
Frucht et al found gastrin binding on only one of ten human colonic cancer cell 
lines, although six of these lines were derived from secondary deposits and not the 
primary tumour (Frucht et al 1992). Furthermore, only one concentration of gastrin was 
used (lOOpM) in the binding studies rather than a range of concentrations. Finally, CCK 
binding was observed in three of the ten lines but as competition assays with CCK 
receptor antagonists were not performed, it is unclear whether the binding represented 
CCK-A or gastrin/CCK-B receptors. While several reports have demonstrated the in 
vitro gastrin-responsiveness of fresh human colorectal cancers (Watson et al 1989a) as 
an indirect marker of gastrin receptor status, very few have directly demonstrated high- 
affinity gastrin binding. Again it is likely that more authors have examined this but not 
published their negative results. High-affinity (Kd = 0.4-0.6nM) gastrin binding sites on 
fresh primary human colorectal tumours were first reported (in abstract form) in 1981 
(Rae-Venter et al 1981). Partially purified membranes from seven of eight human 
tumours contained gastrin receptors albeit at low capacity (0.5 fmol.mg'1 membrane 
protein). Receptors were also found in three samples of normal colorectal mucosa taken 
at colonoscopic biopsy, although little data about assay methodology is available from 
their brief report.
The same group, from the University of Texas at Galveston, then published the 
results of a more detailed study in 1989 (Upp et al 1989). Specimens of colorectal 
tumours and "healthy" colonic mucosa were taken from freshly resected tumours and 
gastrin receptor assays performed on crude membrane fractions. From their results, high 
affinity receptors (Kd < InM) were observed on thirty-eight of sixty-seven cancers 
(56.7%) with a further seven tumours found to have only low-affinity gastrin binding 
(Kd > InM). Positive tumours exhibited only a single class of binding sites with Kd's of 
0.1-0.3nM and the GR content varied widely from 1.5-50ftnol.mg_1 membrane protein.
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Twenty of the thirty-eight people with GR-positive tumours had GR contents above 
lOfmol.mg"1. No correlation with patient age, sex, CEA level nor degree of 
differentiation was found but the mean GR content of Dukes' A or B tumours was twice 
that of Dukes' Stage C or D lesions. Similar high affinity GR were found in the 
"normal" mucosa in twenty-eight of fifty-nine samples available (47.5%) with low 
affinity binding seen in nine more cases. Twenty-two (37%) of samples had no 
detectable gastrin receptors and there was a highly significant correlation between the 
presence of GR on "normal" mucosa and on tumours, although it has to be remembered 
that while microscopically disease-free, this mucosa cannot be considered truly normal. 
Other studies by these authors have also identified high affinity GR in membranes 
prepared from freshly-resected human colorectal tumours (Upp et al 1988; Chicone et 
al 1989). In contrast, in one small study, Kumamoto et al were unable to demonstrate 
significant gastrin receptors in "normal" colonic mucosa from two patients undergoing 
colorectal cancer surgery even though such receptors were found in gastric fimdic and 
duodenal mucosa (Kumamoto et al 1989). Unfortunately no data was presented on the 
colorectal tumours themselves.
5.2.2 Gastrin Receptors in Other Tumours
Detailed discussion of the presence and role of gastrin/CCK-B receptors outwith the 
colorectum is beyond the scope of the present work. In brief, many studies have 
identified high affinity gastrin receptors on membranes from human and rodent gastric 
(Singh et al 1985; Weinstock and Baldwin 1988; Watson et al 1992; Ishizuka et al
1992) and pancreatic (Scemama et al 1987; Watson et al 1991a; Zhou et al 1992; 
Soundararajan et al 1993) carcinomas. They may also be also present on 
enterochromaffin-like cells (ECL-cells) from gastric carcinoid tumours which occur 
spontaneously in Mastomys natalensis animals (Reubi et al 1992; Inomoto et al 1993).
Outwith the gastrointestinal tract CCK-B receptors have been identified on 
several human small cell lung cancer cell lines (Yoder and Moody 1987; Sethi and 
Rozengurt 1992). Increasing attention is being paid to interactions between the immune
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and neuroendocrine systems and it is of interest that CCK receptors with B-type 
pharmacology have been demonstrated on a human T-cell lymphoblastic cell line 
(Lignon et al 1991).
5.2.3 Molecular Characterisation of Gastrin/CCK-B Receptors
Very little is currently known about the molecular basis of gastrin-binding proteins so 
far identified on normal and malignant colonic epithelium. The likelihood of species- 
dependent and tissue-tissue variations in receptor structure, signalling and function 
make extrapolation from available data potentially misleading.
Using covalent cross-linking and protein electrophoresis, Chicone et al have 
reported that gastrin binds predominantly to a single peptide of 33-40 kDa in 
membranes of both MC-26 and fresh human colorectal tumours (Chicone et al 1989) 
but this protein has yet to be sequenced. Alternatively, a monoclonal antibody raised to 
canine parietal cells, and which recognises a 78 kDa gastrin binding protein in porcine 
stomach, also binds to cell membranes in human colorectal tumours (Watson et al
1993).
Since 1992 the gastrin/CCK-B receptor has been cloned and sequenced from a 
variety of sources, including rat brain and pancreas (Wank et al 1992), human brain and 
stomach (Pisegna et al 1992; Miyake et al 1994), canine parietal cells (Kopin et al
1992) and ECL carcinoid tumours from Mastomys natalensis (Nakata et al 1992). A 
high degree of nucleic acid sequence homology among these isolates is apparent but 
whether gastrin/CCK-B receptors are identical in different tissues within the same 
species is not yet entirely clear. Recent evidence suggests that they are the same (Lee et 
al 1993; Miyake et al 1994), although Yamada's group have suggested, on the basis of 
the molecular structure of the human gastrin receptor gene, that alternative splicing 
pathways yielding receptor variants may exist (Song et al 1993). Preliminary data 
published in 1994 has raised the possibility that gastrin receptors in colon cancer may be 
distinct from classical CCK-B receptors (Bold et al 1994). In this study CCK-B 
receptor mRNA was not detected in LoVo cells by Northern hybridisation and the
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trophic effects of gastrin could not be blocked by the CCK-B antagonist L365,260. The 
same group have also reported, however, that another selective CCK-B antagonist 
(JMV 320) does inhibit growth of these cells (Ishizuka et al 1994). Further rapid 
developments in this field will hopefully shed light on the exact nature of the gastrin 
receptor on colonic and other gastrointestinal tumours.
5.3 Ch o l e c y st o k in in  a n d  Ga st r in  R e c e p t o r  A n t a g o n ist s
5.3.1 Introduction
For many years there were few antagonists available for use in studies of gastrin/CCK- 
B receptors and some of these were weak with low affinity for receptors. Recently, 
however, many new classes of peptide and non-peptide antagonists have been 
described, resulting in rapid advances in our knowledge of CCK receptor classification 
and pharmacology. As yet few of these newly available gastrin/CCK-B receptor 
antagonists have been used in studies of colorectal cancer although results of their use 
in this area are likely to be forthcoming and are keenly awaited. At least eight classes of 
CCK receptor antagonists have been described (Jensen et al 1990; Presti and Gardner
1993) and within each class are compounds with sufficient selectivity to distinguish 
between CCK-A and gastrin/CCK-B receptors.
5.3.2 Early Studies Using Proglumide
The earliest studies of gastrin receptor antagonists in experimental colonic cancer 
utilised the glutaramic acid derivative proglumide ((±)-4-(benzolyamino)-5- 
(dipropylamino)-5-oxopentanoic acid). While this compound had been shown to be a 
specific, competitive inhibitor of gastrin-stimulated gastric acid secretion in the late 
1960's, its effects on growth in the gastrointestinal tract were not reported until 1984 
(Johnson and Guthrie 1984). In this study, high doses of proglumide partially inhibited 
pentagastrin-stimulated DNA synthesis and content in scrapings of normal rat colonic 
mucosa. Proglumide had no effects when used on its own and the IC50 was in the
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millimolar range. Other authors have also found proglumide to inhibit gastrin or 
pentagastrin-stimulated growth of colon cancer cells both in vivo and in vitro (Singh et 
al 1986a, 1987; Smith et al 1988; Yactayo et al 1991). In none of these studies did 
proglumide inhibit the basal growth of tumour cells although this was noted in several 
other in vitro studies using a variety of colorectal cancer cell lines (Hoosein et al 1989, 
1990; Guo etal 1990).
Following up their earlier study which found that pentagastrin enhanced 
growth of MC-26 tumours and reduced survival in nude mice (Winsett et al 1985), the 
same group examined the effects of proglumide in this model (Beauchamp et al 1985b). 
Compared to saline-treated control rats, proglumide treatment significantly reduced 
growth, DNA and RNA content in both tumours and in normal colonic mucosa. By day 
twenty-one of treatment mean tumour size was only 46% of control and, of more 
interest, proglumide increased mean survival from 25.3 days in control mice to 39.2 
days.
Not all authors have been able to demonstrate a growth inhibitory effect of 
proglumide on colorectal cancer cells (Romani et al 1994) and in some studies where 
effects were noted, the effective doses for proglumide were often in the micromolar to 
millimolar range. Whether such observed effects are of physiological relevance is 
questionable. In addition one recent study found that while proglumide reduced the 
growth of gastrin-responsive HT29 cells, it also inhibited the growth of fibroblastic 3T3 
cells in vitro (Mauss et al 1994) and similar observations have been made by others 
(Piontek et al 1993). These cells show no gastrin binding, are not trophically stimulated 
by gastrin and the effects of proglumide could not be reversed by adding large 
concentrations gastrin, suggesting that proglumide's actions may be non-specific and 
not due to gastrin-receptor binding. Clinically, the drug has only been used in one small 
study of patients with advanced colorectal cancer and, perhaps not surprisingly, no 
effects on patient survival or tumour growth were found (Morris et al 1990).
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5.3.3 Other Gastrin/CCK-B Receptor Antagonists
Along with proglumide several early investigations used benzotript, a derivative of the 
amino acid tryptophan. This compound also has low affinity for gastrin/CCK-B 
receptors with a in the millimolar range. Using doses of 0.4-1.6mM, Hoosein et al 
(1989) observed inhibitory effects on monolayer growth and anchorage-independence 
using six different human colorectal cancer cell lines. The IC50 for gastrin receptor 
binding was 0.4mM, however, and it would be almost impossible for the drug to 
achieve concentrations in vivo sufficient to cause effective receptor blockade. Similar 
inhibitory effects on the growth of murine MC26 colon cancer cells in vitro have been 
reported (Guo et al 1990). Eggstein et al (1991) found that benzotript only inhibited 
the growth of a gastrin-responsive colonic cancer cell line (SW403) but had no effect 
on cell lines whose growth was not stimulated by gastrin and concluded that the 
antagonist's actions were specifically related to its receptor-blocking properties.
More recently several compounds of varying chemical structure have been 
developed as highly selective and potent antagonists for gastrin/CCK-B receptors. The 
benzodiazepine compound L365,260 is one of the most potent (Presti and Gardner 
1993; Hughes et al 1993) and in one study the in vitro basal growth rates of two human 
colorectal cancer cell lines (LoVo and C l46) were reduced to 44% and 64% of control 
cells, respectively (Watson et al 1991). Once the drug was removed, however, growth 
of the cancer cells rapidly returned to control levels. In contrast L365,260 was reported 
to have no effect on the growth of two other human colorectal cancer cell lines 
(Thumwood etal 1991).
Using the newer non-peptidic glutamic acid derivative CR2093 (R-4-(3- 
chlorobenzamido)-5-(3,3-dimethyl butylamino)-5-oxo-pentanoic acid), Watson et al 
examined its effects on the growth of various gastrointestinal tumour cell lines, both in 
vitro and when grown as xenografts in nude mice (Watson et al 1992). High affinity 
gastrin/CCK-B receptors were demonstrated on C523 cells (Kd 2.2 x 10‘10M) in vitro 
and the IC50 was in the millimolar range (>10^M). Continuous intravenous infusion of 
the antagonist in doses sufficient to inhibit gastric acid secretion inhibited neither basal
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nor gastrin-stimulated growth of C523 xenografts. Conversely, the growth of AR42J 
(rat pancreatic) cells and MKN45 (human gastric) cells was inhibited. These tumours, 
however, possessed lower affinity receptors and the authors suggested that the higher 
the receptor affinity for gastrin, the greater the concentration of antagonist needed to 
compete effectively and displace gastrin. Thus it is possible that higher doses may have 
had an effect on the colorectal cancer cells.
The highly selective and potent gastrin/CCK-B receptor antagonist JMV 320 
has been found in one study to inhibit the gastrin-stimulated growth of several human 
colorectal cell lines in vitro without having any effect when given alone (Ishizuka et al
1994).
Very recently, studies of newly-developed gastrin receptor antagonists have 
been reported in abstract form. In the first, neither M224624 nor M226770 was able to 
inhibit the growth of either MC26 (mouse) or C523 (human) colon cancer xenografts 
when given in the form of slow-release depot injections (Gamer et al 1992). In the 
second report, the in vitro basal growth of four out of six human colonic carcinoma cell 
lines was reduced to 30% of control by the highly potent gastrin/CCK-B receptor 
antagonist C1988 (Romani et al 1994). The CCK-A and CCK-B antagonist CAM 1481 
was also effective and the drugs were said to exert activity at "doses as low as 10_11M" 
suggesting physiological relevance, although few details are currently available. When 
one of the cell lines (LoVo) was grown as a xenograft, C l988 inhibited its in vivo 
growth by 53% when given orally for twenty days.
5.3.4 Studies Involving Antigastrin Antibodies
An alternative approach to the use of pharmacological receptor antagonists is to use 
specific antigastrin antisera and this technique is currently being evaluated. In 1989 
Hoosein et al reported inhibition of the basal growth of two human colon cancer lines 
by a polyclonal antigastrin antibody (Hoosein et al 1989). Non-immune rabbit IgG had 
no effect and pre-incubation of the antibody with G-17 abolished its activity. A later 
study by the same group confirmed these findings in a number of other colorectal cell
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lines (Hoosein et al 1990). A polyclonal antiserum (ICI-925), selective for the N- 
terminal region of gastrin, was able to "markedly inhibit" the growth of C523 human 
colon cancer xenografts when infused continuously into nude mice at a dose sufficient 
to abolish gastric acid secretion (Gamer et al 1992). Curiously, however, a monoclonal 
antibody (Cure Gas -93) was without effect.
The Nottingham group have developed a novel approach to raise antigastrin 
antibodies in vivo by immunising animals with the amino terminus of G-17 linked to 
diphtheria toxoid. The immunogen (called "Gastrimmune") induces specific anti-G-17 
antibodies which do not cross-react with either G-34 or CCK (Watson et al 1993,
1994). In experimental animal models, these authors have found Gastrimmune 
treatment to inhibit significantly the growth of gastrin-receptor positive colonic cancers, 
effects presumed to operate via inhibition of the trophic effects of endogenous gastrin. 
More detailed reports are awaited and a clinical trial in patients with advanced 
colorectal cancer is currently underway (S. Watson, personal communication).
5.4 Su m m a r y
It seems likely that a significant proportion of human colorectal tumours possess high- 
affinity "gastrin-binding sites", although the functional relevance of these has not been 
conclusively shown. Whether such gastrin-binding sites are identical or not to classical 
gastrin/CCK-B receptors in other tissues remains to be settled, although they probably 
are. Early studies involving weak, relatively non-specific receptor antagonists should be 
interpreted with caution and further studies using newly available, more potent 
compounds are needed. Finally, early results of studies involving antigastrin antibodies 
raised by a synthetic immunogen appear promising and further evaluation is awaited.
CHAPTER 6
POST-RECEPTOR SIGNALS MEDIATING 
THE TROPHIC EFFECTS OF GASTRIN
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6.1 P o st-R e c e p t o r  Sig n a l l in g
The mechanisms mediating signal transduction following binding of gastrin to its 
receptor in the colon are poorly understood as are the exact intracellular processes 
stimulated in the proliferative response to the hormone. While much has been 
discovered about the post-receptor signals involved in the acid-secretory response of 
gastric parietal cells to gastrin (Yamada et al 1993) this may not be relevant to the 
colon as the two receptors have not yet been conclusively shown to be identical. Even if 
they are the same their regulation may differ in different tissues, for example, by 
coupling to different G-proteins.
In gastric parietal cells, gastrin stimulates turnover of inositol phospholipids, 
culminating in elevation of intracellular calcium and activation of protein kinase C 
(PKC). PKC also seems to activate an autoregulatory mechanism resulting in receptor 
down-regulation with reduced receptor numbers (Yamada et al 1993). Evidence 
presented by Yassin et al suggests that gastrin does stimulate PKC activity in isolated 
normal rat colonocytes (Yassin et al 1991a). In addition the effects of gastrin could be 
abolished by either proglumide or staurosporine, an inhibitor of PKC (Yassin et al
1993). These authors also demonstrated that gastrin at an optimum dose of lOnM 
induced the transcription of a wide range of mRNA species in these cells and markedly 
stimulated protein synthesis (Yassin et al 1991b). This was also abolished by 
staurosporine. Coupling of gastrin/CCK-B receptors to PKC activation also occurs in 
the rat pancreatic cancer cell line AR42J (Seva et al 1994b).
As PKC activity is closely related to stimulation of membrane 
phosphotidylinositol (PI) hydrolysis, studies have now begun to examine this aspect of 
the response of colon cancer cells to gastrin . In a recent detailed study, gastrin at doses 
of 10'10-10"12M stimulated the growth of several human colorectal cancer cell lines and 
in one of these lines this was associated with a parallel stimulation of PI hydrolysis and 
intracellular calcium mobilisation (Ishizuka et al 1994). These effects were blocked by 
the potent and selective gastrin/CCK-B receptor antagonist JMV 320. Interestingly, the 
other cell lines responded to gastrin with an increase in cAMP turnover but without any
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change in PI or intracellular calcium. It would appear, therefore, that gastrin signalling 
in colonic cancer cells may occur through several different mechanisms.
The same authors have previously found that gastrin stimulates mobilisation of 
intracellular calcium independently of phosphotidylinositol hydrolysis in a gastric 
carcinoma cell line (AGS) which possesses gastrin receptors and responds trophically to 
the hormone (Ishizuka et al 1992). In addition, the hormone had no effect on 
intracellular calcium in a subclone lacking gastrin receptors. Similar effects of gastrin on 
growth and calcium mobilisation have been observed in small cell lung cancer cells 
(Sethi and Rozengurt 1992) and in NIH3T3 fibroblasts expressing the cloned human 
gastrin/CCK-B receptor (Taniguchi et al 1994).
Regulation of cellular proliferation is thought to depend on a readily available 
supply of polyamines although the exact roles of these ubiquitous compounds are not 
fully understood. Activity of the enzyme ornithine decarboxylase (ODC), which 
converts ornithine to putrescine, is the rate-limiting step and an increased level of ODC 
is one of the earliest steps in cellular proliferation (reviewed in Johnson et al 1993). 
High levels of polyamines and increased ODC activity occur in colorectal tumours 
(Kingsnorth et al 1984; Lamuraglia et al 1986). In several parts of the gastrointestinal 
tract, including the colon, exogenous gastrin stimulates ODC activity and increases 
mucosal polyamine content in parallel with its trophic effects (Seidel et al 1985; Arlow 
et al 1990; Majumdar 1990). Similarly endogenous hypergastrinaemia, induced by daily 
treatment with omeprazole, increased rat colonic polyamine content by 74% compared 
to control animals and this was associated with an increase in crypt cell production rate 
(Gray et al 1993). Others have also found gastrin to stimulate increased polyamine 
turnover in both colonic cancer cell lines and xenografts (Eggstein eta l 1991; Smith et 
al 1993). In a study of freshly resected colorectal carcinoma specimens, Upp et al 
reported higher levels of polyamines in colorectal cancers which were gastrin receptor- 
positive than in tumours which did not possess gastrin receptors (Upp et al 1987).
The specific, irreversible inhibitor of ODC, a-difluoromethylomithine (DFMO) 
has been useful in studying the role of polyamines in cell proliferation. Several studies 
have found DFMO to inhibit the proliferative effects of gastrin on the colon, both in
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vivo and in vitro (Seidel et al 1985; Majumdar 1990; Eggstein et al 1991; Smith et al
1993).
Thus, although polyamines would appear to be involved in the trophic 
response to gastrin, much remains to be learned about the cellular events occurring 
prior to this and also subsequently at the level of gene expression. In the study of 
Taniguchi et al (1994) noted above gastrin-signalling was associated with tyrosine 
kinase activation and increased expression of the proto-oncogenes c-myc and c-fos 
which are involved in the early response of cells to mitogenic stimuli. Pentagastrin has 
also recently been reported to stimulate expression of c-myc in cultures of normal small 
intestinal crypt cells (Wang et al 1993). The effects of gastrin on proto-oncogene 
expression in normal and neoplastic colorectal cells has not been reported to date but 
clearly merits investigation.
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CHAPTER 7
GASTRIN AND HUMAN COLORECTAL NEOPLASIA
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7.1 I n t r o d u c t io n
What is the relevance of gastrin to colorectal neoplasia in humans ? Hypergastrinaemia 
occurs in a number of clinical states (Table 7.1) but little is known about whether any 
predisposition to colonic tumour formation occurs in these conditions.
In pernicious anaemia fasting circulating gastrin concentrations may be 
elevated forty to fifty-fold (Lamers 1980; Lanzon-Miller et al 1987a). There is wide 
inter-individual variation in the gastrin levels seen in pernicious anaemia patients, 
however, with some having levels more than one hundred-fold greater than normal 
people. While this condition is established as an important risk factor for subsequent 
gastric cancer development (Elsborg and Mosbech 1979) effects on colorectal cancer 
development are less clear. While a trend towards an increased risk of colorectal cancer 
was observed by Talley et al in a small population-based cohort study (Talley et al 
1989), others have found no such association (Elsborg and Mosbech 1979; Brinton et 
al 1989).
Surgery for peptic ulcer disease, namely vagotomy and Billroth I gastrectomy 
(but not Billroth II surgery) also causes sustained rises in circulating gastrin levels (Blair 
etal 1986; Yamashita et al 1993). Several epidemiological studies have reported a long 
term increased risk of colorectal cancer development after peptic ulcer surgery (Caygill 
et al 1987; Stemmermann et al 1991), although this is still controversial (Kune et al 
1988; Macintyre and O'Brien 1994). The association may be a complex one as factors 
other than hypergastrinaemia may be operative including reduced gastric acidity, altered 
bile acid metabolism, changes in intestinal flora and altered calcium metabolism. 
Interestingly the increased risk noted in the study of Caygill et al (1987) was restricted 
to females treated by either vagotomy or Billroth I gastrectomy (hypergastrinaemia) but 
not Billroth II gastrectomy (where no rise in gastrin occurs). The results of these 
retrospective studies need to be investigated further although prospective studies may 
not be feasible and would possibly take twenty years or more to yield an answer.
Worldwide, gastric acid antisecretory drugs (principally H2-antagonists and 
H+/K+ ATPase inhibitors) are among the most widely prescribed of all drugs with an
Associated with gastric hypoacidity/achlorhydria
pernicious anaemia 
atrophic gastritis
gastric surgery (Billroth I gastrectomy; vagotomy)
treatment with gastric acid-suppressing drugs 
(^-antagonists, H+K+-ATPase inhibitors)
Associated with gastric acid hypersecretion
Helicobacter pylori infection
antral G-cell hyperplasia
Zollinger-Ellison syndrome
chronic renal failure
gastric outlet obstruction
short bowel syndrome/small intestinal resection
Table 7.1. Clinical conditions associated with hypergastrinaemia.
80
estimated 1.7 million prescriptions in Scotland in 1993 alone (Dr. P. Rutledge, Medical 
Prescribing Adviser, Lothian Health Board - personal communication). These drugs 
indirectly cause sustained hypergastrinaemia consequent upon their inhibition of acid 
secretion and the more profound the effect on acid secretion the greater the rise in 
gastrin levels (Lanzon-Miller et al 1987b; Pounder 1993). While the majority of patients 
treated with omeprazole have two to four-fold elevations in fasting gastrin, there is 
marked inter- and intra-individual variation and in one study eight of thirty-two patients 
treated for two years or more had concentrations more than ten times the median level 
(Jansen et al 1990). Levels do return to normal soon after cessation of drug therapy and 
are unlikely to be of clinical relevance when used in short courses; the potential 
concerns relate to their longterm use in the management of acid-related disorders. Even 
though these drugs have been extensively investigated and prescribed for millions of 
people over the last ten to twenty years, this is still a relatively short period of time and 
possibly too early to allow detection of subtle but important effects on the trophic state 
of the gastrointestinal epithelium including that of the colon. This is supported by short 
term animal studies in which omeprazole-induced hypergastrinaemia was shown to 
increase the labelling index (vincristine-arrested metaphases) in normal rat colon 
(Pawlikowski et al 1991). Using the crypt cell production rate (CCPR), regarded by 
many as the most reliable method of assessing cell proliferation, Gray et al also found 
omeprazole to cause a small but statistically significant increase in rat colonic CCPR as 
well as marked stimulation of polyamine turnover (Gray et al 1993). In contrast to this, 
one small study found no significant increase in colonic proliferative markers in eight 
patients with Barrett's oesophagus treated with omeprazole sufficient to cause 
hypergastrinaemia (Murphy et al 1993). The subjects, however, were not 'normal', the 
technique used {in vitro [3H]thymidine uptake into biopsies) is prone to inaccuracies, 
the rectum may not reflect other areas of the colon and there was marked 
interindividual variation noted.
At first glance patients with Zollinger-Ellison syndrome (ZES) could provide 
an attractive model for studying the effects of chronic endogenous hypergastrinaemia 
on the human colon. The rarity of the condition, however, and the fact that nearly all
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such patients will either have had gastric surgery or be taking omeprazole makes it 
difficult to draw conclusions from this group of patients. In one small study Sobhani et 
al found that the labelling index of colonic biopsies (as measured by in vitro 
bromodeoxyuridine labelling) was significantly higher in ZES patients compared to 
healthy controls. No correlation was noted, however, between individual labelling 
indices and plasma gastrin concentrations (Sobhani et al 1993).
Only two small studies have so far examined a possible association between H. 
pylori infection and colorectal neoplasia and these have yielded opposite results 
(Lambert et al 1993; Justin et al 1994). Neither study was of sufficient size to answer 
this question adequately and both used serology alone to diagnose the presence of 
infection, which has a lower positive predictive value than other methods. Much larger, 
prospective, longitudinal studies would be required to address this issue fully.
7.2 C ir c u l a t in g  Ga st r in  C o n c e n t r a t io n s  a n d  H u m a n  C o l o r e c t a l  
N e o p l a sia
Once gastrin had been proposed as a growth factor for colon cancer cells in vitro and in 
animal models, attention soon focused on a possible link with colorectal cancer in 
humans. In 1988, Smith et al reported that mean fasting plasma gastrin was elevated 
eight-fold in patients with colon cancer and was also higher in those with adenomatous 
polyps compared to control patients (Smith et al 1988). Subsequently, a considerable 
number of studies have also addressed this question with several confirming the findings 
of Smith (Seitz et al 1989; Wong et al 1991; Chamley et al 1992; Seitz et al 1992). In 
contrast, a similar number have found no difference in circulating gastrin levels between 
colorectal tumour patients and controls (Suzuki et al 1988; Kauffinann and Ottenjann 
1991; Creutzfeldt and Lamberts 1991; Yapp et al 1992; Kikendall et al 1992; Scotte et 
al 1992). The reasons for such divergent results are many and are discussed more fully 
later (Chapter 10) in relation to the study carried out in this thesis. In brief, several of 
the studies were not well designed with poor matching of patients and controls, failure 
to allow for possible effects of bowel preparation on gastrin levels, failure to control for
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factors which may cause hypergastrinaemia and inappropriate statistical analyses. The 
majority of studies were conducted before the effects of Helicobacter pylori infection 
on gastrin concentrations became widely known and no investigation controlled for the 
presence of this common organism. To date, therefore, the question of whether patients 
with colorectal neoplasia have higher gastrin levels (for whatever reason) has not been 
adequately answered and there is a need for further rigorously controlled investigations. 
Data from a recent intriguing study has suggested that preoperative fasting gastrin 
concentrations correlated directly with the risk of liver metastases being present at the 
time of surgery (Kameyama et al 1993). The authors suggested that measurement of 
serum gastrin in combination with other parameters may be a useful predictor of liver 
metastases. After correcting for other factors, however, the patient numbers were small 
and it is unclear why the authors chose the cut-off value for gastrin that they did. The 
results may well have been non-significant if a higher or lower value had been chosen.
7.3 Ga st r in  a s  a n  A u t o c r in e  Gr o w t h  Fa c t o r  in  H u m a n  C a n c e r
In the last decade or so it has become increasingly recognised that peptide hormones 
may function by mechanisms other than purely endocrine. Advances in tumour 
molecular biology have established the autocrine/paracrine hypothesis as being 
important in the control of cell proliferation (Spom and Todaro 1980). Subsequently 
many hormones and growth factors have become recognised as relevant autocrine 
factors in common human malignancies (Cuttitta 1990).
Whether or not circulating gastrin is elevated in patients with colorectal 
tumours, investigators have recently examined the possibility that it may be an autocrine 
and/or paracrine trophic factor in this condition. In general, for a peptide to be accorded 
the status of an autocrine factor several criteria should ideally be fulfilled: tumour cells 
must produce the peptide with intact transcriptional, translational and post-translational 
processing pathways; peptide secretion should be demonstrated as should interaction of
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the secreted peptide with membrane receptors; and growth stimulation of the same (or 
neighbouring cells) also ought to be seen.
An autocrine role for gastrin in colorectal cancer was first proposed by 
Hoosein et al, who found polyclonal antigastrin antibodies to inhibit the growth of two 
human cell lines in vitro when added to the medium (Hoosein et al 1989). Pre­
incubation of the antiserum with human G-17 abrogated the effect. In a follow-up 
study, the authors confirmed this finding in three other cell lines, detected small 
amounts of a gastrin-like peptide in the cell culture supernatants by radioimmunoassay 
and found evidence for the presence of gastrin mRNA in the cells using northern 
analysis (Hoosein et al 1990). In contrast, Guo et al found the addition of antigastrin 
antibodies to MC-26 mouse colon cancer cells in vitro to have no effect on cell growth 
(Guo etal 1990).
Using a specific antigastrin antibody, with immunofluorescence and flow 
cytometry, Watson et al found six of twenty-eight freshly disaggregated human 
colorectal cancers to possess more than 20% gastrin-positive cells (Watson e ta l 1991). 
Tumour-free mucosa contained less than 5% gastrin-positive cells in the majority of 
cases. The authors suggested that foci of cells within the tumours may be able to 
secrete gastrin which may in turn stimulate proliferation of neighbouring gastrin 
receptor positive cells.
By northern analysis, no gastrin mRNA was found in two human cell lines but 
mRNA for the hormone was detected using the more sensitive polymerase chain 
reaction (PCR) technique (Baldwin et al 1990). The authors subsequently extended 
their findings and, using quantitative PCR, were able to detect gastrin mRNA in all 
seven colonic carcinoma cell lines tested with levels being two - seventy-fold greater 
than those of transforming growth factor-a (Baldwin and Zhang 1992). Singh’s group 
in Texas have also recently described a PCR method for the detection of gastrin gene 
expression and found small but significant amounts of gastrin mRNA in the three human 
colon cancer cell lines tested (Xu et al 1994). Independently, others have found gastrin 
in samples of colon cancers but not in normal colonic mucosa (Monges et al 1993) and
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demonstrated the capacity for gastrin transcription in some colon cancer cell lines 
(Tillotson et al 1993).
Following these reports of gastrin mRNA in colonic cancer cells, recent work 
has centred on synthesis of gastrin peptides in tumours. Using a panel of specific 
antibodies recognising different molecular forms of gastrin Kochman et al found 
equivalent amounts of progastrin in extracts of colorectal tumours and disease-free 
mucosa (Kochman et al 1992). While tumours contained more immature glycine- 
extended gastrins than normal mucosa, the latter contained greater amounts of mature, 
amidated gastrin. In comparison to gastric antrum the amounts detected were small and 
the ratio of amidated gastrin to glycine-extended gastrin was different, suggesting 
altered post-translational processing of gastrin in the tumours. No relationship between 
gastrin content and either tumour site or stage was seen. Around the same time, 
Dockray's group in Liverpool reported almost identical findings with all forty-four 
tumours examined containing progastrin and eleven having detectable mature gastrin 
(Nemeth et al 1993). Again mature gastrin was relatively more abundant in mucosa 
remote from the tumours, while the latter contained more progastrin. They confirmed 
these results with gel filtration and concluded that the gastrin gene is commonly 
expressed in colonic cancers but the ability to process the hormone fully is impaired. 
This was also the conclusion of Van Solinge et al, whose study also demonstrated the 
superior sensitivity of PCR methods over northern blot analysis for detecting small 
amounts of mRNA (Van Solinge et al 1993). While these authors felt the low level of 
expression of mature gastrin may not be relevant to tumour growth, preliminary results 
from others suggest that the more abundant non-amidated gastrin precursors may also 
possess trophic properties (Singh et al 1994). Several other groups have recently 
presented preliminary evidence that progastrin-derived glycine-extended intermediates 
may possess trophic properties, at least in AR42J cells (Seva et al 1994a; Negre et al 
1994). The possible importance of these precursors, traditionally regarded as lacking 
any biological activity, is discussed further in Chapter 12.
One problem with these studies is that they depend on tissue homogenisation 
for peptide extraction and nothing can therefore be said about the cellular source of the
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gastrin. The use of extremely sensitive antibodies and PCR methods could conceivably 
be detecting small amounts of gastrin synthesis occurring in scattered neuroendocrine 
cells found in colonic crypts. One report suggested that in situ hybridisation may 
unfortunately not be sensitive enough to detect low level gastrin gene expression in 
colonic cancers (Xerri et al 1992). In a comprehensive study Finley et al have examined 
gastrin gene expression in the colon using immunohistochemistry, northern analysis and 
PCR (Finley et al 1993). In normal colonic mucosa immunohistochemistry revealed 
occasional crypt cells which stained for progastrin, gastrin and chromogranin A 
suggesting that gastrin is normally only expressed in these scattered cells. In contrast, 
twenty-two of twenty-three colon cancers had over 50% of cells staining for gastrin and 
progastrin and the majority of these cells were non-neuroendocrine as judged by the 
absence of chromogranin A staining. Interestingly, no gastrin staining was found in six 
benign polyps suggesting that gastrin synthesis is a late event in the carcinogenic 
process. The mRNA detected in the tumours by PCR was identical in sequence to that 
published for human gastrin. Very recently this group has confirmed these findings in 
two human colorectal cancer cell lines and found that somatostatin inhibited both 
gastrin mRNA expression and cell growth, the latter effect being prevented when 
gastrin was supplied along with somatostatin (Lebovitz et al 1993). Thus strong 
evidence exists that normal and malignant colonic epithelium may synthesise gastrin but 
the direct effects of this on cell proliferation and the biological importance of immature 
gastrin precursors on colorectal cancer cells remain to be shown beyond all doubt.
Evidence supporting a role for gastrin as an autocrine/paracrine growth factor 
in neoplasia outwith the colorectum has also been presented. Detailed discussion of 
these studies is outwith the scope of this thesis but such a role for gastrin has been 
proposed in gastric carcinoma cell lines (Van Solinge and Rehfeld 1992; Remy-Heintz 
et al 1993), a rat pancreatic carcinoma cell line (Blackmore and Hirst 1992), 
bronchogenic carcinomas (Rehfeld et al 1989), ovarian cancers (Van Solinge et al 
1993), a human nephroblastoma cell line (Blackmore et al 1994) and a variety of 
uncommon neural and endocrine tumours (Rehfeld and Hilsted 1992). The ability to 
express and synthesise gastrin appears to be relatively common in many neoplastic cells
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of diverse origins and may contribute to disordered growth control in these tumours. 
Future studies examining the effects of inhibition of gastrin gene expression on tumour 
cell growth will hopefully shed further light on the importance of gastrin as an 
autocrine/paracrine trophic factor.
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CHAPTER 8 
AIMS OF THESIS
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8.1 In tr o d u c t io n
Much of the evidence presented above is consistent with a plausible role for gastrin as a 
biologically important trophic factor for normal and malignant colorectal epithelium. It 
is clear, however, that there are many conflicting studies yielding results which need to 
be clarified and also a number of questions which remain to be answered.
This is of direct clinical relevance for several reasons. Firstly, 
hypergastrinaemia occurs commonly in a variety of clinical situations, for example 
infection with Helicobacter pylori, pernicious anaemia and during treatment with acid- 
suppressing drugs such as H2-antagonists and H+/K+-ATPase inhibitors. This last 
situation is important as these drugs are among the most widely prescribed worldwide 
and are being increasingly used for long term maintenance therapy of common acid- 
related disorders. Secondly, an increasing number of new, potent and highly specific 
gastrin/CCK-B receptor antagonists have been described and if gastrin is shown to be a 
biologically relevant trophic factor for colorectal neoplasia, then these drugs could be a 
useful additional therapeutic option in a disease which still carries an overall five-year 
survival rate of only 40-50 %.
8.2 Pl a n  of  In v e st ig a t io n
1. To study the effect of omeprazole-induced chronic endogenous 
hypergastrinaemia on chemical colorectal carcinogenesis in a well-established 
animal model.
Given the enormous number of prescriptions each year for acid-suppressing drugs, even 
a small enhancing effect of hypergastrinaemia on colorectal carcinogenesis would be 
important to detect. Despite the many studies of gastrin on animal models of colorectal 
cancer, none has investigated the possible role of chronic endogenous 
hypergastrinaemia resulting from prolonged treatment with such widely used drugs.
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2. To clarify further the role of gastrin in human colorectal neoplasia.
Many aspects of this particular area remain unclear and to date no studies have 
addressed the issue comprehensively in one group of patients. This thesis aims to study 
circulating gastrin levels, tumour gastrin content and gastrin/CCK-B receptor content in 
the same group of patients and answer the following questions :-
a) Once all known factors causing hypergastrinaemia are controlled for, do fasting and 
meal-stimulated gastrin levels differ between tumour and control patients ?
b) In patients with colorectal cancer, do circulating gastrin concentrations fall following 
tumour resection, as has been suggested ?
c) Do tumours from these patients contain measurable amounts of gastrin and/or 
gastrin-processing intermediates and is there any correlation between tumour peptide 
content and circulating levels ?
d) Are measurable gastrin/CCK-B receptors present on the colorectal tumours of these 
patients and is there any correlation between circulating gastrin levels, tumour gastrin 
content and tumour gastrin receptor content ?
PART TWO 
EXPERIMENTAL WORK
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CHAPTER 9
OMEPRAZOLE AND EXPERIMENTAL 
COLONIC CARCINOGENESIS IN RATS
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9.1 In t r o d u c t io n
To date very few studies have investigated the influence of drug-induced endogenous 
hypergastrinaemia on the development and/or progression of experimental colorectal 
tumours in animal models. Pawlikowski et al (1991) observed an increase in the number 
of vincristine-arrested metaphases in colonic crypts of rats treated with omeprazole 
compared to placebo. Others found omeprazole-induced hypergastrinaemia to have no 
effect on the growth rate of established gastrin-responsive murine (MC-26) colonic 
cancer xenografts (Graffner et al 1991).
The aim of this study was to assess the effects of omeprazole-induced 
hypergastrinaemia on the development of azoxymethane-induced colorectal carcinomas 
in rats. As described in Chapter 4 this model is well characterised and has become 
widely used in studies of factors influencing colorectal carcinogenesis.
9.2 M a t e r ia l s  a n d  M e th o d s
9.2.1 Experimental Animals
Five-week old female Sprague-Dawley rats (Harlan Olac Ltd., UK), weighing 125-150g 
were used throughout the study. Animals were maintained in the Joint Animal Facility 
of the University of Glasgow and housed two per cage, the cages being made of 
moulded polypropylene with stainless steel mesh lids. Animal bedding consisted of 
wood shavings and was changed weekly. Both experimental groups were kept in one 
room, separate from all other animals, under controlled environmental conditions 
(temperature 21°C ± 1°C, humidity 50% ± 5% and alternating 12 hour light-dark 
lighting cycle).
All rats were allowed food and water ad libitum. The diet consisted of 
standard rat and mouse formulation (Bantin and Kingman Ltd., Hull, UK). Animals 
were weighed once weekly until the end of carcinogen administration (week seventeen) 
and were then weighed three times per week. At each weighing, careful inspection was
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made for signs of possible tumour development including inappetance, fur loss or 
textural change, abdominal swelling and rectal bleeding.
All procedures were licensed by the Home Office (Personal Investigator 
Licence No. PIL 60/03942) under the Animals (Scientific Procedures) Act 1986. In 
addition all work adhered to both the Code of Practice for the Joint Animal Facility, 
University of Glasgow and United Kingdom Coordinating Committee for Cancer 
Research (UKCCCR) guidelines.
9.2.2 Food Consumption
During weeks ten, fourteen, sixteen, twenty-one and twenty-four a measured quantity 
of food was provided for each cage and the amount remaining at the end of seven days 
weighed. This allowed calculation of the weight of diet consumed per cage per week 
and from this, the amount (gms.) eaten per rat per day was derived. Although this 
assumes that both rats in a given cage ate equal amounts, it was relative differences in 
food consumption between the two groups which were being sought, not absolute 
differences between individual rats and so this assumption is of less importance.
9.2.3 Experimental Design and Omeprazole Dosing
This is summarised diagrammatically in Figure 9.1. After a one week acclimatisation 
and quarantine period, rats were randomly divided into two groups to receive either 
omeprazole at a dose of 40pmol.kg'1.day'1 or an equivalent volume of 0.25% buffered 
methylcellulose (the vehicle in which omeprazole was suspended), once daily by oral 
gavage. Gavage was carried out between 0900 and 1200 each day using a 2ml syringe 
attached to a stainless steel intragastric feeding tube (International Market Supplies, 
Cheshire, UK). Dosing was continued for the entire twenty-seven weeks of the study. 
Details of the method for reconstitution and formulation of omeprazole and dose 
calculation can be found in Appendices 2 and 3.
Illlll azoxymetImne |||||
omeprazole/vehicle
0 1 6  17 27
week number
T  T  T
gastrin gastrin gastrin
Figure 9.1. Schematic representation o f study design.
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9.2.4 Carcinogen Treatment
Azoxymethane (AOM) was purchased in 500mg ampoules from Sigma Chemical Co. 
(Poole, Dorset, UK), and stored at -20°C until required. The methods used for dilution, 
storage and handling azoxymethane (including safety precautions) are given in 
Appendix 1.
During weeks six to seventeen all rats received twelve weekly subcutaneous 
injections of azoxymethane at a dose of lOmg.kg.'1 injection"1. Immediately prior to 
each injection of azoxymethane, rats were weighed and lightly anaesthetised with 
halothane. Based on the individual weight, the appropriate dose of AOM was then 
drawn up and injected into the paravertebral region. Injections were performed without 
knowledge of the group of origin of each rat as it was injected.
Because of the potent carcinogenic nature of AOM only authorised personnel 
wearing full protective clothing handled either the drug or recently injected animals. To 
minimise any potential exposure of personnel to exhaled carcinogenic metabolites 
(principally azomethane gas), all injections were performed between 1400 and 1600 on 
Friday afternoons. After each injection access to animals was denied for twenty-four 
hours except to authorised staff employing full protective measures. Furthermore, the 
animals were housed in a room with negative pressure ventilation to minimise any 
possible escape of exhaled carcinogenic metabolites.
9.2.5 Serum Gastrin Analysis
Serum gastrin levels in the two groups were measured at the following times:
(a) Week One - prior to commencing treatment with either omeprazole or vehicle.
Six freely-fed rats from each group were bled to measure baseline gastrin levels. Blood 
samples (0.7ml) were taken from the tail vein under light halothane anaesthesia.
(b) Week Five - prior to commencing azoxymethane injections.
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In order to assess not only the peak gastrin levels obtained with omeprazole dosing, but 
also the duration of hypergastrinaemia over a twenty-four hour period between two 
doses, rats were bled at regular intervals over a twenty-four hour period. This was 
carried out immediately prior to dosing with either omeprazole or vehicle. As rat gastrin 
responses have been well documented elsewhere (Larsson et al 1986; Earl and Man 
1990), only three rats from each group were selected at each time point. Blood (0.7ml) 
was again taken from the tail vein under halothane anaesthesia.
(c) Week Twenty-Seven - at termination of the experiment.
At death, blood was taken by cardiac puncture from all rats. Vehicle-treated rats were 
bled four hours after the last dose whereas omeprazole-treated rats were bled either 
four hours (n=6) or twenty-four hours (n=13) after the final dose of the drug.
Blood samples were collected on ice in plain tubes, allowed to clot and 
centrifuged at 3000 r.p.m. for ten minutes at 4°C to separate serum. Serum was then 
stored at -70°C until analysis which was performed (in duplicate) by radioimmunoassay 
using antibody R98 (Ardill 1973). This recognises the C-terminal end of both human 
and rat gastrin and has a sensitivity of approximately 3ngL_1.
9.2.6 Post mortem analysis
At the end of the study in week twenty-seven, animals were killed by exsanguination 
under C02 anaesthesia. All animals were killed between 1200 and 1600 to minimise 
possible effects of diurnal variation on serum gastrin levels. Following division of the 
pubic symphisis the entire colon from anorectal junction to caecum was excised, opened 
along the length of the antimesenteric border, pinned flat on a cork mat with the 
mucosal surface uppermost and rinsed thoroughly with ice-cold 0.9% saline to remove 
faeces and clot. Total colon length was measured and the number, position (in
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millimetres from the anorectal junction) and volumes (the product of length x width x 
depth in mm3) of all lesions recorded. Samples of liver (approximately lg) and 
macroscopically normal ascending and descending taken from 75% and 25% along the 
length of the colon, respectively, were snap frozen in liquid nitrogen and stored at - 
70°C until further analysis.
After the remainder of the colon and liver had been fixed overnight in 10% 
neutral-buffered formalin, all lesions plus samples of macroscopically ascending and 
descending colon (as above) and liver were removed, individually coded, processed for 
routine histopathology and embedded in paraffin wax. Sections (4pm) were stained 
with haematoxylin and eosin and examined "blind" i.e. without knowledge of their 
group of origin. As previously described (Sunter et al 1978), all neoplastic lesions were 
described as either benign adenomas or adenocarcinomas, the latter being classified into 
Group 1-3 carcinomas according to the degree of invasiveness and differentiation.
9.2.7 Chemicals
Pure omeprazole (a gift from Dr. H. Mattsson, Astra Hassle, AB Molndal, Sweden) 
was suspended in 0.25% methylcellulose (Dow Chemicals), buffered with 2mg.ml'1 
sodium bicarbonate and adjusted to pH 9.0 with sodium hydroxide. The solution was 
stored at -20°C prior to use and fresh aliquots thawed for use every four to five days 
and kept at 4°C. Azoxymethane (Sigma Chemical Co., Dorset, UK) was dissolved in 
sterile 0.9% sodium chloride, kept as a stock solution of lOOmg.ml'1 at 4°C and further 
diluted to a final concentration of lOmg.ml"1 with sodium chloride immediately prior to 
use. Further details are given in Appendix 3.
9.2.8 Statistics
All statistical testing was performed using the statistical software package MINITAB 
8.0 (Minitab Inc., USA). Tumour incidence was analysed by Fischer's exact test and 
tumour distribution and multiplicity by the Mann Whitney U-Test. Correlations between 
animal weight and tumour development were assessed using Spearman's rank
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correlation coefficient. The unpaired t-test was used for all other tests including tumour 
volumes after logarithmic transformation of the data. Statistical significance was taken 
as a value of P < 0.05 in all tests.
9.3 R e s u l t s
9.3.1 Animal Survival
One animal in the omeprazole group (rat number eight) died during week eleven as a 
result of oesophageal perforation during oral gavage. At necropsy a pneumothorax and 
mediastinitis were found but close examination of the opened colon and rectum 
revealed no evidence of tumour formation or other abnormality. A further rat (number 
sixteen) in the omeprazole group developed respiratory distress and weight loss of 
greater than ten per cent and was therefore killed in week twenty-two. Again, no 
abnormality was found in the large intestine or elsewhere in either the small intestine, 
peritoneal cavity or liver at necropsy. There was evidence, however, of pulmonary 
congestion and significant frothy upper airways secretions, suggesting either pulmonary 
aspiration or oesophageal perforation during oral gavage.
In the vehicle-treated group two rats (numbers one and ten) developed 
diarrhoea and rectal bleeding in week twenty-five. At necropsy both were found to have 
colonic tumours. All other animals survived until the end of the study and were killed in 
week twenty-seven.
9.3.2 Animal Growth and Development
Both groups of animals grew at similar rates although the omeprazole-treated group 
were consistently lighter throughout the study (Figure 9.2). At the end of the 
experiment the omeprazole-treated rats weighed (± S.D.) 342.5 (± 41.7) g compared to 
a mean weight of 389.3 (± 44.6) g in vehicle-treated control animals (P = 0.004). 
Throughout the study period all animals in both groups appeared healthy and no 
differences in fur quality or other subjective measures of animal wellbeing were noted
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Figure 9.2
Rat growth during study period (mean ± S.D.)
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between the groups. Individual animal weights are detailed in Table 9.1. All animals, 
except the omeprazole-treated rat which died during week eleven were included in 
effective numbers for analysis.
9.3.3 Food Consumption
No consistent pattern in differences in food consumption was found throughout the 
study (Tables 9.2 and 9.3). Calculated food consumption, expressed as grams per rat 
per day, was significantly greater in the omeprazole group in week ten (P < 0.05) and 
week fourteen (P < 0.001). In contrast, food intake was higher in vehicle-treated 
animals in week twenty-one (P < 0.001) whereas no significant difference was noted in 
either of the two other weeks when food consumption was measured (weeks sixteen 
and twenty-four).
9.3.4 Serum Gastrin Levels
(a) Week One - Six freely-fed rats from each group were bled in week one for 
measurement of baseline serum gastrin concentrations. Mean gastrin levels (± S.D.) in 
the omeprazole group were 204 (± 57) ng.L'1 compared to 220 (± 61) ng.L"1 in the 
vehicle group (P = not significant). Results are shown in Figure 9.3 and Table 9.4 
shows individual gastrin concentrations in the two groups of rats.
(b) Week Five - Omeprazole treatment resulted in greatly elevated serum gastrin 
concentrations with peak levels occurring two hours after dosing. Peak values in the 
omeprazole group were 1700 ng.L'1 (an approximate nine-fold increase) and levels 
remained elevated for most of the twenty-four hour period. Even twenty hours after 
dosing (at 0800) mean gastrin concentration (383ngL_1) was still twice that in the 
vehicle group (184ngL_1). In contrast, little variation in serum gastrin concentrations 
occurred throughout the twenty-four hour period following dosing with vehicle. The 
results are depicted in Figure 9.4 and individual gastrin levels are shown in Table 9.5.
week 10 week 14 week 16 week 21 week 24
Omeprazole 18.24 ±0.92* 19.76 ± 1.43 ** 19.02 ± 1.39 19.75 ±0.98 19.08 ±2.30
Vehicle 17.15 ± 1.17 16.61 ±0.83 19.90 ±0.75 22.79 ± 1.56 ** 18.73 ±2.45
Table 9.2. Mean (± SD) food consumption.
Results are expressed as gms.rat^.day'1. * P < 0.05. ** P < 0.001.
week 10 week 14 week 16 week 21 week 24
cage 1 17.30 18.40 20.40 18.50 20.30
cage 2 18.40 20.00 20.40 19.90 21.40
cage 3 19.00 19.90 17.10 19.00 20.60
cage 4 19.20 18.10 18.40 20.10 15.40
cage 5 18.10 20.90 19.90 19.80 20.30
cage 6 16.60 18.10 19.60 19.10 16.90
cage 7 18.70 19.00 17.90 18.70 17.60
cage 8 17.30 20.10 17.10 19.90 16.40
cage 9 19.40 22.70 18.60 21.60 22.00
cage 10 18.40 20.40 20.80 20.90 19.90
Mean 18.24 19.76 19.02 19.75 19.08
S.D. 0.92 1.43 1.39 0.98 2.30
Table 9.3a. Food consumption per cage (gms.rat_1.day_1) for Omeprazole group.
week 10 week 14 week 16 week 21 week 24
cage 1 16.60 18.20 20.00 24.20 21.10
cage 2 14.70 15.90 19.40 21.60 15.70
cage 3 17.50 15.90 19.90 22.90 17.10
cage 4 16.30 15.60 19.50 21.30 15.60
cage 5 18.30 17.30 21.40 25.70 22.80
cage 6 16.70 16.60 19.30 20.50 21.60
cage 7 17.80 16.10 20.10 21.70 18.90
cage 8 17.00 16.60 19.00 23.90 18.60
cage 9 17.80 16.40 19.50 22.90 18.50
cage 10 18.80 17.50 20.90 23.20 17.40
Mean 17.15 16.61 19.90 22.79 18.73
S.D. 1.17 0.83 0.75 1.56 2.45
Table 9.3b. Food consumption per cage (gms.rat^.day'1) for Vehicle group.
Rat Number Omeprazole Vehicle
1 225 180
2 165 120
3 300 220
4 195 260
5 135 260
6 195 280
Mean 204 220
S.D. 57 61
Table 9.4. Serum gastrin concentrations (ng.L-1) in six rats per group in week one.
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Serum gastrin concentrations (ng.L"*) during a 24 hour period in week 5.
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(c) Week Twenty-Seven - Two samples taken from omeprazole-treated rats twenty- 
four hours after the final dose of omeprazole were haemolysed and unsuitable for 
analysis. Mean serum gastrin values in omeprazole-treated rats both four hours (2470 ± 
796 ng.L'1, P = 0.001) and twenty-four hours (331 + 113ngL_1, P < 0.05) after the last 
dose were significantly higher than in vehicle-treated controls (245 + 72ngL_1). The 
results are represented in Figure 9.3 and Table 9.6. Figure 9.3 also shows the 
considerable variation in gastrin levels in response to omeprazole with levels four hours 
after dosing ranging from 1360-3520 ng.L"1. There was also a three-fold variation 
among rats in the gastrin levels twenty-four hours after the last dose (range 200-600 
ng-L'1).
9.3.5 Tumour Development
(i) Tumour Incidence and Number
Significantly fewer rats in the omeprazole-treated group (12/19, 63%) developed 
histologically confirmed tumours, compared to the rats treated with vehicle only (19/20, 
95%; P < 0.02, Fischer's exact test). Furthermore, in the omeprazole group both the 
total number of tumours (twenty-eight) and the median number of tumours per rat (1.0, 
range 0-5) were significantly lower (P = 0.02, Mann-Whitney U test) than in the 
vehicle-treated group (fifty-nine tumours, median 3.0, range 0-10). Close examination 
of sections taken from samples of macroscopically normal ascending and descending 
colon did not reveal any early or microscopic lesions. Liver metastases were not found 
in either group but deposits of tumour were seen in the omentum of one rat in the 
vehicle-treated group. The results are shown in Table 9.7.
(ii) Tumour Histology
Histologically the relative numbers of benign adenomas and adenocarcinomas were 
similar in both groups with six adenomas (21%) and twenty-two carcinomas (79%) in 
the omeprazole-treated rats compared to eleven adenomas (19%) and forty-eight (81%)
Rat
Number
Omeprazole 
(4 hours)
Omeprazole 
(24 hours)
Vehicle 
(4 hours)
1 1360 - n/a
2 2080 - 340
3 2560 - 180
4 3520 - n/a
5 3200 - 280
6 2100 - 220
7 - 600 260
8 - * 260
9 - 320 120
10 - 400 220
11 - 280 n/a
12 - 200 200
13 - 240 220
14 - 280 300
15 - 400 300
16 - 260 400
17 - 260 220
18 - 400 220
19 - n/a 160
20 - n/a n/a
Mean 2470 331 245
S.D. 796 113 72
Table 9.6. Individual serum gastrin concentrations (ng.L-1) at death 
(week twenty-seven). *Rat excluded, n/a = no result.
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carcinomas in rats treated with vehicle. In the vehicle-treated group, three tumours had 
typical cytological features of malignancy but invasiveness could not be assessed 
because the tumour stalk was not adequately seen and these lesions have been termed 
"carcinomas unclassified". The relative proportions of Group 1 and Group 2 carcinomas 
were similar in the two groups of animals but there were considerably more Group 3 
carcinomas (nine, 15%) in vehicle-treated animals than in the omeprazole-treated group 
(one, 3.6%). Tumour classification is detailed in Tables 9.8 - 9.10. Examples of 
azoxymethane-induced tumours are shown in Figures 9.5 - 9.7.
(iii) Tumour Distribution
There was no significant difference between the groups in the site distribution of the 
tumours, the majority occurring in the distal colon and rectum in each group. Mean 
colon length was 196 (± 14.7) mm in the Omeprazole group and 201 (± 16.8) mm in 
the Vehicle group (P = 0.35). To control for variations in colon length among animals, 
tumour sites were expressed as percentage distance along the length of the colon with 
'O' representing the anorectal margin and '100' representing the caecum. In both groups 
the majority of lesions occurred in the distal colon and rectum, the median distances 
being 32.5% (range 3-95%) for the Omeprazole group and 31% (range 3-70%) for the 
Vehicle group (P = 0.86, Mann-Whitney U test). Tumour site distributions are detailed 
in Table 9.11 and 9.12 and graphically represented in Figure 9.8.
(iv) Tumour Volumes
There was no significant difference in average tumour size in the two groups as 
measured by the median tumour volume, the results being 27mm3 (range 1-288mm3) 
for the Omeprazole group and 30mm3 (range 1-800mm3) for the Vehicle group (P = 
0.90, Mann-Whitney U test). There was, however, a preponderance of small tumours (< 
10mm3) in the vehicle group (22/59, 37%) compared to the omeprazole group (4/28, 
14%). Table 9.13 and 9.14 and Figure 9.9 show the tumour volume results.
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Animal
number Omeprazole Vehicle
1 0 10
2 2 3
3 1 3
4 4 2
5 0 5
6 2 3
7 4 4
8 * 3
9 1 3
10 1 4
11 0 1
12 0 0
13 2 1
14 0 1
15 5 2
16 0 1
17 0 4
18 1 5
19 4 2
20 1 2
Total 28 59
Median 1.0 3.0
Range 0-5 0-10
Table 9.9. Number of histologically confirmed tumours per rat. * Rat excluded.
Rat
No.
No. of 
Lesions
Lesion
No.
Histological
Classification
1 0
2 2 1 benign adenoma
2 group 3 carcinoma
3 1 1 group 2 carcinoma
4 4 1 group 1 carcinoma
2 group 2 carcinoma
3 group 2 carcinoma
4 group 2 carcinoma
5 0
6 2 1 group 2 carcinoma
2 group 1 carcinoma
7 4 1 group 2 carcinoma
2 group 2 carcinoma
3 benign adenoma
4 benign adenoma
8 * ♦ *
9 1 1 group 2 carcinoma
10 1 1 group 1 carcinoma
Table 9.10a. (2 pages). Histological classification of tumours in Omeprazole group.
Rat
No.
No. of 
Lesions
Lesion
No.
Histological
Classification
11 0
12 0
13 2 1 benign adenoma
2 group 2 carcinoma
14 0
15 5 1 group 1 carcinoma
2 group 2 carcinoma
3 group 2 carcinoma
4 benign adenoma
5 benign adenoma
16 0
17 0
18 1 1 group 2 carcinoma
19 4 1 group 2 carcinoma
2 group 2 carcinoma
3 group 2 carcinoma
4 group 1 carcinoma
20 1 1 group 2 carcinoma
Table 9.10a contd.(page 2 of 2). Histological classification
of tumours in Omeprazole group.
Rat
No.
No. of 
Lesions
Lesion
No.
Histological
Classification
1 10 1 group 1 carcinoma
2 group 2 carcinoma
3 benign adenoma
4 group 2 carcinoma
5 group 2 carcinoma
6 group 2 carcinoma
7 group 2 carcinoma
8 group 2 carcinoma
9 benign adenoma
10 carcinoma - unclassified
2 3 1 group 2 carcinoma
2 group 2 carcinoma
3 group 3 carcinoma
3 3 1 group 2 carcinoma
2 group 2 carcinoma
3 group 3 carcinoma
4 2 1 benign adenoma
2 benign adenoma
5 5 1 group 3 carcinoma
2 group 2 carcinoma
3 group 1 carcinoma
4 group 2 carcinoma
5 group 2 carcinoma
Table 9.10b (3 pages). Histological classification of tumours in Vehicle group.
Rat
No.
No. of 
Lesions
Lesion
No.
Histological
Classification
6 3 1 group 2 carcinoma
2 group 1 carcinoma
3 group 2 carcinoma
7 4 1 benign adenoma
2 group 2 carcinoma
3 carcinoma - unclassified
4 carcinoma - unclassified
8 3 1 group 1 carcinoma
2 group 2 carcinoma
3 benign adenoma
9 3 1 group 1 carcinoma
2 group3 carcinoma
3 group 2 carcinoma
10 4 1 group 2 carcinoma
2 group 1 carcinoma
3 group3 carcinoma
4 benign adenoma
11 1 1 group 3 carcinoma
12 0
Table 9 .10b contd. (page 2 of 3). Histological classification of tumours in Vehicle group.
Rat
No.
No. of 
Lesions
Lesion
No.
Histological
Classification
13 1 1 group 2 carcinoma
14 1 1 group 2 carcinoma
15 2 1 benign adenoma
2 group 2 carcinoma
16 1 1 group 2 carcinoma
17 4 1 benign adenoma
2 group 2 carcinoma
3 group 2 carcinoma
4 group 3 carcinoma
18 5 1 benign adenoma
2 benign adenoma
3 group 2 carcinoma
4 group 2 carcinoma
5 group 3 carcinoma
19 2 1 group 3 carcinoma
2 group 2 carcinoma
20 2 1 group 2 carcinoma
2 group 1 carcinoma
Table 9.10b contd. (page 3 of 3). Histological classification of tumours in Vehicle group.
Figure 9.5
Multiple tumours of varying stages induced by azoxymethane in a vehicle-treated rat.
Figure 9.6
Example of an azoxvmethane induced benign adenoma (with superficial dysplasia) in 
a rat treated w ith omeprazole.
Figure 9.7
Example of an azoxymethane-induced group 2 carcinoma in a rat treated with vehicle.
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9.5 D isc u ssio n
The aim of this study was to assess whether persistent endogenous hypergastrinaemia 
secondary to prolonged omeprazole treatment would enhance colorectal carcinogenesis 
induced in rats by azoxymethane. Despite causing marked hypergastrinaemia (levels 
raised up to ten-fold) the results show that, contrary to the hypothesis, chronic 
omeprazole therapy significantly inhibited tumour formation. There are several possible 
explanations for this observation.
Firstly, it is possible that omeprazole-treated rats developed tumours with 
similar frequency but that the drug inhibited their growth, resulting in many microscopic 
lesions being missed in the omeprazole group. This is unlikely because the samples of 
normal flat colon taken from all rats failed to reveal any early microscopic lesions. 
Furthermore, if omeprazole inhibited the growth of tumours once they developed, then 
one would have expected this group to have on average smaller tumours but this was 
not the case. It is possible to speculate, however, that omeprazole may have exerted its 
effects on tumour initiation by the mechanisms discussed below but that once tumours 
developed the trophic effects of the elevated gastrin levels in this group resulted in more 
rapid tumour growth with the final result being an overall similarity in the measured 
tumour volumes in the two groups. Further experiments using antrectomised rats or 
doses of omeprazole which do not significantly raise gastrin levels would be needed to 
dissociate the effects of the drug per se from those due to gastrin. Finally, Graffher et al 
(1992) did not find any effect of omeprazole on the growth of colonic tumour 
xenografts in mice and so inhibitory effects of omeprazole on tumour growth seem 
unlikely.
Secondly, underfeeding and/or calorie restriction with reduced weight gain and 
growth have been shown to inhibit the development of tumours at various sites, 
including the colon, in animals (Albanes 1987; Kritchevsky et al 1990). In the present 
study, the omeprazole-treated animals did grow more slowly than the vehicle-treated 
rats and were on average 12% lighter at the end of the study. Calculated food intake 
measured frequently throughout the experiment (Table 9.2) did not show that rats in the
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omeprazole group consumed less - in fact food intake was either similar or greater in 
the omeprazole group at four of the five time points measured. These findings of 
increased food intake but slightly reduced weight gain are entirely consistent with what 
was noted during the development and testing of omeprazole (Ekman et al 1985) 
although it is not known why it occurs. When the nineteen omeprazole rats included in 
effective numbers for analysis were subdivided into those with tumours (n = 12) and 
those without tumours (n = 7) there was no significant difference between their mean 
weights (Mann Whitney U test). Using Spearman's rank correlation coefficient there 
was no correlation between final weight and the number of tumours per rat (ps = 0.195; 
P > 0.2) or between animal weight and the total tumour "burden" per rat, "burden" 
being the total volume of all lesions in that rat (ps = -0.149; P > 0.2). Furthermore, the 
study of Kumar et al found significant inhibition of azoxymethane-induced tumours 
only at levels of calorie restriction of 20% or more (Kumar et al 1990) and from other 
published data on calorie restriction and experimental carcinogenesis (Kritchevsky et al 
1990; Albanes 1987), the minor weight difference in this study is unlikely to have made 
more than a minor contribution to the results.
An alternative possibility for the reduced tumour incidence in the omeprazole 
group is that the gastrin levels were excessively high and may even have inhibited cell 
growth. The levels of gastrin reported to stimulate colonic epithelial proliferation vary 
greatly. While modest two to three-fold rises in gastrin have been found to be trophic, 
even G-17 concentrations as high as 1600pmol.L_1 (equivalent to 3200ng.L'1) 
stimulated a colorectal cancer cell line in vitro (Yactayo et al 1991) although maximal 
stimulation occurred at lower doses (400pmol.L_1 i.e. 800ng.L_1). Durrant et al also 
found that the optimum concentration of gastrin for several cell lines was 3ng/ml (i.e. 
3000ng.L_1) when testing gastric and colorectal cancer cell lines for their trophic 
responses to added gastrin (Durrant et al 1991). The maximum stimulation of HT29 
colon cancer cells in one study occurred in response to 400pmol.L"1 of G-17 
(equivalent to 800ng.L_1) but even a dose of 4000pmol.L'1 (8000ng.L-1) stimulated 
growth, albeit to a lesser degree (Smith et al 1988). In addition the same authors found
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that very high doses of pentagastrin (500 and 1000 pg.kg'1) stimulated the growth of 
colonic cancer xenografts in mice.
In a study of thirty-one fresh human colorectal tumours, screened in vitro for 
their trophic responsiveness to gastrin (Watson et al 1989b), seventeen of the thirty-one 
tumours were found to be gastrin responsive, the majority responding maximally to high 
concentrations of gastrin (2-50pg.L_1 i.e. 2000-50000ng.L_1). Normal rat colonic 
epithelium in vivo has been found to respond trophically to doses of pentagastrin 
ranging up to lOOOpg.kg"1 with a significant quadratic dose response relationship 
(Fatemi et al 1984) and a similar dose response relationship for gastrin on gastric ECL 
cells has also been found (Brenna et al 1993). In this study constant infusions of gastrin 
were trophic to the ECL cells with the maximal effect occurring at circulating gastrin 
levels of 250-400pmol.L-1 (equivalent to 500-SOOng.L’1, a seven to eleven-fold 
elevation of gastrin levels compared to control animals). Even the highest infusion dose 
of gastrin, which resulted in a fourteen-fold elevation in serum gastrin levels, was 
trophic to the cells. Thus, the levels of gastrin obtained in this thesis are similar to those 
which have previously been demonstrated to be trophic for rat gastrointestinal 
epithelium.
The gastrin levels in the rats were comparable to those which may be seen 
during chronic omeprazole therapy in man. While the majority of patients have three or 
four-fold rises in gastrin, in the study by Jansen et al eight out of thirty-two patients 
during longterm omeprazole treatment had fasting gastrin levels of over 500 ng.L'1 
which was more than ten times the median level (Jansen et al 1990). Bearing in mind 
that the postprandial rise in gastrin is maintained during omeprazole treatment, their 
postprandial levels would be more than lOOOng.L'1. Also, pernicious anaemia patients 
may have gastrin levels of around 2000-4000ng.L_1 (Lamers 1980). Thus, the 
hypergastrinaemia produced in the current study is relevant to the levels seen clinically 
in patients with pernicious anaemia and also during omeprazole therapy.
It therefore seems unlikely that the above reasons are unlikely to explain the 
reduced prevalence of tumours in the omeprazole group and an effect of omeprazole 
itself on the carcinogenic process must be considered. Longterm therapy with acid
104
inhibitory drugs has been shown to result in bacterial overgrowth in the upper 
gastrointestinal tract (Sharma et al 1984), altering the composition of the intestinal 
microflora. Such bacteria may be important in colonic carcinogenesis and contribute to 
the tumourigenicity of azoxymethane (Reddy et al 1974), possibly by participating in 
metabolism of the carcinogen in the colon and it is conceivable that the omeprazole 
effect on colonic carcinogenesis was secondary to the drug affecting the composition 
and enzymatic activity of the intestinal microflora.
Alternatively, omeprazole may have exerted its effects by modifying the 
metabolism of azoxymethane, thereby reducing its effectiveness. Most known 
carcinogens exist as procarcinogens and require metabolic activation, usually by 
hydroxylation in the liver, in order to exert their genotoxic effects (Guengerich 1988; 
Snyderwine et al 1992) and these reactions are carried out by members of the 
cytochrome P450 supergene family of enzymes (Gonzalez and Gelboin 1991). 
Cytochromes P450 IA1 and IA2 (CYPIA1 and CYPIA2) have been found to be the 
main ones involved in the metabolic activation of a variety of carcinogens including 
numerous heterocyclic amines commonly present in cooked food (Turesky et al 1991; 
Wakabayashi et al 1992) and polycyclic aromatic hydrocarbons. The levels of 
expression of these enzymes, and their activities, both in the liver and also in 
extrahepatic tissues such as small intestine and colon can be modified by various 
factors. These include dietary lipid (Yoo et al 1992), extracts of cruciferous vegetables 
(Vang et al 1991) and xenobiotics including other carcinogens (Harper et al 1990; 
Kleman et al 1990). It is possible that the relative expressions of these and other P450 
enzymes in different tissues may be important in determining the overall balance 
between activation and detoxification of a given xenobiotic and its carcinogenic 
effectiveness. Cytochrome P450 enzymes capable of metabolising azoxymethane have 
also been found in the colon of humans and animals (Stralka and Strobel 1991; 
Rosenberg 1991; White et al 1991). While CYP IIE1 appears to be important in the 
activation of azoxymethane (Sohn et al 1991), the full pathway of azoxymethane 
metabolism has not been elucidated and the role of other cytochrome P450 enzymes, 
notably CYP IA1 and IA2 remains to be determined.
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Omeprazole has been shown to interact with the cytochrome P450 system. In 
1990, Diaz et al (1990) showed that omeprazole was a potent inducer of both CYPIA1 
and IA2 in human hepatocytes in vitro (although no effect CYPIIE1 was noted) and 
raised fears that this may result in increased activation of carcinogens metabolised by 
these enzymes. Subsequently the newer H+/K+ ATPase inhibitors, pantoprazole and 
lansoprazole, have also been found to modulate cytochrome P450 enzyme activity in 
animals (Simon et al 1991). Also, McDonnell et al (1992) have recently demonstrated 
that omeprazole treatment for seven days induced CYP LAI gene expression and 
enzyme activity in vivo in endoscopic biopsies from human volunteers with the most 
marked effects seen in the duodenum. These are probably direct effects of the drug or a 
metabolite rather than the resulting hypergastrinaemia as continuous infusions of 
pentagastrin do not seem to affect cytochrome P450 enzyme activity, at least in the 
small intestine (Pascoe and Correia 1988).
These findings and the concerns expressed about omeprazole have proved 
controversial and stimulated much debate (Farrell and Murray 1990; Lucier et al 1992; 
Parkinson and Hurwitz 1991; Moldeus et al 1991). While it appears logical to assume 
that induction of CYP IA proteins, with increased activation of heterocyclic amines and 
increased mutagenicity, would result in enhanced carcinogenicity, this has not been 
found to be the case when studied in animal models of cancer development. Indeed the 
contrary has been found to be the case, with induction of IA proteins being repeatedly 
shown to be associated with protection against tumour formation (Anderson and 
Seetharam 1985; Miller et al 1958; Wattenberg and Leong 1970). Similarly, inhibition 
of these enzymes is associated with enhanced carcinogenesis in animals (Wheatley 
1968), despite the reduced activation of the carcinogens under study. Thus, 
demonstrating increased carcinogen activation and mutagenicity in vitro on the one 
hand does not necessarily correlate with increased tumour formation. In fact the 
opposite seems to apply, highlighting our relative lack of understanding of this 
extremely complex subject.
The reduced carcinogenic activity of azoxymethane during omeprazole therapy 
may be related to the latter modifying the metabolism of the carcinogen in the colon or
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liver or affecting P450 isoenzymes differentially at these two sites. Further studies on 
both the pathway of azoxymethane metabolism and the effects of omeprazole on this 
pathway are obviously needed before conclusions can be made regarding the 
mechanism(s) by which omeprazole exerts its protective effects. For instance, it is not 
known whether the omeprazole-inducible enzymes IA1 and IA2 are important in 
azoxymethane metabolism.
Due to the unexpected inhibitory effects of omeprazole on colorectal 
carcinogenesis, the present model is unsuitable for assessing the effect of chronic 
hypergastrinaemia on colonic carcinogenesis. Chronic hypergastrinaemia due to other 
causes, however, cannot be excluded as important in colorectal cancer development. 
The present studies do suggest that fears regarding the potential deleterious effects of 
omeprazole on carcinogenesis (Diaz et al 1990; Simon et al 1991; McDonnell et al 
1992) may be unfounded. Further studies on the mechanism(s) by which omeprazole 
protects against chemical colorectal tumourigenesis and the doses at which this occurs 
are merited and may shed light on the pathogenesis of this common disease.
CHAPTER 10
PLASMA GASTRIN CONCENTRATIONS 
IN HUMAN COLORECTAL NEOPLASIA
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10.1 In t r o d u c t io n
Some authors have reported that patients with conditions which result in 
hypergastrinaemia (such as pernicious anaemia and following truncal vagotomy or 
Billroth I gastrectomy) are at increased risk of subsequent development of colorectal 
cancer (Bundred et al 1985; Talley et al 1989; Stemmermann et al 1991) although 
others have not confirmed these findings (Kune et al 1988; Brinton et al 1989). In view 
of this, and the results of experimental work supporting a possible role for gastrin in 
colorectal cancer, several studies have examined circulating gastrin concentrations in 
patients with such tumours. In 1989 Smith et al (1989) reported that a proportion of 
patients with colonic polyps and carcinomas have elevated circulating gastrin levels. 
Since then at least four studies have confirmed this finding (Seitz et al 1989; Wong et al 
1991; Seitz et al 1992; Chamley et al 1992) but a similar number have found no 
evidence of hypergastrinaemia in tumour patients compared to controls (Suzuki et al 
1988; Kaufmann and Ottenjann 1991; Yapp et al 1992; Kikendall et al 1992; Scotte et 
al 1992). Differences in study design and selection of patients and controls, along with 
differing methods of statistical analysis of the results may account for these conflicting 
results. In particular, none of the above studies has controlled for the presence of 
gastric colonisation with Helicobacter pylori (HP), a common infection resulting in 
chronic gastritis and significantly raised fasting and meal-stimulated gastrin levels which 
fall after eradication of the organism (McColl et al 1989). The need for further carefully 
controlled studies of gastrin in patients with colorectal neoplasia has recently been 
stressed (Boland 1991; Wolfe 1992).
The aim of the present study was to compare fasting and meal-stimulated 
plasma gastrin levels in colorectal tumour patients and in closely matched control 
patients. In addition we proposed to assess whether resection of the tumour altered the 
gastrin concentration.
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10.2 M a t e r ia l s  a n d  M e th o d s
10.2.1 Patients
Forty-two newly diagnosed patients with histologically confirmed sporadic colorectal 
neoplasia and who were in hospital awaiting elective surgery were studied. Forty 
patients had carcinomas and two had large (> 5cm), severely dysplastic adenomas. 
These forty-two patients were selected from a total of one hundred and twenty who 
were initially considered for the study but excluded because they were too unwell or 
because of one or more of the factors outlined below. Patients with familial 
adenomatous polyposis, intestinal obstruction or requiring emergency surgery were 
excluded. Thirty-four age- and sex- matched inpatients, awaiting elective surgery under 
general anaesthesia for relatively minor conditions (for example inguinal hernia, 
varicose veins, haemorrhoids) and with no history of intestinal disease served as 
controls. These patients were chosen as controls in preference to healthy volunteers in 
order to control for any possible effects that the stress of hospitalisation and waiting for 
surgery may have on gastrin levels. Those with a history of malignancy at any other site, 
treatment with acid suppressing drugs (H2 antagonists or proton pump inhibitors), 
previous peptic ulcer surgery, documented pernicious anaemia, renal failure, 
hypercalcaemia, recent antibiotic therapy (within one week) or any form of bowel 
preparation in the two days prior to the tests were excluded from study. Informed 
written consent was obtained from all patients and the studies were approved by the 
Western Infirmary Ethical Committee. Patient details are given in Tables 10.1 - 10.3.
10.2.2 Measurement of Basal and Meal-Stimulated Gastrin Levels
All studies were performed between 0900 and 1000 after subjects had fasted overnight. 
A 16F gauge cannula attached to a three-way tap was inserted into an antecubetal vein 
and kept patent with heparinised saline. Measurement of meal-stimulated gastrin 
concentrations and the [14C]urea breath test for H. pylori status were performed 
simultaneously and the schedule for both tests is schematically shown in Figure 10.1.
Tumours Controls
NUMBER 42 34
AGE
mean 68.3 65.7
S.D. 11.25 13.5
median 69.5 67.5
range 44-93 36-88
SEX
male 25 (60%) 20 (59%)
female 17 (40%) 14 (41%)
Table 10.1. Patient characteristics.
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Table 10.3. (2 pages). Clinical and preoperative 
details of control patient group.
Case No. Initials Age Sex Diagnosis
806016 O.I. 65 F Gallstones
n/a P.K. 60 M Haemorrhoids
650775 J.M. 36 M Haemorrhoids
836047 G.M. 74 M Inguinal hernia
593439 L.M. 85 M Inguinal hernia
317466 H.McB. 76 F Varicose veins
426207 J.McG. 46 M Inguinal hernia
754914 S.McI. 77 F Skin cyst
933860 W.McL. 72 M Inguinal hernia
640994 P.McP. 39 M Inguinal hernia
874293 A.M. 49 M Inguinal hernia
707804 M.P. 87 F Ovarian cyst
468860 S.R. 64 F Ovarian cyst
613277 H.S2. 74 F Adhesions
741481 M.T. 80 F Rectal prolapse
504402 B.T2 64 F Lipoma
643689 W.T. 66 M Haemorrhoids
Table 10.3 contd. (page 2 of 2). Clinical and preoperative 
details of control patient group.
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Blood samples (10ml lithium heparin tube) were taken fasting (00 minutes) and 
at 15, 30, 45 and 60 minutes following a test meal. The test meal consisted of 150ml of 
a high lipid drink ("Ensure plus", Abbott Laboratories Ltd., Maidenhead, UK) followed 
by 200mls of a beef-extract drink consisting of 2 "oxo" cubes (Brooke Bond Foods 
Ltd., Croydon, UK) dissolved in water at 50°C. Blood samples were centrifuged at 
3000 rpm at 4°C for 10 minutes and plasma stored at -70°C until required for analysis. 
Plasma gastrin was measured in duplicate by an in-house radioimmunoassay using 
antibody R98 as previously described (Ardill 1973). This antibody recognises both 
human G-17 and G-34 in equimolar concentrations with a sensitivity of 3ng.L_1 and 
does not cross-react with cholecystokinin.
10.2.3 Determination of H elicobacter p y lo r i Status
The presence or absence of gastric colonisation with HP was confirmed in all patients 
using the [l4C]urea breath test as previously described (Marshall and Surveyor 1988). 
Briefly, this test utilises the production of urease enzyme by HP as a means of detecting 
the organism. Patients swallow 0.4MBq of urea isotopically labelled with i4C and if HP 
is present the urease hydrolyses the urea to produce 14C02. By collecting breath 
samples at different times the presence of exhaled 14C02 can be detected using a liquid 
scintillation counter. This test has been shown to be a sensitive and reliable non-invasive 
method of diagnosing the presence of HP (Atherton and Spiller 1994). The standard 
protocol used in the Western Infirmary, Glasgow is given in Appendix 4. In addition 
serum antibodies (IgG) to the bacterium were measured using a commercial enzyme 
immunoassay kit (Helico-G™, Porton Cambridge, UK) with a sensitivity of 95% and 
specificity of 88% (Newell etal 1988).
10.2.4 Measurement of Gastric AutoAntibodies
An important cause of hypergastrinaemia is autoimmune-type atrophic gastritis (Lamers 
1980). As a screening test for this fasting serum from all patients was analysed for the 
presence of parietal cell and intrinsic factor (type I) antibodies. The former was assayed
I l l
using a commercially available immunofluorescent kit (Zeus Autoantibody Screen Kit, 
Bayer Diagnostics, Basingstoke, UK) and the latter by a commercial radioassay kit 
(Immophase™, Blocking Antibody Radioassay, Ciba Coming Diagnostic Corporation, 
Medfield, MD, USA).
10.2.5 Post-Operative Reassessment
Twenty-five colorectal tumour patients were reassessed at a median of 79 days post- 
operatively (range 11-213 days). Of the seventeen patients not seen post-operatively 
four had died, four had inoperable disease, three were too ill with ongoing medical 
problems and only six were lost to follow-up or refused to return. The tests were 
carried out at or after hospital discharge once patients had resumed a normal or near­
normal lifestyle. They were examined clinically for evidence of tumour recurrence and a 
careful drug history was taken, including note of any antibiotic therapy prescribed since 
the time of operation. Patients had repeat measurement of basal and meal-stimulated 
gastrin levels and reassessment of their HP status by means of the [14C]urea breath test 
and serology. In all twenty-five of these patients, pre- and post-operative plasma gastrin 
samples were analysed together in the same assay to exclude interassay variation as a 
possible source of differences in gastrin levels between the two study days.
10.2.6 Statistics
Differences in HP status and in pernicious anaemia autoantibody prevalence between 
the groups were assessed using the Gastrin levels in all groups were not
normally distributed (see Results and Discussion) and so non-parametric tests were 
used throughout: Mann-Whitney U Test for differences between tumours and controls; 
Wilcoxon signed ranks test (matched pairs) for comparisons of tumour patients pre- and 
post-operatively; and Kruskal-Wallis for analysis of gastrin levels by tumour site and 
stage. Analysis of a possible correlation between timing of post-operative reassessment 
and gastrin levels was performed using Spearman's rank correlation coefficient. A P
112
value of < 0.05 was considered significant. Results are presented as medians and inter­
quartile ranges unless otherwise stated.
10.3 R e su l t s
10.3.1 Gastrin Levels: Patients versus Controls
Figures 10.2 and 10.3 show the preoperative pattern of meal-stimulated gastrin 
responses in tumour patients and controls, as well as fasting and peak plasma gastrins in 
both groups. Median fasting gastrin in preoperative tumour patients was 55ng.L-1 (45- 
82.5) and this was not significantly different from that of 77.5ng.L_1 (53.7-137.5) in 
control patients (P = 0.10, Mann Whitney). Similarly, median peak gastrins in tumour 
patients (200 ng.L'1, 137.5-312.5) and control patients (247.5ng.L_1, 147.5-375) were 
similar (P = 0.21, Mann Whitney). Table 10.4 shows individual meal-stimulated gastrin 
concentrations in the two groups.
10.3.2 Gastrin Levels: Pre- and Post- Operative Levels in Tumour Patients
In twenty-five of the forty-two colorectal tumour patients the studies were repeated 
postoperatively at a median follow up time of 79 days (range 11-213). Of these patients 
eighteen were considered (on the basis of clinical details, operative findings and 
histology) to have had a "curative" resection. In addition, of the original twenty-five 
patients, HP status had changed from positive preoperatively to negative 
postoperatively in five, including three of the eighteen with a "curative" resection. Thus, 
data were available on fifteen patients with a presumed curative resection and no 
change in HP status (Figure 10.4). Their median fasting gastrin was similar before 
(52.5ng.L_1, 43.8-76.2) and after resection (52.5ng.L_1, 43.8-71.3; P = 0.27, Wilcoxon) 
and, likewise, their median peak levels were similar preoperatively (150ng.L_1, 117.5- 
240) and postoperatively (162.5ng.L_1, 120-270; P = 0.30, Wilcoxon).
The seventeen patients not reassessed post-operatively were similar to the 
twenty-five who were seen again, with respect to age and sex as well as tumour site,
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Figure 10.2
Meal-stimulated plasma gastrin concentrations preoperatively in 
tumour and control patients.
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stage and differentiation (Table 10.12). They had a similar median fasting plasma gastrin 
(60ng.L_1, 50 - 97.5) to the twenty-five who were seen post-operatively (55ng.L_1, 45- 
80; P = 0.38, Mann Whitney). Similarly their median peak plasma gastrin (240ng.L_1,
137.5 - 395) did not differ significantly from that in the patients who were reassessed 
(175 ng.L’1, 127.5 - 251.2; P = 0.52, Mann Whitney).
10.3.3 H elicobacter p y lo ri Status and Gastrin
Using the [14C]urea breath test and serology, both tumour and control groups were 
well matched for the presence of HP infection. Preoperatively twenty-five of the forty- 
two tumour patients (60%) and eighteen of the thirty-four controls (53%) were positive 
by urea breath test (%2 = 0.331, P > 0.5). Similarly, 57% of patients and 50% of 
controls were positive by serology, with circulating IgG levels greater than 15 U.mF 
(see Figure 10.5 and Tables 10.5 and 10.6). Of the twenty-five tumour patients studied 
before and after tumour resection, twelve were HP positive before surgery but only 
seven were positive after surgery, the infection having been cleared or eradicated in five 
cases (see Discussion). When reassessed postoperatively, fasting gastrin was lower in 
four of the five patients and peak gastrin was lower in all five (Figure 10.6 and Table 
10.7). The effect of loss of HP infection on gastrin levels in one patient is shown in 
Figure 10.7.
10.3.4 Parietal Cell/Intrinsic Factor Antibody Status and Gastrin
Intrinsic factor (type I) antibodies were present in three tumour patients (7.1%) and in 
two control patients (5%). Less specific parietal cell antibodies were not found in any 
tumour patients but were present in four controls (12%). One of the three tumour 
patients with positive antibodies had a fasting gastrin preoperatively of 600ng.L_1 which 
did not rise with the test meal. When seen postoperatively, his fasting and peak levels 
were 750 and 900ng.L_1, respectively. Similarly, three of the six control patients with 
positive antibodies also had markedly elevated gastrin levels (see Table 10.7). In none 
of these cases was the diagnosis of pernicious anaemia known and no patient had
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Case No. Initials Age Sex
Preop. 
IgG titre +/-
Postop. 
IgG titre +/-
502088 G.A. 68 F <6.25 - 8 -
322234 J.A. 70 M 51 + 14 -
835887 H.B. 66 M 19 + 80 +
242117 J.B. 59 M 9 -
936325 D.BU. 61 F <6.25 - <6.25 -
251770 i.e. 78 M <6.25 -
649010 J.CO. 71 M 28 + 18 +
847494 AC. 53 F <6.25 - 22 +
936921 J.C3. 46 M 37 + 17 +
855961 ID. 67 F <6.25 -
473785 A.F. 79 F 100 +
454435 J.G. 78 M 7 -
480507 E.G. 52 F 27 + <6.25 -
497088 J.H. 47 M <6.25 - <6.25 -
121591 M.H. 66 F 117 + 35
516043 A.J. 79 M 63 + 38 +
738266 J.K. 69 M 14 +
62502 A.L. 93 F 11 - <6.25 -
222730 P.L. 75 M 54 - 89 +
850663 I.M. 64 F 56 +
542878 I.McC. 79 M 18 +
657891 J.McD. 76 F <6.25 -
402383 M.McD. 68 F 25 +
165739 W.McI. 79 M <6.25 - <6.25 -
394247 G.McK. 71 M 80 + 10 -
443246 T.McL. 57 M 10 - <6.25 -
474018 R.McN. 75 M 9 -
928284 E.McN. 55 F 15 + 34 +
564327 N.McR. 54 M <6.25 -
709277 M.McR. 80 F <6.25 -
810870 M.M. 56 M 29 +
410814 G.N. 69 M 22 + <6.25 -
636073 M.P. 65 F 20 + <6.25 -
817655 I.R. 73 M <6.25 -
807750 M.R. 75 F 100 +
929989 H.S. 73 F 36 +
562802 A.S. 79 F 63 + 37 +
922552 J.S. 81 M 11 - 77 +
372926 B.T. 44 M 24 + <6.25 -
632272 T.T. 87 M 21 + 23 +
850891 C.W 70 M 18 + <6.25 -
440457 T.W. 63 M 16 + 13 -
Table 10.6a. H. Pylori IgG titres (U.mT1) in tumour patients. + positive, - negative.
Case No. Initials Age Sex
Preop. 
IgG titre +/-
338439 DA. 66 M 11 -
328904 W.BR. 75 M 91 +
349280 A.C2 65 F 51 +
543298 A.CH 59 M 22 +
857008 H.C. 52 M 70 +
502346 M.C2. 79 F 10 -
436192 T.C. 71 M >200 +
673591 J.C. 42 M <6.25 -
99707 J.C2. 75 M 49 +
298909 M.C3. 68 F <6.25 -
66109 J.DOC. 71 M 56 +
485107 J.DU. 88 F <6.25 -
570157 E.E. 46 F >200 +
922689 J.F. 56 M 17 +
850006 J.F2. 73 M 129 +
532357 C.G. 63 F 43 +
698715 H.H. 72 M 105 +
806016 O.I. 65 F <6.25 -
n/a P.K. 60 M 17 +
650775 J.M. 36 M <6.25 -
836047 G.M. 74 M <6.25 -
593439 L.M. 85 M 12 -
317466 H.McB. 76 F <6.25 -
426207 J.McG. 46 M >200 +
754914 S.McI. 77 F 17 +
933860 W.McL. 72 M 11 -
640994 P.McP. 39 M <6.25 -
874293 A.M. 49 M <6.25 -
707804 M.P. 87 F <6.25 -
468860 S.R. 64 F <6.25 -
613277 H.S2. 74 F 21 +
741481 M.T. 80 F >200 +
504402 B.T2 64 F <6.25 -
643689 W.T. 66 M 11 -
Table 10.6b. H. Pylori IgG titres (U.ml-1) in control patients. + positive, - negative.
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macrocytosis, low serum vitamin B12 levels or other evidence of this condition. 
Autoantibody results are given in Table 10.9.
10.3.5 Gastrin Levels and Tumour Stage
Two patients had large benign adenomas with severe dysplasia and only one patient was 
classified as having a Dukes' stage A lesion. Details of the tumour histology in these 
patients is given in Table 10.2. There were no significant differences in either fasting (P 
= 0.07) or peak (P = 0.18, Kruskal-Wallis) plasma gastrin levels when analysed 
according to tumour stage. Median gastrin concentrations for patients with Dukes' B, C 
and D carcinomas are given in Table 10.10.
10.3.6 Gastrin Levels and Tumour Site
Of the forty-two tumour patients there were eight caecal carcinomas, nine descending 
colon or sigmoid carcinomas and twenty-five rectal tumours (twenty-three carcinomas 
and two large, severely dysplastic adenomas). Results of analysis of gastrin levels 
according to tumour site are summarised in Table 10.11. There were no significant 
differences among the subgroups with respect to either fasting (P = 0.62) or peak 
gastrin levels (P = 0.47, Kruskal-Wallis).
10.4 D isc u ssio n
The present study demonstrates that colorectal cancer patients have similar gastrin 
levels (fasting and peak) to control patients when studied in a carefully controlled 
manner. In addition, plasma gastrin did not fall following apparently curative tumour 
resection. The finding of no difference in gastrin levels between tumour and control 
patients is in keeping with that of Kikendall et al (1992) and several others (Suzuki et al 
1988; Kaufinann and Ottenjann 1991; Yapp eta l 1992; Scotte e ta l 1992). The findings 
differ, however, from those of previous studies which found tumour patients to have
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Case No. Initials Age Sex Parietal Cell 
Antibodies (+/-)
Intrinsic Factor 
Antibodies (+/-)
502088 G.A. 68 F - -
322234 J.A. 70 M - -
835887 H.B. 66 M - -
242117 J.B. 59 M - -
936325 D.BU. 61 F - -
251770 i.e. 78 M - -
649010 J.CO. 71 M - -
847494 AC. 53 F - -
936921 J.C3. 46 M - -
855961 ID. 67 F - -
473785 A.F. 79 F - +/-
454435 J.G. 78 M - -
480507 E.G. 52 F - -
497088 J.H. 47 M - -
121591 M.H. 66 F - -
516043 A.J. 79 M - -
738266 J.K. 69 M - -
62502 A.L. 93 F - -
222730 P.L. 75 M - +
850663 I.M. 64 F - -
542878 I.McC. 79 M - -
657891 J.McD. 76 F - -
402383 M.McD. 68 F - -
165739 W.McI. 79 M - -
394247 G.McK. 71 M - -
443246 T.McL. 57 M - -
474018 R.McN. 75 M - -
928284 E.McN. 55 F - -
564327 N.McR. 54 M - -
709277 M.McR. 80 F - -
810870 M.M. 56 M - +
410814 G.N. 69 M - -
636073 M.P. 65 F - -
817655 I.R. 73 M - -
807750 MR. 75 F - -
929989 H.S. 73 F - -
562802 A.S. 79 F - -
922552 J.S. 81 M - -
372926 B.T. 44 M - -
632272 T.T. 87 M - -
850891 C.W 70 M - +
440457 T.W. 63 M - -
Table 10.9a. Gastric autoantibody status of tumour patients. + positive, - negative.
Case No. Initials Age Sex Parietal Cell 
Antibodies (+/-)
Intrinsic Factor 
Antibodies (+/-)
338439 D.A. 66 M - -
328904 W.BR. 75 M - -
349280 A.C2 65 F - -
543298 A.CH 59 M + -
857008 H.C. 52 M - -
502346 M.C2. 79 F + -
436192 T.C. 71 M - -
673591 J.C. 42 M - -
99707 J.C2. 75 M - +
298909 M.C3. 68 F - -
66109 J.DOC. 71 M - -
485107 J.DU. 88 F - -
570157 E.E. 46 F - -
922689 J.F. 56 M - -
850006 J.F2. 73 M - -
532357 C.G. 63 F - +
698715 H.H. 72 M - -
806016 O.I. 65 F - -
n/a P.K. 60 M - -
650775 J.M. 36 M - -
836047 G.M. 74 M - -
593439 L.M. 85 M - -
317466 H.McB. 76 F - -
426207 J.McG. 46 M - -
754914 S.McI. 77 F + -
933860 W.McL. 72 M - -
640994 P.McP. 39 M - -
874293 AM. 49 M - -
707804 M.P. 87 F - -
468860 S.R. 64 F + -
613277 H.S2. 74 F - -
741481 M.T. 80 F - -
504402 B.T2 64 F - -
643689 W.T. 66 M - -
Table 10.9b. Gastric autoantibody status of control patients. + positive, - negative.
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25 patients 
reassessed
17 patients not 
reasssessed
Patients
males 16 9
females 9 8
median age (range) 67 (44-93) 72 (54-80)
Site
caecum 5 3
desc ./sigmoid colon 7 3
rectum 13 11
Stage
adenoma 0 2
A 1 0
B 11 1
C 9 6
D 4 8
Median Gastrin
fasting (IQ range) 55 (45-80) 60 (50-97.5)
peak (IQ range) 175 (127.5-251.2) 240 (137.5-395)
Table 10.12. Details of colorectal tumour patients 
reassessed and not reassessed postoperatively.
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higher gastrin levels than controls (Smith et al 1989; Wong et al 1991; Seitz et al 1992; 
Chamley et al 1992).
Several reasons may account for these conflicting reports. The first explanation 
is that different methods of statistical analysis have been used to interpret gastrin 
concentrations in previous studies. In the original study of Smith et al (1989), mean 
fasting gastrin levels were elevated eight-fold compared to controls but this was 
because a subgroup (8/20) of tumour patients had very high gastrin levels. Other 
authors have also found elevated gastrin levels to exist in only a minority of patients 
although the aetiology of these high levels was unexplained (Wong et al 1991; Yapp et 
al 1992; Kikendall et al 1992). In these studies, therefore, gastrin levels were most 
unlikely to have been normally distributed making the use of means, standard deviations 
and parametric statistical tests inappropriate. When these high values (or "outliers") 
have been excluded from analysis there has been no significant difference in gastrin 
levels between tumour patients and controls (Yapp et al 1992; Kikendall et al 1992). 
Analysis of results in this study showed that the distribution of both fasting and peak 
gastrin levels in both groups deviated significantly from normality (Wilk-Shapiro, P < 
0.01). In keeping with the findings of Kikendall et al (1992), logarithmic transformation 
failed to normalise the results and so non-parametric tests were used for analysis of 
gastrins. Inspection of the individual gastrin levels in Figure 10.3 shows that very high 
fasting gastrin levels (>200ng.L_1) occurred in only one tumour patient (with positive 
intrinsic factor antibodies) but in five control patients of whom three had positive 
gastric autoantibodies. Expressing results as medians rather than means, combined with 
non-parametric statistical analysis, is more appropriate.
The second reason is failure to control for factors which may have raised 
gastrin in some patients. Thus, patients taking acid-suppressing drugs (H2-antagonists, 
proton pump inhibitors) were excluded from the study as were those with 
hypercalcaemia or renal impairment. Another confounding factor in previous studies 
may have been failure to control for the presence of pernicious anaemia. Although 
patients with known pernicious anaemia have been excluded from most of the earlier 
studies the condition is relatively common and often asymptomatic in this age group.
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This is the first study to try and control for the presence of pernicious anaemia. 
Although not definitive, the presence of positive gastric autoantibodies in combination 
with very high gastrin levels is highly suggestive of this diagnosis. Positive 
autoantibodies were found in three tumour patients and in six control patients (Table 
10.8) and these could readily explain all the very high gastrin concentrations seen in the 
study with the exception of one patient in the control group with a fasting gastrin of 
750ng.L_1.
A further potential source of error in previous studies may have arisen because 
of failure to appreciate the possible effects on gastrin levels of bowel preparation given 
prior to colonoscopy or surgery. Several studies measured gastrin concentrations 
immediately prior to these procedures i.e. after bowel preparation (Suzuki et al 1988; 
Smith et al 1989; Seitz et al 1989; Chamley et al 1992). Many aspects of 
gastrointestinal function, including motility, are under neuroendocrine regulation 
(Sakomoto et al 1987) and are clearly affected by use of powerful laxatives or intestinal 
lavage. While the effects of bowel preparation on gastrin levels per se are unknown it is 
a cause for concern, especially as postoperative gastrin levels were measured without 
the effects of such bowel preparation making interpretation of differences in hormone 
levels difficult.
A final reason for the conflicting results of previous studies may be failure to 
control for the prevalence of HP in the different study groups. This is potentially very 
important as the infection causes significant hypergastrinaemia (McColl et al 1989; Levi 
et al 1989). Using the [14C]urea breath test and serology the prevalence of the infection 
was similar in tumour patients and controls. One can thus exclude differences in the 
relative prevalence of HP infection between the two groups as a confounding factor in 
this study. In contrast, no other study of gastrin levels in colorectal tumour patients has 
controlled for the presence of this infection. It is therefore possible that previously 
reported hypergastrinaemia in tumour patients may have been due, at least in part, to 
different proportions of HP positive subjects in the tumour and control groups. Very 
recently preliminary results from another group have supported this finding in that only
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HP-positive colorectal cancer patients had higher gastrin levels than the control group 
(Meier etal 1994).
The second finding of this study is that no fall in gastrin was observed after 
apparently curative resection. While this is in agreement with the results of Scotte et al 
(1992) and others (Kikendall et al 1992), it differs from the findings of several authors 
who have reported a fall in gastrin levels postoperatively (Wong et al 1991; Seitz et al 
1992; Chamley et al 1992). Although the possible effect of bowel preparation noted 
above may have contributed, it cannot fully explain the apparent fall in gastrin as Wong 
et al were careful to avoid bowel preparation in their study (Wong et al 1991). Perhaps 
more importantly, none of the studies which noted postoperative reductions in gastrin 
controlled for the presence of HP infection and it is possible that clearance or 
eradication of the infection in the perioperative period may have occurred in some 
patients, as noted in the present study. In this study the infection had been cleared or 
eradicated in five of the twenty-five patients who were restudied postoperatively and 
this was associated with falls in both fasting and meal-stimulated gastrin levels. When 
these five patients were excluded from analysis there was no difference in median 
gastrin levels before and after surgery. From Figure 10.4 it can be seen that, of the 
fifteen patients, reductions in fasting gastrin occurred in only four. Likewise peak 
gastrin levels fell in only five cases, whereas they rose in eight. Furthermore the falls 
were minor and unlikely to be of biological significance. It seems unlikely, therefore, 
that curative tumour resection results in a lowering of gastrin concentrations by removal 
of the source of gastrin (or a peptide which stimulates gastrin release). If gastrin is an 
autocrine growth factor in this condition it is probably effective at very low tissue 
concentrations without affecting circulating levels.
Alternatively, the reductions in gastrin seen postoperatively in five (20%) of 
our patients can readily be explained by clearance or eradication of HP infection in each 
of them. The reason for the loss of the infection is unclear but may have resulted from 
the perioperative intravenous antibiotics given routinely to patients undergoing 
colorectal surgery. All five patients received three doses of metronidazole (effective 
against HP) and cefotaxime and it is possible that this contributed to eradication of the
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infection. In addition, three of the five had required postoperative antibiotics for either 
chest or urinary tract infections and this may also have been important in eradicating the 
organism. Figures 10.6 and 10.7 demonstrate the effect of perioperative loss of HP 
infection on meal-stimulated plasma gastrin concentrations in this study. It is therefore 
possible that previously reported postoperative reductions in gastrin (Wong et al 1991; 
Seitz et al 1992; Chamley et al 1992) may have resulted, not from tumour resection per 
se, but from coincidental eradication of HP infection in the perioperative period.
For reasons explained above (see Results), only twenty-five of the forty-two 
colorectal tumour patients were reassessed postoperatively. The seventeen who were 
not restudied were similar to these twenty-five with respect to patient characteristics 
and tumour details (Table 10.12). In addition, their fasting and peak plasma gastrin 
levels were similar making it unlikely that those seen again postoperatively differed in 
any way from the overall group.
There was also a wide range in the timing of postoperative reassessment in the 
study. Rather than seeing the patients at one fixed time point postoperatively, and at 
different stages in their recovery, the principal concern was to reassess patients once 
they had fully recovered from the effects of surgery and had returned to as near a 
normal lifestyle as possible. In this elderly population, recovery rates vary considerably. 
Furthermore, there is no evidence that gastrin levels in an individual change significantly 
over a six month period, unless possibly due to acquisition of HP infection and the 
study controlled for such a possibility. Analysis of the data shows no correlation 
between timing of postoperative reassessment and either fasting (Spearman's rank 
correlation coefficient, ps = 0.187; P > 0.1) or peak plasma gastrin (ps = 0.246; P > 
0.1). For these reasons it is likely that the range in timing of postoperative reassessment 
had no significant influence on the results and the study design used was appropriate in 
this patient population.
In this present study, which has controlled for factors which may elevate 
circulating gastrin levels, normal levels were found in colorectal tumour patients with 
no fall following apparently curative tumour resection. The findings therefore provide 
no support for colorectal tumours directly or indirectly causing elevated circulating
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gastrin concentrations and have subsequently been corroborated by the results of Rogy 
et al (1994). While the study only involved patients with sporadic tumours, there is little 
reason to suspect that the situation is different in patients with familial adenomatous 
polyposis and this has subsequently been confirmed (Svendson et al 1994).
The finding of normal levels, however, does not exclude gastrin having a 
trophic effect on colorectal tumours as the hormone can exert such effects at 
physiological levels (Johnson 1987). In addition the study does not exclude the local 
production of gastrin by colorectal tumours with consequent autocrine or paracrine 
effects on tumour growth. Recent studies demonstrating gastrin gene expression in 
some colonic cancer cell lines (Baldwin 1992) and progastrin-derived peptides in human 
tumours (Kochman et al 1992; Nemeth et al 1993) do support the concept of a role for 
gastrin as an autocrine growth factor in this condition. The next chapter addresses 
whether measurable amounts of gastrin and its precursors are present in the tumours of 
this group of colorectal tumour patients.
CHAPTER 11
GASTRIN AND GASTRIN PRECURSORS 
IN HUMAN COLORECTAL NEOPLASMS
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11.1 I n t r o d u c t io n
As discussed in Chapter 7, recent research has addressed the possible involvement of 
gastrin as an autocrine or paracrine growth factor for colorectal cancer cells. If this 
proves to be the major effect of gastrin in this disease then one would not expect 
circulating gastrin levels to differ between tumour patients and healthy people because 
autocrine growth factors may have important effects on tumour growth even at very 
low levels of expression. Indeed, the results of the previous chapter would seem to 
indicate that plasma gastrin concentrations are not higher in colorectal tumour patients.
The aim of this study was to determine whether human colorectal tumours 
contained measurable amounts of either bioactive, carboxyamidated gastrins or their 
precursors, namely progastrin and glycine-extended gastrins.
11.2 M e t h o d s
11.2.1 Patients and Tumours
Samples of tumour and macroscopically normal mucosa were taken from patients with 
colorectal cancer at surgical resection. Of the forty-two patients who took part in the 
study of plasma levels (Chapter 10), tissue samples were available in thirty. Eighteen 
tumour and mucosal samples were obtained from other unselected patients undergoing 
elective surgery for sporadic colorectal carcinoma. Patient details are given in Table 
11 . 1.
Immediately on removal from the patient resection specimens were opened 
along the antimesenteric border and washed thoroughly in ice-cold Ringer Lactate 
solution to remove faeces and blood clot. Small pieces (approximately 0.5-1.0g) were 
excised from the tumour with care being taken to avoid areas of obvious necrosis, 
placed in plastic containers, snap frozen in liquid nitrogen and then stored at -70°C until 
required. Samples of macroscopically normal colonic mucosa were taken from an area 
as far removed from the tumour as possible (5-15cm) and stored as above.
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11.2.2 Extraction of Peptides
While still frozen, tissue samples were split into two approximately equal pieces, 
quickly weighed and labelled Sample A (for assay without trypsin treatment) and 
Sample B (for assay following trypsin treatment). Sample A was added to 1ml of 
boiling phosphate-buffered saline (PBS), finely minced with a scalpel and boiled for ten 
minutes to inactivate tissue enzymes. After being left to stand for one hour at 37°C, the 
sample was centrifuged at 10,000G for 30 minutes, the supernatant decanted and boiled 
again as above. The final supernatant was made up to a total volume of 2ml with PBS.
Sample B was treated in the same way except that it was incubated with lOmg 
trypsin beads for one hour at 37°C after initial boiling. This form of trypsin (TPCK- 
treated insoluble enzyme, Sigma Chemical Co., Poole, U.K.) is highly pure and easily 
removed by centrifugation. Final supernatants of all samples were saved at -70°C until 
analysed. This method has been widely used and gives good recovery of progastrin and 
its major processing products.
11.2.3 Radioimmunoassay of Gastrin and its Processing-intermediates
All samples were assayed using two different region-specific antisera (Figure 2.1, 
repeated after page 120 for clarity). Antibody R98 recognises the C-terminal of gastrins 
and requires the presence of the amidated C-terminal amino acid. It therefore detects all 
bioactive, carboxyamidated gastrins (Component I, G-34, G-17 and G-14) and both 
sulphated and unsulphated forms are recognised with equal potency. Cross-reactivity 
with CCK is < 0.005% (Ardill 1973). In standard use for measurement of plasma 
gastrin this antisera has a sensitivity of 3ng.L_1 and an interassay coefficient of variation 
of 3-6%. In the present study R98 was used at higher sensitivity with a detection limit 
of 300pg.L_1 (equivalent to 0.14pmol.g-1) but with a higher coefficient of interassay 
variation (12.6%). Higher sensitivity was achieved by increasing assay volume, 
decreasing the concentrations of antisera and label and increasing the incubation time. 
Trypsin treatment of peptide extracts cleaves progastrin to yield glycine-extended
AMINO TERMINUS CARBOXYL TERMINUS
PREPROGASTRIN
PROGASTRIN
GP168
\
Gly-Arg-Arg
*
SIGNAL
PEPTIDASE
Gly-Arg-Arg
PROHORMONE
CONVERTASE/TRYPSIN
G17 G34
y  y  /  y  y  /  /
, GASTRIN ;  ,  
/ / / / / / / / / /
Gly-Arg-Arg ASTRIN Gly-Arg-Arg
GP168
CARBOXYPEPTIDASE H I
GLYCINE- 
EXTENDED -< 
GASTRINS
GASTRIN
GP168
GASTRIN
GASTRIN
I
GASTRIN
/ / / / / / /
GP168
\
I AMIDATING ENZYME
GASTRIN ASTRIN
\
NH'
V
R98 R98
Figure 2.1
Schematic representation of gastrin processing. Arrows indicate 
binding sites of antigastrin antisera (R98, GP168) used in this study 
(see chapter 11).
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gastrins and should not, therefore, affect the levels of mature, carboxyamidated gastrin 
measured with R98.
Antibody GP168 recognises the N-terminal region of gastrin and requires the 
presence of the N-terminal pyroglutamyl residue of G-17. As such it detects 
carboxyamidated gastrin-17, glycine-extended processing intermediates (G-17-gly and 
G-17-gly-arg-arg) and other short N-terminal fragments but not G-34. GP168 has a 
standard detection limit of approximately 7-15ng.L_1 but in this assay sensitivity was 
increased to 3ng.L-1 (equivalent to 1.43pmol.g_1). It shows no cross-reaction with CCK 
(Mulholland et al 1993). Following trypsin digestion of preprogastrin, increased 
concentrations of gastrin processing intermediates should be detected by this antibody.
Peptide concentrations were measured as ng.L'1 and expressed as pmol.g"1 wet 
weight of tissue.
11.2.4 Statistics
Results are given as medians and ranges. Mann Whitney U test was used for 
comparisons between tumour tissue and disease-free mucosa, while differences in 
peptide content before and after trypsinisation of each tissue were assessed using 
Wilcoxon's matched pairs test. Correlation of peptide content in tumour tissue and 
matched normal mucosa was made using Spearman's rank correlation coefficient. All 
statistical analyses were performed using Minitab statistical software, version 8.0 
(Minitab Inc., Pennsylvania, USA) on an IBM-compatible personal computer.
11.3 R e s u l t s
11.3.1 Radioimmunoassay
Of the samples of tumour and normal mucosa which were initially available, final results 
were available for fifteen cases. Initial assay with R98 was performed using standard 
sensitivity and a lower detection limit of 3ng.L_1. In this way, no detectable gastrin-like 
peptides were found during analysis of samples from seventeen patients. Further
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analysis was performed on twenty-five samples using an assay of greater sensitivity. In 
this second assay method peptide extraction was performed on one piece of tissue and 
the supernatant was then split into two aliquots to be assayed with or without 
trypsinisation. Although gastrin (1-lOpg.g"1 wet weight) was detected in almost all 
samples, levels did not consistently dilute in parallel, most likely because of non-specific 
interference. These results were therefore excluded.
A third, modified assay was repeated on the fifteen samples still available. Each 
sample (tumour or disease-free mucosa) was split into two representative pieces while 
still frozen, as described in Methods (above). High sensitivity with a lower detection 
limit of 300pg.L_1 (i.e. 0.14pmol.g_1) was achieved by increasing assay volume from 
lOOpL to 200pL, decreasing antibody and label concentrations by 50% and lengthening 
incubation time to five days. In all cases the results obtained were reproducible in at 
least two doubling dilutions.
11.3.2 Tissue Peptide Contents
(i) Carboxyamidated gastrins
Small but measurable amounts of carboxyamidated gastrins were found in all fifteen 
tumour samples (median 5.4pmol.g_1, range 1.0 - 141.0) and in fourteen of the fifteen 
samples of matched disease-free mucosa (5.0pmol.g_1 , 0.0 - 15.7). Results are shown 
in Tables 11.2 and 11.3 and Figure 11.1. There was no statistically significant difference 
in peptide content between tumour tissue and disease-free mucosa ( P = 0.48, Mann 
Whitney).
As expected levels of carboxyamidated gastrins measured in disease-free 
mucosa were the same before (median 5.0pmol.g_1, range 0.0 - 15.7) and after 
trypsinisation (4.8pmol.g'1, 1.3 - 21.0; P = 0.57, Wilcoxon). There was, however, a 
small but statistically significant increase in carboxyamidated gastrins in tumours 
following trypsin digestion (P = 0.03). The results are depicted in Figure 11.1.
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Content of carboxyamidated gastrins (pmol.g"^wet weight of tissue) 
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(ii) Gastrin precursors and processing-intermediates
All fifteen tumours contained measurable amounts of gastrin processing-intermediates 
(median 6.1pmol.g_1, range 1.0 - 141.0) as did thirteen of the fifteen matched samples 
of disease-free mucosa (8.3pmol.g_1, 0.0 - 61.0). The amounts were not significantly 
different in the two tissues (P = 0.92, Mann Whitney). Individual results are shown in 
Table 11.4 and Figure 11.2.
Following trypsin digestion there was a non-significant increase in measurable 
immunoreactive gastrin processing-intermediates in samples of disease-free mucosa 
(median 9.8pmol.g_1, range 3.2 - 83.3; P — 0.09, Wilcoxon). In tumour tissues, 
however, trypsin treatment greatly increased the content of immunoreactive peptides 
(20.6pmol.g-1, 3.5 - 226.2; P = 0.001, Wilcoxon). The median content of post- 
trypsinisation peptides (i.e. progastrin and glycine-extended gastrins) was considerably 
greater in tumours than in disease-free mucosa but the difference failed to reach 
statistical significance (P = 0.07, Mann Whitney). The content of trypsin-digested 
gastrin processing-intermediates measured with GP168 (Table 11.4) was significantly 
greater than the content of carboxyamidated gastrins in both disease-free mucosa {P = 
0.026) and tumours (P = 0.001, Mann Whitney).
There was significant correlation in the content of carboxyamidated gastrins in 
normal mucosa and cancer tissue (Spearman's rank correlation coefficient ps = 0.624, P 
< 0.02). Likewise, the content of gastrin-processing intermediates was also strongly 
correlated (ps = 0.605, P = 0.02). In contrast, after trypsin digestion no significant 
correlation existed in the content of these precursors in the two tissues (ps = 0.402, P > 
0 . 1).
11.4 D i s c u s s i o n
Increasing evidence supports a role for gastrin as an important autocrine/paracrine 
growth factor for some gastrointestinal and other tumours. Initial studies used an anti- 
gastrin antiserum added to the medium of colonic carcinoma cell lines and noted an
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inhibition of growth as well as suggesting the presence of gastrin mRNA in cells 
(Hoosein et al 1989, 1990). Using highly sensitive PCR methods, several groups have 
reported gastrin gene expression in colonic carcinoma cell lines (Baldwin et al 1990; 
Baldwin and Zhang 1992; Xu et al 1994) and fresh colonic cancers (Monges et al
1993). Using flow cytometry Watson et al found six of twenty-eight disaggregated 
fresh colonic cancers to contain more than 20% gastrin-positive cells (Watson et al
1991). Others have also found cell line homogenates and fresh tumours to contain 
variable amounts of gastrin and its precursors by radioimmunoassay (Kochman et al 
1992; Van Solinge et al 1993a; Nemeth et al 1993; Singh et al 1994). The levels of 
bioactive carboxyamidated gastrins have been very low and the biological importance of 
immature precursors is unclear (see below).
Gastrin-like peptides with autocrine trophic properties have also been observed 
in other neoplastic cell lines including gastric (Remy-Heintz et al 1993), pancreatic 
(Blackmore and Hirst 1992) and renal (Blackmore et al 1994). In addition, gastrin 
production has been noted in a significant proportion of human bronchogenic (Rehfeld 
et al 1989) and ovarian cancers (Van Solinge et al 1993b) and reports of 'ectopic' 
gastrin production by a carcinoma of oesophagus and a hepatic carcinoid tumour have 
been made (Nishimaki et al 1993; Inoue et al 1993). Gastrin production may thus be a 
feature shared by many neoplastic cells of diverse origin. Both gastrin and CCK may 
play important roles during gastrointestinal development (at least in rodents) with 
expression being 'switched off in normal adult tissues (Liittichau et al 1993; Marino et 
al 1994).
In this study nearly all colorectal tumours and most samples of normal mucosa 
were found to contain small but measurable amounts of progastrin-derived peptides. 
Both bioactive, carboxyamidated peptides and processing-intermediates (C-terminal 
glycine-extended gastrins and progastrin) were detected in both types of tissue. Overall 
the concentrations of carboxyamidated gastrins measured with antisera R98 were 
similar in both tumours and matched samples of macroscopically normal mucosa. The 
content of gastrin processing-intermediates detected by antisera GP168 was also similar 
in the two tissues and trypsin treatment greatly increased the concentration of
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immunoreactive material detected by GP168 but made little difference in normal 
mucosa, suggesting that colorectal tumours may contain relatively greater amounts of 
progastrin than normal mucosa.
There was a wide range in measured concentrations (see Tables 11.3 and 11.4) 
among samples and this has also been observed by others (Kochman et al 1992; 
Nemeth et al 1993). In some reports carboxyamidated gastrins were present in much 
smaller concentrations (£ lpmol.g'1) than observed in this study (Kochman et al 1992) 
and in one study amidated gastrins were found in only one of twelve human colorectal 
tumours (Van Solinge et al 1993). Much higher levels have been found in ovarian and 
bronchogenic tumours (Van Solinge et al 1993; Rehfeld et al 1989) and found in 
extracts of gastric antrum but sufficiently large samples of normal gastric antrum were 
not available for comparison as 'positive control' tissues in this study.
Most studies observed significantly greater amounts of progastrin in tumours 
relative to normal mucosa and the present findings support this. Overall, the few studies 
which have examined this subject have reported both quantitative and qualitative 
differences in gastrin peptide contents. This is possibly the result of differences in 
antibody specificities and sensitivities and differences in tumour characteristics such as 
stage, differentiation and cellular composition. Furthermore, when tissue is split into 
two aliquots (as in this study) the two pieces may not be entirely comparable and this 
has to be borne in mind when interpreting such studies.
There are several ways of studying expression of gastrin in colorectal tumours, 
each with its own relative merits. Study of gastrin mRNA expression by Northern 
analysis, and especially polymerase chain reaction, is very sensitive at detecting low 
levels of gene expression but the presence of mRNA may not necessarily mean that 
functional peptide is also present. Measurement of such peptides by radioimmunoassay 
of tissue extracts, as used here, is less sensitive but is semiquantitative and does allow 
study of the relative amounts of different processing products. Both of these methods 
fall down in one important respect in that they depend on tissue homogenisation and the 
cellular localisation of the gastrin-derived peptides therefore remains undetermined. The 
possibility that the peptides simply originate from specialised endocrine cells normally
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present in sparse numbers in the colon cannot be excluded. Alternatively it is impossible 
to say whether all cells in a given tumour, or just a subclone, express gastrin. To answer 
these questions requires techniques such as in situ hybridisation or 
immunohistochemistry. Xerri et al reported that in situ hybridisation was suitable for 
demonstrating gastrin mRNA in antral mucosa but not sufficiently sensitive to allow 
detection of low level expression in colonic carcinomas (Xerri et al 1992). This is 
supported by the results of Northern analysis which has also been generally 
unsuccessful at detecting gastrin mRNA in the colon (Baldwin et al 1992; Finley et al 
1993; Singh et al 1994). Immunohistochemical studies with the antibodies used in this 
study have not been performed but this is currently being considered. Finley et al found 
gastrin and progastrin to be localised to scattered endocrine cells in normal colon using 
commercially available region-specific antibodies (Finley et al 1993). In contrast the 
majority of malignant cells in most colorectal carcinomas stained positively for gastrin. 
This study is at odds with others which failed to detect significant amounts of G-17 in 
colonic neoplasms by radioimmunoassay (Van Solinge et al 1993) and highlights the 
need for complimentary experimental approaches to answer such questions.
As described above (Results), the assay methodology had to be modified to 
allow reliable detection of these peptides. Initial assay conditions had a lower limit of 
detection of approximately 3ng.L-1 (as used to measure plasma gastrin) and so gastrin- 
derived peptides may well have been present at levels below this detection limit. In 
support of this, when further tissue samples were analysed using assay conditions of 
ten-fold greater sensitivity, progastrin-derived peptides were found in virtually all 
tumours and corresponding normal mucosa. Because of presumed non-specific 
interference in the assay, however, the concentrations obtained were poorly 
reproducible when measured in doubling dilutions. For this reason these results have 
been excluded and only data for the remaining fifteen patients has been considered. The 
data are therefore insufficient to allow meaningful correlation of tumour gastrin content 
and circulating plasma gastrin levels in individual patients. In general, however, 
carboxyamidated gastrins were present in the colon at concentrations approximately 
twenty to fifty-fold lower than were found in plasma from both colorectal cancer and
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control patients (Chapter 10). It is very unlikely that this source of amidated gastrin 
contributes significantly to circulating levels. Nothing is known about the plasma 
concentration of gastrin-processing intermediates in colorectal neoplasia.
No antibody specific for progastrin itself was available and the presence of 
progastrin has been assessed indirectly from the results obtained with antibody GP168 
after trypsinisation of samples. Although an antibody to measure progastrin directly 
would have been ideal several other studies have utilised trypsin digestion as a reliable 
means of measuring progastrin (Kochman et al 1992; Liittichau et al 1993; Van Solinge 
et al 1993). It is unclear why increased amounts of carboxyamidated gastrins were seen 
following treatment of tumours with trypsin as the antibody used (R98) does not 
measure progastrin. No difference at all was observed in normal mucosa and although 
the difference in tumour tissues reached statistical significance (P = 0.03), the actual 
difference in median concentrations was small (5.4pmol.g_1 before and 6.2pmol.g-1 after 
trypsin). The biological significance of this is uncertain and unlikely to be important. In 
contrast, the content of gastrin precursors and processing-intermediates measured by 
GP168 greatly increased in tumour extracts following trypsin digestion but not in 
samples of unaffected mucosa. These findings are in keeping with those of others 
(Kochman et al 1992; Van Solinge et al 1993) and suggest that colorectal tumours may 
synthesise preprogastrin at relatively higher rates than normal colon, but lack the ability 
to carry out full post-translational processing of the hormone.
It had been widely assumed that progastrin and glycine-extended intermediates 
lack biological activity and are unimportant. Unpublished results found gastrin 
precursors to have neither receptor binding activity nor growth stimulatory properties 
(quoted in Van Solinge et al 1993a). In 1994 several group presented preliminary 
evidence to contradict this finding. High concentrations (> lO^M) of glycine-extended 
gastrin (G-gly) were trophic to DLD-1 human colon cancer cells in vitro (Singh et al
1994). The gastrin/CCK-B receptor-positive AR42J cell line was also mitogenically 
stimulated by G-gly with increases in [3H]thymidine uptake and ODC activity (Seva et 
al 1994). The evidence also suggested that G-gly acts through a separate as yet 
unidentified receptor mechanism. Others have also shown that an antibody to G-gly, but
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not one to amidated gastrins, inhibited AR42J cell growth in vitro (Negre et al 1994). 
Finally, nanomolar concentrations of G-gly stimulated gene expression of the H+, K+- 
ATPase alpha subunit in primary cultures of parietal cells (Kaise et al 1994), again 
possibly via a receptor subtype distinct from gastrin/CCK-B receptors. Gastrin 
processing intermediates may thus possess biological activity and their possible 
physiological and pathological relevance clearly merits reappraisal.
In conclusion, this study has found that the majority of colorectal tumours 
contained carboxyamidated gastrins at levels considerably higher than in some other 
studies. The levels were not significantly greater than found in matched samples of 
unaffected mucosa. Glycine-extended precursors were also present at comparable levels 
in both types of tissue but the data do suggest that tumours may contain significantly 
greater amounts of progastrin. Levels of peptides in tumours were significantly 
correlated with those in normal mucosa. Further experiments are needed to locate the 
precise cellular origin of these peptides as is evaluation of the possible trophic effects of 
progastrin and other processing intermediates on colorectal cancer cells.
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CHAPTER 12
GASTRIN/CCK-B RECEPTORS IN 
COLORECTAL CARCINOMA
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12.1 I n t r o d u c t i o n
Knowledge of gastrin/CCK-B receptors has been increasing rapidly since the cloning of 
the receptor gene from different tissues in several species (Wank et al 1992; Pisegna et 
al 1992; Kopin et al 1992). High-affinity gastrin/CCK-B binding sites have been 
identified on a number of established human colorectal cancer cell lines but in contrast 
little is known about such receptors in fresh human colonic tissues. Only one substantial 
study (Upp et al 1989), along with one brief report (Chicone et al 1989) and one 
abstract (Rae-Venter et al 1981), all from the same group, have demonstrated high- 
affinity gastrin receptors on crude membranes from fresh human colorectal tumours by 
radioligand binding. Others have used in vitro 'gastrin-responsiveness' to indicate the 
presence of receptors without demonstrating them directly (Watson et al 1989b). Only 
one negative study (which examined only two samples of normal human colonic 
mucosa) has been published (Kumamoto et al 1989) although publication bias may 
contribute to this.
Before the increasing number of new gastrin receptor antagonists can be 
considered as possible treatments for patients with colorectal cancer, the presence and 
characterisation of such receptors must be shown unequivocally. Also, selection of 
patients who might benefit from these drugs would depend on knowledge of their 
receptor status. The aim of this study was to establish a reliable and sensitive assay 
capable of detecting gastrin/CCK-B receptors on cell membranes and to apply this to 
primary human colorectal neoplasms. The well characterised rat pancreatic cancer cell 
line AR42J (Jessop and Hay 1980) possesses high-affinity CCK-A and gastrin/CCK-B 
receptors (Scemama et al 1987; Watson et al 1991) and was chosen as a 'positive 
control' for this study.
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12.2 M e th o d s
12.2.1 Materials
Bovine serum albumin (BSA), calcium chloride (CaCl2), dimethylsulphoxide (DMSO), 
human gastrin-17-1 (met), N-[2-Hydroxyethyl]-piperazine-N'-[2-ethanesulphonic acid] 
(HEPES), magnesium chloride (MgCl2.6H20), soya bean trypsin inhibitor (SBTI) and 
glycerol were all purchased from Sigma Chemical Co. (Poole, Dorset, UK). BCA 
protein reagent assay kit was purchased from Pierce Chemical Co. (Rockford, Illinois, 
USA). 125I-tyr-human Gastrin-17 was purchased from NEN-Dupont (Stevenage, UK).
12.2.2 Gastrin Receptor Antagonists
L-364,718 and L-365,260 are highly selective and potent non-peptide antagonists 
capable of distinguishing CCK-A and CCK-B receptors, respectively (Lotti and Chang 
1989; Chang et al 1986). Both were kindly provided by Dr B. Evans of Merck Sharp 
and Dohme (West Point, Pennsylvania, USA) and were dissolved in dimethylsulpoxide 
(DMSO). G-17 was dissolved in whole cell assay buffer and stored frozen at -20°C.
12.2.3 AR42J Cells
(i) Cell Culture
AR42J was kindly donated by Dr S. Watson, CRC Labs, University of Nottingham. 
Cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum 
(Gibco, Paisley, Scotland) in a humidified atmosphere at 37°C containing 5% CO2.
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(ii) Preparation of Plasma Membranes
AR42J cells were harvested with ImM EDTA. After centrifugation at 1000 g for ten 
minutes at 4°C, the pellet was resuspended in ice cold homogenisation buffer (50mM 
Hepes, lOmM MgCl2.6H20, lpM soya bean trypsin inhibitor, pH 7.0) and sonicated on 
ice in three 15 second bursts before centrifugation at 1000 g for ten minutes at 4°C. The 
supernatant was centrifuged at 30000 g for thirty minutes at 4°C in an ultracentrifuge. 
The resulting membrane pellet was resuspended in ice cold assay buffer and processed 
immediately for protein estimation using a Pierce protein assay kit. Aliquots used for 
membrane ligand binding were stored frozen at -70°C in assay buffer (plus 0.1% BSA 
and 15% glycerol).
(iii) Radioligand Binding
Either 1 x 106 cells.tube"1 of AR42J whole cells or lOOpg protein.tube"1 of AR42J 
membranes were incubated in duplicate with 114pM 125I-G-17 for 180 minutes at 22°C 
in a final volume of 0.4mls of assay buffer (50mM Hepes, lOmM MgCl2.6H20, 0.1% 
BSA, pH 7.0) or membrane assay buffer (homogenisation buffer plus 0.1% BSA) for 
the measurement of total binding. The reaction was terminated by addition of 0.8mls of 
ice cold assay buffer and bound 125I-G-17 was separated immediately by centrifugation 
at 13000 g for three minutes. The pellet was washed twice and then counted in a 
gamma counter. Non-specific binding was defined as binding in the presence of 119nM 
unlabelled G-17. Specific binding was obtained by subtracting the radioactivity of 
nonspecific binding from total binding and expressed as fmol G-17 bound.mg membrane 
protein"1.
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12.2.4 Human Colorectal Tumours
(i) Collection and Storage of Tumours
Paired samples of human colorectal tumours and macroscopically normal mucosa were 
obtained at surgical resection and collected as described in Chapter 11. Patient details 
are given in Table 12.1.
(ii) Preparation of Membranes
To assess whether the method of tissue preparation affected gastrin binding, tissues 
were prepared in one of two ways. Samples from three patients were mounted on ice in 
a cryostat (-30°C) from which multiple sections were cut and placed in tubes precooled 
on dry ice. Samples from a further seven patients were pulverised to a fine powder 
under liquid nitrogen. All tissue was stored at -70°C until assayed. It was then 
homogenised in 3mls of ice cold homogenisation buffer (50mM Hepes, lOmM 
MgCl2.6H20, 15% glycerol, 0.1% soya bean trypsin inhibitor, 0.1% bacitracin, 0.1% 
phenylmethylsulphonyl fluoride, 0.1% bestatin, 1.5mM dithiothreitol and lOOKIU.ml'1 
aprotinin, pH 7.0) using a precooled polytron homogeniser. The homogenate was 
filtered through gauze mesh (100pm) and centrifuged at 400g for five minutes at 4°C. 
After the supernatant was centrifuged at 30000g for 60 minutes at 4°C, the resulting 
pellet was resuspended in 2.5mls ice cold homogenisation buffer and homogenised by 
hand using a hand held glass teflon homogeniser. Protein estimation was carried out as 
above and membranes stored (100-200pg.tube_1) overnight at -70°C prior to 
radioligand binding.
(iii) Radioligand Binding
Membrane binding (100-200pg.tube_1) was performed as for AR42J cell membranes 
although a range of concentrations of 125I-G-17 was used (0.01 - 0.5nM). Reactions 
were carried out at 22°C for either 15 or 60 minutes and the assay buffer consisted of 
homogenisation buffer plus 0.1% BSA. Assays were performed in duplicate.
Case No. Initials Age Sex Tumour
site
Histology Different­
iation
Dukes’
stage
932616 M.McL. 48 M rectosigmoid adenocarcinoma moderate C
372926 B.T. 44 M sigmoid
mucinous
adenocarcinoma moderate C
882211 PS. 56 F sigmoid adenocarcinoma poor C
394247 G.McK. 71 M caecum adenocarcinoma poor D
649444 A.B. 84 F rectosigmoid adenocarcinoma moderate C
835887 H.B. 66 M sigmoid adenocarcinoma moderate D
502088 G.A. 67 F rectum adenocarcinoma moderate B
322234 J.A. 70 M rectum adenocarcinoma moderate B
440457 T.W. 63 M rectum adenocarcinoma moderate B
926357 E.L. 56 F sigmoid adenocarcinoma poor D
Table 12.1. Patient and tumour details.
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12.3 R e su l t s
12.3.1 Assay Optimisation Using AR42J Cells
(i) Effect of Cell Number and Incubation Conditions
Thorough optimisation of the gastrin/CCK-B receptor assay was carried out as part of 
another ongoing study into these receptors (data not shown) and only details of the final 
optimised assay are given here. Specific binding of 125I-G-17 to both whole cells and 
membranes increased linearly over cell concentrations ranging from 2 x 105 to 1 x 106 
cells.tube"1. Optimum binding to cell membranes occurred with lOOpg of membrane 
protein at which binding was less than 10% of total. In all subsequent experiments a 
concentration of 1 x 106 cells.tube"1 or lOOpg protein.tube'1 was used.
Specific binding of 125I-G-17 to AR42J cells reached a maximum after 180 
minutes incubation and addition of lpM unlabelled G-17 into the incubation medium at 
this time (when the reaction was at steady state) caused dissociation of bound 
radioactivity.
For whole cells optimum binding occurred between pH 6.5 and 7.0 and 
decreased thereafter. The pH optimum for AR42J cell membranes was 7.0. These were 
therefore chosen for subsequent assays.
Maximum binding of gastrin to AR42J cells occurred at 22°C after incubation 
for 180 minutes. At 4°C binding was also increased compared to that seen at 37°C but 
not to the same extent as at 22°C. At 37°C binding decreased possibly as a result of 
proteolytic degradation of radiolabel and this was almost complete after 180 minutes. 
Thus 22°C was selected as the most practical temperature and subsequent experiments 
were performed in an ambient temperature water bath. Figures 12.1 and 12.2 show 
binding curves for gastrin under these optimised conditions.
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(ii) Scatchard Analysis
From Scatchard analysis of three separate AR42J cell experiments the apparaent 
dissociation constant (K J for gastrin was 4 x 10‘10M. Using membrane preparations the 
Kd for gastrin was 1 x 10"9M.
(iii) Effect of Antagonists on Binding to AR42J Whole Cells and Membranes
Using the optimised conditions above both L365,260 and L364,718 inhibited binding of 
125I-G-17 to AR42J whole cells and membranes (Figures 12.1 and 12.2). In these two 
preparations L365,260 caused half maximal inhibition (IC50) at 0.9 x 10‘8M and 2.0 x 
10'8M, respectively. L364,718 was less potent in both preparations with IC50's of 2.5 x 
10'7M and 2.0 x 10 "7M, respectively.
12.3.2 Gastrin Binding in Human Colorectal Tumours
Details of patients and tumours are given in Table 12.1. Using concentrations of 125I-G- 
17 ranging from 0.05 - 0.5nM (18 000 - 170 000 total counts added, approximately), 
little or no specific binding was observed in samples of either normal mucosa or 
colorectal carcinomas from any of ten patients. The amount of membrane protein used 
(100 or 200 pg) made no difference nor did the method of tissue preparation 
(pulverising under liquid nitrogen or cryostat sectioning). Binding data are shown in 
Table 12.2 and Figures 12.3 - 12.12. The figures are shown as histograms depicting 
actual binding data to emphasise that most of the binding was non-specic. In general 
there was insufficient tissue to allow multipoint saturation experiments to be run. As 
little specific binding was found in any of the samples analysed from ten consecutive 
colorectal tumour patients, it was felt unlikely that receptor binding would be observed 
in further samples using this methodology. Tumours from a further forty patients were 
not therefore assayed and this is discussed in detail below.
bi
nd
in
g 
(% 
of 
co
nt
ro
l)
Whole cell L365260  
Whole Cell L364718 
Whole Cell G17
110
100
90
80
70
60
50
40
30
20
10
0
57 6-12 -10 9 8-11 1010
competitor concentration (M)
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Case
Number
Initials Tissue
[125n-
G-17
(nM)
Total
Binding
Non-
Specific
Binding
Specific
Binding
932616 M.McL. normal 0.5 331 396 0
0.25 145 130 15
0.1 90 80 10
0.05 <50 <50 0
932616 M.McL. tumour 0.5 1433 1269 164
0.25 497 433 64
0.1 252 282 0
0.05 131 128 3
372926 B.T. normal 0.5 311 299 12
0.25 222 189 33
0.1 117 89 28
372926 B.T. tumour 0.5 1512 1113 399
0.25 740 736 4
0.1 348 303 45
882211 PS. normal 0.5 272 279 0
0.25 <50 <50 0
0.1 155 82 73
0.05 79 <50 0
882211 PS. tumour 0.5 633 697 0
0.25 296 339 0
0.1 170 131 39
0.05 <50 89 0
Table 12.2. Radioligand binding data (page 1 of 3).
Levels of binding indicate actual counts of radioactivity detected.
Case
Number
Initials Tissue
[125I]-
G-17
(nM)
Total
Binding
Non-
Specific
Binding
Specific
Binding
394247 G.McK. normal 0.5 398 403 0
0.25 224 198 26
0.1 <50 <50 0
0.05 <50 <50 0
394247 G.McK. tumour 0.5 669 735 0
0.25 434 366 68
0.1 123 198 0
0.05 89 103 0
649444 A.B. normal 0.5 1894 1527 367
0.25 1060 881 179
0.1 478 410 68
649444 A.B. tumour 0.5 4223 3929 294
0.25 2453 2144 309
0.1 896 870 26
835887 H.B. normal 0.5 1104 791 313
0.25 592 406 186
0.1 225 162 63
835887 H.B. tumour 0.5 2561 2015 546
0.25 1406 1059 347
0.1 458 443 15
Table 12.2. Radioligand binding data (page 2 of 3).
Levels of binding indicate actual counts of radioactivity detected.
Case
Number
Initials Tissue
[125I]-
G-17
(nM)
Total
Binding
Non-
Specific
Binding
Specific
Binding
502088 G.A. normal 0.5 763 688 75
0.25 326 285 41
0.1 213 163 50
502088 G.A. tumour 0.5 2673 2202 471
0.25 1336 1235 101
0.1 559 513 46
322234 J.A. normal 0.5 474 462 12
0.25 267 215 52
0.1 131 109 22
322234 J.A. tumour 0.5 883 729 154
0.25 483 384 99
0.1 235 183 52
440457 T.W. normal 0.5 215 132 83
0.25 161 121 40
0.1 89 83 6
440457 T.W. tumour 0.5 156 116 40
0.25 60 53 7
0.1 96 71 25
926357 E.L. normal 0.5 233 172 61
0.25 101 83 18
0.1 84 66 18
926357 E.L. tumour 0.5 1686 1567 119
0.25 882 823 59
0.1 423 292 131
Table 12.2. Radioligand binding data (page 3 of 3).
Levels of binding indicate actual counts of radioactivity detected.
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Figure 12.3. Radioligand binding o f | 125I|-G -17 to a) normal mucosa and
b) tum our mucosa from patient M .M cL.. cpm = counts per minute.
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Figure 12.4. Radioligand binding o f  [12~I]-G-17 to a) normal m ucosa and
b) tum our mucosa from patient B.T.. cpm = counts per minute.
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b) tum our mucosa from patient P.S.. cpm = counts per minute.
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Figure 12.6. Radioligand binding o f  [125I]-G-17 to a) normal mucosa and
b) tum our mucosa from patient G .M cK.. cpm = counts per minute.
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Figure 12.7. Radioligand binding o f  [125I]-G-17 to a) normal mucosa and
b) tum our mucosa from patient A.B.. cpm = counts per minute.
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b) tum our mucosa from patient H.B.. cpm = counts per minute.
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12.4 D i s c u s s i o n
The aim of this study was to assess whether or not membranes from human colorectal 
cancers possessed measurable high-affinity gastrin/CCK-B receptors by radioligand 
binding. The technique itself was satisfactory as receptors were reliably and consistently 
measured on AR42J cells. In addition no significant loss of binding was observed in 
crude plasma membranes prepared from the cells. In contrast crude plasma membranes 
from samples of normal and malignant human colonic mucosa exhibited little or no 
specific binding when assayed in a similar way. There are a number of possible reasons 
why the human tumours gave such negative results.
Firstly, it is possible that typical gastrin/CCK-B receptors were not present on 
the colonic tissues examined. Although paired samples from only ten patients were 
analysed, the lack of specific binding made it unlikely that high-affinity binding sites 
would be found in further samples, at least using the current methodology. While 
gastrin/CCK-B receptors have been identified in normal and malignant colonic cells 
from a number of species (Singh et al 1985, 1986b; Guo et al 1990; Watson et al
1992), little is known about primary human colorectal tumours.
Upp et al found such receptors in approximately two-thirds of membranes 
from normal and malignant human colon but this is the only published detailed study 
which has measured gastrin/CCK-B receptor content directly in a substantial number of 
samples. In contrast Kumamoto reported no specific binding of gastrin in normal 
colonic mucosa from two patients (Kumamoto et al 1991). Other investigators have 
either used established human tumour cell lines (Frucht et al 1992) or have utilised in 
vitro 'gastrin-responsiveness' as an indirect measure of the presence of receptors in fresh 
human tumours (Watson et al 1988, 1989b). In these studies only a proportion of 
tumours or cell lines possessed receptors or responded to gastrin. Nevertheless, while 
only a proportion of colonic neoplasms may possess functional receptors, it seems 
statistically unlikely that all ten tumours analysed consecutively in this study would be
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truly receptor negative. It is equally possible that gastrin/CCK-B receptors were present 
but were not detected by the protocol used.
The use of radioligand binding assays to detect peptide receptors in tissue 
preparations can be problematic with many points at which difficulties can arise. These 
have been described in detail elsewhere, both in general terms (Bylund & Yamamura 
1990) and with reference to gastrin/CCK-B receptors (Kleveland and Waldum 1991). 
As the gastrin/CCK-B receptor may have a short half-life, the first possibility is that 
receptors were lost during tumour resection. The vascular supply to the region of bowel 
being resected is usually ligated early during surgery, resulting in an unavoidable period 
of ischaemia before actual resection and freezing of samples. It is unlikely that this 
could be responsible for loss of more or less all binding activity.
Secondly, the method of tissue storage may have resulted in loss of receptors 
although this seems unlikely as snap freezing in liquid nitrogen is widely used and this is 
the method used by the group from Texas (Upp et al 1989; Chicone et al 1989). They 
did not store their tumours in 20% sucrose as has been suggested by others as a means 
of preserving receptor structure.
Alternatively, either the method of membrane preparation or the radioligand 
binding protocol itself may have contributed to the negative results. In this study crude 
membranes were prepared from the colonic tissues in a manner similar to that of Upp et 
al, itself a standard technique. Again it is unlikely that all receptors would be lost during 
tissue break-up although some receptor damage may well occur. Pulverising tissue to 
powder under liquid nitrogen has been successfully used for studying a number of 
receptors in gastrointestinal tumours, including those for gastrin-releasing peptide 
(Preston et al 1993) and oestrogen (Singh et al 1993). To assess this further, however, 
tumours from three patients were prepared by cutting thick (20pm) sections using a 
cryostat at -30°C, followed by manual homogenisation. Again no specific binding was 
noted (data not shown). Thus, powdering of tumours under liquid nitrogen probably 
made little difference to receptor binding.
The binding assay itself was also very similar to that of Upp et al. Only minor 
modifications were made to incorporate the optimum conditions which had been
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carefully determined for gastrin/CCK-B receptors in AR42J cell membranes. As such 
failure to detect binding is unlikely to result from choice of incubation conditions such 
as temperature, duration and pH, although further modifications to the assay conditions 
are still required. The protease inhibitors used should have been adequate to prevent 
proteolytic receptor degradation.
This study did differ from that of the Texas group who iodinated their own 
gastrin as opposed to using commercially iodinated gastrin-17 (NEN-Dupont), as used 
here. As excellent and reliable binding was noted in the AR42J cells, it would appear 
that biological activity of the [125I]-labelled gastrin was unaffected.
If low concentrations of high-affinity binding sites were indeed present at 
concentrations below the level of detection of the assay, then steps such as increasing 
the concentrations of either tissue (above 200pg.tube"^) or [125I]-G-17 (above 0.5- 
l.OnM) may be worth exploring. It would also be interesting to perform the radioligand 
binding using membranes prepared from freshly resected, unfrozen tumours and this is 
currently planned.
In the widely quoted paper of Upp et al (1989) high affinity gastrin binding 
sites were present in 38 of 67 human colon cancers. The authors do not state what 
levels of total binding (as a percentage of total radioactivity added) were obtained or 
what proportion of this binding was specific. Close inspection of their data (especially 
Figure 1) suggests that maximum specific binding (5 finoles) represented only 10% of 
total radiolabelled gastrin added. It is unclear what percentage of total binding this was. 
In general total binding in radioligand assays should be around 20-40% of that added 
and the higher the relative specific binding the better (certainly above 50% and ideally 
around 90%). Results should therefore be viewed in this context. In the present study 
total binding was no greater than 4% of added radioactivity, of which 10-30% was 
specific. These results are insufficient to allow one to say that high-affinity receptors are 
present but may be comparable to those of Upp. The low levels of specific binding seen 
in several patients (see Figures 12.7 - 12.11) could alternatively represent binding to 
low-affinity sites which have been noted by several groups. Unfortunately lack of tissue 
precluded enough data points to be performed for estimation of Kd's in these tumours.
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Interestingly it is now increasingly recognised that receptors for CCK and gastrin may 
exist in multple affinity states (including a very low affinity state) and move between 
states by poorly understood mechanisms (Yu et al 1990; Talkad et al 1994a, 1994b; 
Huang et al 1994). Whether these low affinity receptors are of physiological relevance 
is currently unknown.
From the data in Table 12.2 it can be seen that total binding in tumours 
(expressed per mg of membrane protein) was generally two-three fold greater in 
tumours compared to corresponding normal mucosa from the same patient. Taken 
together the results suggest that receptors, possibly in low numbers, may be present at 
levels which are difficult to detect with the current assay. Further refinements to the 
assay protocol as discussed above are warranted before considering alternative methods 
of studying these receptors.
Given the apparent difficulties with radioligand binding, what alternatives are 
there ? Following the recent isolation and sequencing of the genes for CCK-A and 
CCK-B receptors from human and other species (Wank et al 1992; Pisegna et al 1992; 
Kopin et al 1992; Miyake et al 1994), one approach would be to examine receptor 
mRNA expression by in situ hybridisation or Northern analysis. Alternatively, 
immunohistochemical studies using specific antibodies may also be fruitful. To date only 
one such antibody, raised to canine parietal cells, is available (Mu et al 1987) but 
preliminary reports suggest that it may be useful for studies of human gastrointestinal 
tumours (Watson et al 1993). Hopefully further antibodies will become available in the 
near future. These approaches have the advantage of giving information about receptor 
distribution at the cellular level but are poorly quantitative and do not allow 
pharmacological receptor characterisation.
In summary, high affinity gastrin receptors were not found in samples of 
normal and malignant human colon, despite being measured reliably in a control cell 
line. Whether such receptors are truly absent, or present only as low affinity sites or 
whether limitations of the assay are responsible is unclear. Further refinements are 
required and then alternative strategies should be considered if high affinity receptors 
can still not be shown unequivocally.
PART 3
SUMMARY AND CONCLUSIONS
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CHAPTER 13
SUMMARY, CONCLUSIONS 
AND FUTURE WORK
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13.1 In t r o d u c t io n
The evidence for and against an important trophic role for gastrin in human colorectal 
neoplasia has been presented in this thesis and several aspects of the subject have been 
investigated. Firstly, a well established animal model of the disease was used to study 
the influence of omeprazole-induced hypergastrinaemia on experimental carcinogenesis. 
Then plasma gastrin levies in patients with establishe colorectal neoplasia were 
examined in a detailed study and the content of gastrin and its precursors in samples of 
normal and malignant colonic mucosa from these patients was also assessed. Finally, 
radioligand binding techniques were used to investigate the presence of gastrin/CCK-B 
receptors in membranes from human colorectal tumours.
13.2 O m e p r a z o l e  a n d  a z o x y m e t h a n e  stu d y
This study examined the effects of omeprazole-induced endogenous hypergastrinaemia 
on the subsequent development of azoxymethane-induced colorectal neoplasia in rats. 
Omeprazole was chosen because of the well documented elevations in circulating 
gastrin concentrations seen during therapy with this commonly prescribed drug. The 
azoxymethane model was chosen because of its similarities to human carcinogenesis and 
because it has been well characterised and widely used in recent years.
Despite having marked hypergastrinaemia throughout the study, significantly 
fewer rats in the omeprazole group developed tumours and had fewer tumours per rat. 
The reasons for this are unclear but omeprazole is a potent inducer of the cytochrome 
P450 enzymes responsible for the metabolism of numerous carcinogens. It is possible 
that omeprazole treatment altered hepatic and/or intestinal azoxymethane metabolism, 
rendering it less effective as a colonic carcinogen.
Future experiments are merited to investigate further the results of this study. 
In particular, experiments are planned to assess the effects of omeprazole when given 
only during the promotion phase of carcinogenesis i.e. after initiation with carcinogen
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has been completed. In this way any effects of omeprazole on carcinogen metabolism 
would be controlled for. Secondly, it is important to try and dissociate the effects of 
omeprazole itself from those of the hypergastrinaemia it produces. This could be done 
either by using a group of antrectomised rats (low gastrin) or by treating a group of rats 
with a potent and specific gastrin receptor antagonist (for example, L365,260 or JMV 
320) in addition to omeprazole. Both approaches, however, may introduce other 
potential compounding factors such as the effects of surgery on growth and weight gain 
and the possible independent effects of another drug on tumourigenesis. Finally, short 
term experiments to establish whether omeprazole acutely affects the metabolism of 
[14C]-azoxymethane, by measuring exhaled [14C]-azomethane, are feasible if expensive 
and may be worthwhile depending on the results of the other studies outlined above.
13.3 HUMAN PLASMA GASTRIN STUDY
This study was designed to address the unresolved issue of whether patients with 
colorectal neoplasia have elevated circulating gastrin concentrations relative to a 
control group of patients. Previous studies have often been poorly designed and none 
had controlled for the presence of HP infection, a common and important cause of 
hypergastrinaemia.
The study controlled for all known causes of hypergastrinaemia and measured 
both fasting and meal-stimulated plasma gastrin concentrations pre- and 
postoperatively. When studied in this manner, gastrin levels were similar in both tumour 
and control patients. In all but one case very high gastrins occurred in patients with 
positive gastric autoantibodies and were likely to result from undiagnosed atrophic 
gastritis or pernicious anaemia.
Furthermore, no fall in gastrin concentrations was seen following presumed 
curative resection. It was notable that five tumour patients with perioperative loss of 
HP infection had reductions in postoperative plasma gastrin. The results of previous 
studies should be reconsidered in the light of the important effects of HP infection on
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plasma gastrin. The results of this study have shown conclusively that colorectal tumour 
patients do not have higher circulating gastrin concentrations than well-matched 
controls.
The design of the study, however, did not address the question of whether 
patients with pre-existing, chronic hypergastrinaemia are predisposed to development of 
colorectal neoplasia. In this study, the prevalence of HP infection was similar in the two 
groups and this has subsequently been supported by the results of two other small 
studies (Meier et al 1994; Justin et al 1994). Much larger, carefully designed 
epidemiological studies would be required to answer this question with certainty.
13.4 TUMOUR GASTRIN CONTENT STUDY
This study assessed whether measurable amounts of gastrin or its precursors are present 
in human colonic cancers and whether there are qualitative and/or quantitative 
differences between normal and malignant colon. The method used was chosen in 
preference to analysis of RNA content because RNA content may not reflect that of 
translated peptide(s). It was also used in preference to immunocytochemistry as the 
latter cannot give either quantitative results or reliable information about the content of 
various processing-intermediates of gastrin.
The study demonstrated the practical difficulties encountered in accurately 
measuring peptide levels in extracts of heterogeneous tissues. Once early technical 
problems of non-specific interference were resolved, the results showed that significant 
amounts of both bioactive, carboxyamidated gastrin and its processing-intermediates 
were present in both normal and malignant colon. Levels were similar in the two tissues 
although the results of trypsinisation suggest that tumours contain markedly more 
progastrin than corresponding normal mucosa. This is compatible with defective post- 
translational processing of gastrin in tumour cells although the lack of an antibody 
specific for progastrin itself prevents a definitive answer on this point. It would be
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useful to extend this study using such an antibody and efforts to obtain one are 
currently being made.
As peptide concentrations were similar in both tissues it is unlikely that 
synthesis of gastrin peptides is a novel feature restricted to neoplastic colorectal 
epithelium. It does not detract, however, from the hypothesis that gastrin produced 
locally may be a relevant trophic factor for tumour cells at this site.
The main drawback of the study methodology was that precise cellular 
localisation of the site of gastrin production in the colon was not possible. Correlation 
of the current findings with those of immunocytochemical studies would be of value and 
are planned. Lastly, given the very recent preliminary reports that gastrin precursors 
may indeed possess functional activity, it is now timely to look more closely at what 
trophic roles these peptides may play in colorectal carcinogenesis.
13.5 Ga str in /C C K -B  r e c e pt o r  a ssay
In this study the well characterised cell line AR42J was used as a 'positive control' to 
establish whether high affinity gastrin/CCK-B receptors could be detected by 
radioligand binding. This proved to be the case and no loss of binding was noted in 
crude membranes prepared from the cells. When a similar assay was applied to 
membranes from normal and malignant human colon, no convincing evidence for high 
affinity receptors was found and the possible reasons for this have been discussed. 
Despite following the methodology of Upp et al (1984) closely, significant high affinity 
binding was absent in ten consecutively analysed tumours. Further modifications to the 
assay protocol are necessary but it is unlikely that this will result in a great increase in 
binding above that which has been seen. Preliminary results from experiments using 
membranes prepared from freshly resected, unfrozen tumours are encouraging and 
suggest that a some tumours may exhibit high affinity receptors (J. McKenzie, personal 
communication).
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As discussed in Chapter twelve, alternative methods to study these receptors 
are being considered. cDNA encoding rat and human CCK-B receptor genes has kindly 
been gifted by Dr. S. Wank, (Digestive Diseases Branch, National Institute of Health, 
USA) and plans are underway to develop an in situ hybridisation assay for 
gastrointestinal tumours.
Furthermore a panel of monoclonal antibodies specific for the gastrin/CCK-B 
receptor has recently been developed (Dr. S. Watson, personal communication) and it is 
hoped that these may soon be available for use in studies of human colorectal tumours. 
If satisfactory staining can be obtained in formalin-fixed, wax embedded tissues then it 
should be possible to analyse the colorectal tumours from the patients who participated 
in the studies described in Chapters eleven and twelve. Combined with radioligand 
binding studies of fresh cancers, these approaches may yield valuable information about 
whatever gastrin/CCK-B receptors may be present in normal and neoplastic colonic 
epithelium.
13.6 C o n c l u s io n s
Reports of the role of gastrin as a trophic hormone for colonic epithelial cells continue 
to appear and yet its relevance to human colorectal neoplasia remains enigmatic. 
Resolution of this issue is important given the common and serious nature of the 
condition, the increasing longterm use of powerful acid-suppressing drugs with their 
attendant hypergastrinaemia and the development of new, potent and selective gastrin 
receptor antagonists as possible therapeutic agents.
The studies presented in this thesis have examined the role of gastrin in several 
ways. No convincing evidence supporting a simple trophic role in colorectal neoplasia 
was found. If such a relationship exists it is likely to be more subtle and complex than 
hitherto supposed. Further studies focusing on the autocrine/paracrine effects of gastrin 
peptides (especially progastrin and glycine-extended intermediates) are required and 
advantage needs to be taken of the recent cloning and sequencing of the gastrin/CCK-B
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receptor genes. Together these approaches may define more closely what relevance, if 
any, gastrin has for tumours arising from the colon and rectum.
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APPENDIX ONE
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R e c o n s t it u t io n  o f  A z o x y m e t h a n e
1. Prepare stock solution (lOOmg.ml'1) by diluting lOOOmg azoxymethane (=lml) with 
9mls 0.9% sodium chloride. This stock solution should be kept in a lightproof glass 
container and stored at 4°C for up to one month.
2. On the day of injection, further dilute azoxymethane 10-fold with 0.9% sodium 
chloride (i.e. 1ml AOM stock solution + 9ml NaCl) to give a working solution of 
lOmg.mT1. Working solution should be made fresh each day and any unused 
solution discarded.
3. For a dose of lOmg.kg'1 body weight, this is equal to lml.kg-1 thus making 
calculation of dosing volume easier. This is further facilitated by using graduated 
U100 1ml insulin syringes (Becton Dickinson, Oxford, UK) which allows doses to 
be drawn up easily and accurately.
Sa f e t y  P r e c a u t io n s
1. All handling of azoxymethane must be done only by authorised personnel, after 
appropriate COSHH forms have been completed, approved and signed by all 
involved.
2. All handling must be performed in an approved fume cupboard or laminar flow 
hood with independent exhaust ventilation.
3. The following should be worn when handling azoxymethane:
a) Plastic safety glasses - ("ARCO 40/1", Arco Walker, Glasgow, UK).
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b) Organic Vapour Respirator ("3M5651", Arco Walker, Glasgow, UK).
c) Disposable theatre gown.
d) Plastic apron.
e) Two pairs surgical gloves.
f) Disposable overshoes.
4. All contaminated and used instruments, syringes etc. should be kept inside the fume 
cupboard and left to soak in a plastic "Sharpsafe" bin containing copious amounts of 
a strong oxidising solution such as sodium hypochlorite or potassium permanganate 
in sulphuric acid. At the end of the experimental period the bin should be sealed, 
double-bagged and incinerated.
5. Animal bedding and faeces should be handled with full precautions (as above), 
double-bagged, sealed and incinerated without opening.
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APPENDIX TWO 
R e c o n s t it u t io n  o f  O m e p r a z o l e
1. Molecular formula :C j7 H i9 N3 03S.
2. Molecular weight: 345.42.
3. Required dose : 40pmol.kg"1 day'1.
4. Required dose volume : 5ml.kg'1, to give dosage volumes ranging from 0.75ml (for 
a rat weighing 150g) to 2.5ml (for a rat weighing 500g).
5. Conversion : lpmol = 2.76mg.
6. Required omeprazole concentration: 22.08mg.ml"1.
7. Range of dose volumes given : 0.75 (150g) - 2.5ml (500g).
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APPENDIX THREE
P r e p a r a t io n  o f  O m e p r a z o l e  Su s p e n s io n  f o r  T o x ic o l o g ic a l  St u d ie s
Raw materials
Omeprazole, micronised
Hydroxypropylmethylcellulose 15000 cps (Merrell Dow Ltd., Uxbridge, UK).
Sodium bicarbonate
2M sodium hydroxide
Distilled water
Preparation
1. Prepare a 0.5% HPMC solution as follows:
2. heat 1/4 of the total amount of water to 80-90°C and disperse the HPMC powder in 
the hot water under rigorous stirring with an intensive mixer (e.g. Ultra Turrax). 
Continue mixing until all particles are wet and then add most of the remaining cold 
water and stir until the solution is smooth.
3. add sodium bicarbonate (2mg.ml_1) and adjust pH to 9.0 with sodium hydroxide.
4. add water to final desired volume.
5. place omeprazole in a suitable vessel, wet with a small amount of the HPMC 
solution and add the remaining HPMC solution slowly while continuously stirring.
6. dispense into sterile glass or plastic containers for a maximum of five days usage.
7. stir the suspension thoroughly before use to ensure no sediment remains.
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Storage and stability
Store deep frozen (below -20°C) for no more than 24 months.
Thaw the suspension in a refridgerator (2-8°C).
The buffered suspension is stable for one week in a refridgerator, during which time it 
can be handled for two hours per day at room temperature.
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APPENDIX FOUR 
[14C ]-U r e a  B r e a t h  T e st  
Summary
Fasting subjects are given 0.4 MBq [14C]-labelled urea and breath samples collected in 
hyamine hydroxide/thymolphthalein indicator solution at 10 minute intervals for varying 
lengths of time. The [14C]-C02 collected in the solution is expressed as body weight in 
kilogrammes x % administered dose of [l4C] in sample/mmol of collected x 100 - i.e. 
Kgm % dose/mmol CO2 x 100.
Reagent List
1. Water for injection - 1 x 10 ml Vial.
2. Hyamine hydroxide (1 molar) solution in methanol.*
3. Ethanol* (Industrial quality, obtained from University).
4. Thymolphthalein crystals (BDH Chemicals, Lutterworth, Leicester, UK).
5. Emulsifier-safe scintillation fluid*
6. Anhydrous calcium chloride (BDH Chemicals, Lutterworth, Leicester, UK).
7. "Ensure Plus" - 200ml (Abbott Laboratories Ltd., Maidenhead, UK).
* stored in an inflammable liquid safe.
3) Protocol
The subject is fasted from 2200 hours the previous night and then weighed with indoor 
clothes and shoes on.
The subject is asked to clean their teeth without swallowing any water, discarding all 
rinsings into running water in the basin.
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The subject is shown how to give a breath sample - this is the baseline.
The subject is given the test meal to drink.
The subject is given the test dose (0.4 MBq [i4C]urea in 0.3ml water in 25ml water),
then two rinsings of 25ml water. Note time i.e. Time 0.
The subject gives breath samples every 10 minutes for 30 minutes.
4) Isotope preparation and calculation of results
1. The dose is added into 25ml of water in a disposable paper cup and given to the 
subject to drink. The cup is flushed out twice with 25ml water and the subject also 
drinks this.
2. Two doses are diluted up to 50ml in a volumetric flask with ethyl alcohol and 2 x 3  
x lml aliquots taken as standards and 1ml of 1M hyamine hydroxide/methyl alcohol 
added to each. Dilution factor = 50 i.e. Nett DPM x 50 = Counts/dose.
3. 2ml of indicator solution is used as a "machine negative [14C]-C02 background" 
and unlabelled air is exhaled through this until the hyamine hydroxide is neutralised 
i.e. the blue colour disappears completely.
4. 2ml aliquots of indicator solution are used in the breath test for the subjects. They 
exhale through a kit containing calcium chloride until the hyamine hydroxide is 
neutralised i.e. the blue colour disappears completely.
5. Background, standards and samples have 10ml of emulsifier-safe scintillation fluid 
added into each. They are capped, mixed and the outsides wiped with an alcohol 
swab.
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6. Samples are then counted on a liquid scintillation counter which has a [14C] quench 
correction curve.
7. The subject's weight is incorporated into the calculation to correct for endogenous 
C02.
8. Calculation:
Sample Nett PPM x Subject Weight in Kgm x 100 x 100 
Given dose DPM
= Kgm % dose/mmol CO? x 100 excreted
9. The results are plotted on a graph of time (minutes) versus Kgm % dose/mmol C02 
x 100 excreted.
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APPENDIX FIVE
R a d io l ig a n d  B in d in g  A ssa y  f o r  H u m a n  C o l o r e c t a l  T u m o u r s
Assay volume 
Membrane concentration 
[125I]-G-17 concentration 
G-17 concentration 
Time
Temperature 
Homogenisation buffer
0.4ml
lOOpg.tube'1 
0.05 - 0.5nM 
0.1 -0.5pM 
15 minutes 
22°C
50mM HEPES 
lOmM MgCl2.6H20 
15% glycerol
0.1% soya bean try sin inhibitor 
1.5mM dithiothreitol 
0.1% bestatin 
0.1% bacitracin 
lOOKIU.ml"1 aprotinin 
pH 7.0
Assay buffer as above plus 0.1% BSA
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APPENDIX SIX
PUBLICATIONS AND PRESENTATIONS TO LEARNED SOCIETIES
Some of the work of this thesis has been presented to learned societies and published in 
either abstract or full form.
Presentations to learned societies
"Omeprazole-induced hypergastrinaemia and experimental colorectal carcinogenesis in 
rats." Surgical Research Society, London, January 1993.
"Omeprazole inhibits azoxymethane-induced colorectal carcinogenesis in rats."
Caledonian Society of Gastroenterology, Glasgow, February 1993.
"Omeprazole inhibits azoxymethane-induced colorectal carcinogenesis in rats."
American Gastroenterological Association, Boston, May 1993.*
"Fasting and meal-stimulated gastrin levels pre- and post- operatively in colorectal 
tumour patients". Caledonian Society of Gastroenterology, Dundee, November 1993.**
* Also presented as a poster at the British Society of Gastroenterology in Manchester, 
March 1993.
** Also presented as a poster at the British Society of Gastroenterology in Manchester, 
March 1994 and the American Gastroenterological Association, New Orleans, May 
1994.
Publications
Penman ID, El-Omar E, McGregor JR, Hillan KJ, O'Dwyer PJ and McColl KEL. 
Omeprazole inhibits azoxymethane-induced colorectal carcinogenesis in rats. Gut 
1993;34:1559-1565.
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Penman ID, El-Omar E, McGregor JR, Hillan KJ, O'Dwyer PJ and McColl KEL. 
Omeprazole inhibits azoxymethane-induced colorectal carcinogenesis in rats. 
Gastroenterology, 1993; 104: A441 (abstract).
Penman ID, El-Omar E, McGregor JR, Hillan KJ, O'Dwyer PJ and McColl KEL. 
Omeprazole-induced hypergastrinaemia and experimental colorectal carcinogenesis in 
rats. Br. J. Surg., 1993; 80: 660 (abstract).
Penman ID, El-Omar E, Ardill JES, McGregor JR, Galloway DJ, O'Dwyer PJ and 
McColl KEL. Plasma gastrin concentrations are normal in patients with colorectal 
neoplasia and unaltered following tumour resection. Gastroenterology 1994; 106:1263- 
1270.
Penman ID, El-Omar E, Ardill JES, McGregor JR, Galloway DJ, O'Dwyer PJ and 
McColl KEL. Plasma gastrin concentrations are normal in patients with colorectal 
neoplasia and unaltered following tumour resection. Gut 1994;35: S32 (abstract).
MacKenzie JF, Dorrian CA, Penman ID, Gerskowitch VP, McColl KEL. Development 
of an assay to detect gastrin receptors in gastrointestinal tumours. Gut 1994; 35: S73 
(abstract).
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